---
document_datetime: 2025-02-14 16:07:08
document_pages: 78
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/fasenra-h-c-004433-ii-0052-epar-assessment-report-variation_en.pdf
document_name: fasenra-h-c-004433-ii-0052-epar-assessment-report-variation_en.pdf
version: success
processing_time: 86.7964091
conversion_datetime: 2025-12-28 05:30:20.260583
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 September 2024 EMA/598631/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Fasenra

International non-proprietary name: Benralizumab

Procedure No. EMEA/H/C/004433/II/0052

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                | .............................................. 7                                                           |
|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation .................................................................................................. | 7                                                                                                          |
| 2. Scientific discussion ................................................................................                 | 8                                                                                                          |
| 2.1. Introduction                                                                                                         | ........................................................................................................ 8 |
| 2.1.1. Problem statement                                                                                                  | ............................................................................................ 8             |
| 2.1.2. About the product                                                                                                  | ........................................................................................... 10             |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                 | advice ...... 10                                                                                           |
| 2.1.4. General comments on compliance with GCP                                                                            | ........................................................ 11                                                |
| 2.2. Non-clinical aspects                                                                                                 | ............................................................................................ 11            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                          | ......................................................... 11                                               |
| 2.2.2. Conclusion on the non-clinical aspects                                                                             | ............................................................... 11                                         |
| 2.3. Clinical aspects                                                                                                     | .................................................................................................. 11      |
| 2.3.1. Introduction                                                                                                       | .................................................................................................... 11    |
| 2.3.2. Pharmacokinetics                                                                                                   | ............................................................................................ 12            |
| 2.3.3. Pharmacodynamics                                                                                                   | .......................................................................................... 19              |
| 2.3.4. Discussion on clinical pharmacology ...................................................................            | 21                                                                                                         |
| 2.3.5. Conclusions on clinical pharmacology                                                                               | ................................................................. 21                                       |
| 2.4. Clinical efficacy                                                                                                    | .................................................................................................. 21      |
| 2.4.1. Dose response study ........................................................................................       | 21                                                                                                         |
| 2.4.2. Main study                                                                                                         | ..................................................................................................... 22   |
| 2.4.3. Discussion on clinical efficacy ............................................................................       | 58                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy                                                                               | .................................................................... 61                                    |
| 2.5. Clinical safety                                                                                                      | .................................................................................................... 61    |
| 2.5.1. Discussion on clinical safety ..............................................................................       | 70                                                                                                         |
| 2.5.2. Conclusions on clinical safety ............................................................................        | 71                                                                                                         |
| 2.5.3. PSUR cycle                                                                                                         | ..................................................................................................... 72   |
| 2.6. Risk management plan                                                                                                 | ....................................................................................... 72                 |
| 2.7. Update of the Product information                                                                                    | ........................................................................ 73                                |
| 2.7.1. User consultation ............................................................................................     | 73                                                                                                         |
| 3. Benefit-Risk Balance .............................................................................                     | 73                                                                                                         |
| 3.1. Therapeutic Context ...........................................................................................      | 73                                                                                                         |
| 3.1.1. Disease or condition                                                                                               | ........................................................................................ 73                |
| 3.1.2. Available therapies and unmet medical need                                                                         | ....................................................... 74                                                 |
| 3.1.3. Main clinical studies .........................................................................................    | 74                                                                                                         |
| 3.2. Favourable effects ..............................................................................................    | 74                                                                                                         |
| 3.3. Uncertainties and limitations about favourable effects                                                               | ............................................. 75                                                           |
| 3.4. Unfavourable effects ...........................................................................................     | 75                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                             | ......................................... 75                                                               |
| 3.6. Effects Table                                                                                                        | ...................................................................................................... 76  |
| 3.7. Benefit-risk assessment and discussion .................................................................             | 77                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects                                                                  | .............................................. 77                                                          |
| 3.7.2. Balance of benefits and risks                                                                                      | ............................................................................ 78                            |
| 3.8. Conclusions                                                                                                          | ....................................................................................................... 78 |

<div style=\"page-break-after: always\"></div>

4. Recommendations

.................................................................................

5. EPAR changes

..................................................

78

Error! Bookmark not defined.

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACQ-6

Asthma Control Questionnaire (6-item version)

ADA

Anti-drug antibodies

ADCC

Antibody-dependent cellular cytotoxicity

ADR

Adverse drug reaction

AE

Adverse Event

AI

Autoinjector

ANCA

Anti-neutrophil cytoplasmic antibody(ies)

ANCOVA

Analysis of covariance

APFS

Accessorised pre-filled syringe

BVAS

Birmingham Vasculitis Activity Score

CI

Confidence interval

CL

Clearance

COVID-19

Coronavirus disease - 2019

CSR

Clinical Study Report

CV

Coefficient of variation

CYC

Cyclophosphamide

DB

Double-blind

EBEs

Empirical Bayes estimates

ECG

Electrocardiogram

ECL

Electrochemiluminescence

EGPA

Eosinophilic granulomatosis with polyangiitis

EoE

Eosinophilic esophagitis

EoI

Extension of the indication

EULAR

European alliance of associations for rheumatology

F

Bioavailability

FDA

US Food and Drug Administration

IIV

Inter-individual variability

FAS

Full Analysis Set

Fc

Fragment crystallisable

FcγR

Fc-gamma receptor

GCP

Good Clinical Practice

GI

Gastrointestinal

<div style=\"page-break-after: always\"></div>

| HES    | Hypereosinophilic syndrome                                                |
|--------|---------------------------------------------------------------------------|
| HIV    | Human immunodeficiency virus                                              |
| HRQoL  | Health-related quality of life                                            |
| ICF    | Informed consent form                                                     |
| ICH    | International Council for Harmonisation                                   |
| IEC    | Independent Ethics Committee                                              |
| Ig     | Immunoglobulin                                                            |
| IIV    | Inter-individual variability                                              |
| IL-5   | Interleukin-5                                                             |
| IL-5R  | Interleukin-5 receptor                                                    |
| IL-5Rα | Interleukin-5 receptor subunit alpha                                      |
| IP     | Investigational product                                                   |
| IPD    | Important protocol deviation                                              |
| IRB    | Institutional Review Board                                                |
| IV     | Intravenous(ly)                                                           |
| LLOQ   | Lower limit of quantification                                             |
| LPC    | Low positive control                                                      |
| mAb    | Monoclonal antibody                                                       |
| MRD    | Minimum required dilution                                                 |
| nAb    | Neutralizing antibody                                                     |
| NI     | non-inferior/non-inferiority                                              |
| NK     | Natural killer                                                            |
| NYHA   | New York Heart Association                                                |
| OCS    | Oral corticosteroids (i.e., prednisone/prednisolone or equivalent dose of |
| OLE    | Open label extension                                                      |
| PD     | Pharmacodynamic                                                           |
| PDGFRA | Platelet-derived growth factor receptor alpha                             |
| PGIC   | Patient global impression of change                                       |
| PGIS   | Patient global impression of severity                                     |
| PK     | Pharmacokinetic                                                           |
| PPK    | Population pharmacokinetic                                                |
| PT     | Preferred term                                                            |

<div style=\"page-break-after: always\"></div>

| Q4W     | Every 4 weeks                                                            |
|---------|--------------------------------------------------------------------------|
| RoW     | Rest of World                                                            |
| RUV     | Residual unexplained variability                                         |
| SAE     | Serious Adverse Event                                                    |
| SAP     | Statistical analysis plan                                                |
| SC      | Subcutaneous                                                             |
| SD      | Standard deviation                                                       |
| SF-36v2 | Short Form 36 Item Health Survey (Version 2, Acute Recall)               |
| SNOT-22 | Sino-Nasal Outcomes Test 22                                              |
| SOC     | System organ class                                                       |
| SSQ     | Sino-nasal Symptoms Questionnaire                                        |
| Vc      | Central volume of distribution                                           |
| VDI     | Vasculitis Damage Index                                                  |
| Vp      | Peripheral volume of distribution                                        |
| WPAI    | Work Productivity and Activity Impairment Questionnaire                  |
| WPAI-GH | Work Productivity and Activity Impairment Questionnaire - General Health |
| WT      | Body weight                                                              |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 22 November 2023 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of eosinophilic granulomatosis with polyangiitis for Fasenra, based results from study D3253C00001 (Mandara); this was a randomised, double-blind, multicentre, parallel group, active-controlled, non-inferiority study that evaluated the efficacy and safety of benralizumab compared with mepolizumab in treatment of patients with EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.1 of the RMP has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes. As part of the application, the MAH is requesting a 1-year extension of the market protection.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication. The MAH withdrew the request during the procedure.

## Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Fátima Ventura

Co-Rapporteur:

N/A

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 22 November 2023 |
| Start of procedure:                                  | 23 December 2023 |
| CHMP Rapporteur Assessment Report                    | 20 February 2024 |
| PRAC Rapporteur Assessment Report                    | 21 February 2024 |
| PRAC members comments                                | 28 February 2024 |
| PRAC Outcome                                         | 7 March 2024     |
| CHMP members comments                                | 11 March 2024    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 15 March 2024    |
| Request for supplementary information (RSI)          | 21 March 2024    |

<div style=\"page-break-after: always\"></div>

| Timetable                                   | Actual dates      |
|---------------------------------------------|-------------------|
| CHMP Rapporteur Assessment Report           | 3 June 2024       |
| PRAC Rapporteur Assessment Report           | 3 June 2024       |
| PRAC members comments                       | 5 June 2024       |
| Updated PRAC Rapporteur Assessment Report   | 6 June 2024       |
| PRAC Outcome                                | 13 June 2024      |
| CHMP members comments                       | 17 June 2024      |
| Updated CHMP Rapporteur Assessment Report   | 21 June 2024      |
| Request for supplementary information (RSI) | 27 June 2024      |
| CHMP Rapporteur Assessment Report           | 4 September 2024  |
| CHMP members comments                       | 9 September 2024  |
| Updated CHMP Rapporteur Assessment Report   | 13 September 2024 |
| Opinion                                     | 19 September 2024 |

## 2. Scientific discussion

## 2.1. Introduction

Benralizumab is currently indicated 'as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting βagonists'. The Applicant is seeking an extension of the marketing authorization (MA) for the following indication: 'Fasenra is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis'.

## 2.1.1. Problem statement

## Disease or condition

Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare disease characterised by potentially life-threatening systemic eosinophilic vasculitis of small and medium sized vessels in association with asthma, sinusitis, transient pulmonary infiltrates, and neuropathy. The mean age at diagnosis of EGPA is 50 (± 14) years, with a gender ratio of approximately 1:1. The EGPA is a part of group of vasculitis associated with Anti-neutrophil cytoplasmic antibody(ies) (ANCAs). Eosinophils play a pathological role across the spectrum of EGPA regardless of ANCA status.

## State the claimed therapeutic indication

Authorised: Fasenra is indicated as an add on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long acting β agonists (see section 5.1).

## Claimed:

Eosinophilic granulomatosis with polyangiitis (EGPA)

<div style=\"page-break-after: always\"></div>

Fasenra is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (see section 5.1).

## Epidemiology and risk factors, screening tools/prevention

The incidence and prevalence of EGPA, respectively, is 1.22 per million and 15.27 per million globally, 1.07 per million and 12.13 per million in the EU, and 4.0 per million and 17.0-18.0 per million in the US (Jakes et al 2021). The prevalence of ANCAs in patients with EGPA varies widely (30-47% EGPA patients are ANCA positive) and their clinical significance remains uncertain. The prevalence of EGPA has increased over recent years likely due to an improvement in diagnostic methods, disease recognition, and improved survival. The cumulative survival rates at 5 and 10 years from the disease onset are 88-97% and 78-89%, respectively. Despite the primary causes of mortality changing over time from cardiac manifestations to treatmentrelated causes, including infection and toxicity, the morbidity remains high. Patients with EGPA experience a relapsing, remitting disease course, with a reported relapse rate of 20% to 30% despite standard of care treatment.

## Biologic features

Eosinophils are the key effector and immunoregulatory cells in all stages of EGPA. Eosinophilia and vessel inflammation are hallmarks of EGPA and main effectors of organ damage. Eosinophils induce pathogenesis by means of tissue and vascular infiltration and inflammation through various mediators; it is therefore hypothesized that direct or indirect depletion of eosinophils through blockade of IL-5 or the IL-5R could be efficacious in the treatment of EGPA.

## Clinical presentation, diagnosis

Published classification criteria highlight the importance of blood eosinophilia, asthma, and nasal polyps to classify EGPA among other forms of vasculitis.  Almost all patients with EGPA have asthma, which is typically severe, corticosteroid dependent, and precedes the onset of systemic disease by several years. Multiple organs  can  be  affected  by  EGPA,  including  the  heart,  upper  and  lower  airways,  skin,  vasculature, gastrointestinal system, kidneys, and nervous system. Patients with EGPA have reduced Health-related quality of life (HRQoL) compared with the general population, with decreased scores across all dimensions of the SF-36v2 questionnaire: general health, physical functioning, emotional role limitations, physical role limitations, social functioning, mental health, bodily pain, and vitality.

Patients with EGPA experience a relapsing, remitting disease course, with a reported relapse rate of 20% to 30% despite standard of care treatment. Recurrent relapse is considered to place the patient at risk of permanent tissue and/or organ damage, secondary to the vasculitis process.

Vasculitis  damage  index  (VDI)  records  organ  damage  related  to  chronic  changes  or  scarring  that  has occurred since the onset of vasculitis, either as a result of the disease itself, the side effects of treatment, or any other comorbidity occurring after the diagnosis of vasculitis. Higher VDI scores are associated with disease burden and mortality and have been reported in older EGPA patients, those with longer duration of corticosteroid use, and those with a history of disease relapse.

## Management

Systemic corticosteroids, immunosuppressants, and biologics (rituximab and mepolizumab) are currently recommended in treatment guidelines for EGPA, with mepolizumab being the only approved therapy. Systemic corticosteroids and immunosuppressants are widely used for the treatment of patients with

<div style=\"page-break-after: always\"></div>

EGPA despite a paucity of evidence supporting their efficacy in this disease. A key therapeutic goal in the treatment of EGPA is to induce and maintain remission while reducing the burden of corticosteroids and immunosuppressants often associated with significant adverse events, including toxicity, and a high relapse rate. Rituximab has limited evidence to support efficacy in EGPA, particularly in controlling airway manifestations and reducing corticosteroid dependency. A high proportion of EGPA patients treated with mepolizumab either do not achieve remission and/or relapse, with limited reduction in corticosteroid dependency. Therefore, a significant unmet medical need remains for patients with EGPA.

## 2.1.2. About the product

Benralizumab is a humanized, afucosylated mAb (IgG1, IgG1κ) that binds to the human IL-5Rα on the target cell and induces direct, rapid, and nearly complete depletion of eosinophils through antibodydependent cellular cytotoxicity. Benralizumab was approved by the FDA and by the EMA for the add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype. AstraZeneca is pursuing the development of benralizumab for the treatment of patients with EGPA. Benralizumab is a sterile liquid solution presented in accessorised pre-filled syringe (APFS) or autoinjector (AI) intended for subcutaneous administration. Each APFS contains a nominal label claim of 30 mg of benralizumab in a 1.0 mL volume. Drug Product contains a target of 30 mg/mL benralizumab in histidine/histidine-HCl, trehalose dihydrate, polysorbate 20. There were no formulation changes to the commercial Drug Product (APFS presentation) used in the MANDARA study. For the EGPA indication, the applicant proposes to use the currently approved 30 mg Drug Product formulation and presentations (APFS and AI).

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

There were no formal or informal interactions with EMA regarding MANDARA study design. Furthermore, the PDCO reviewed the MANDARA study design in relation to the paediatric study design and requested efficacy outcomes for the paediatric study to be similar to the adult (MANDARA) study (P/0173/2023).

Key points of the regulatory advice obtained from FDA in formal interactions regarding MANDARA study design are summarised below:

- The applicant initially proposed a single Phase III, randomised, placebo-controlled study to support registration in EGPA. Given the severity of disease, the applicant proposed an eventdriven study design that would permit patients who discontinue to be allowed to go onto best available therapy.
- The FDA found a single pivotal study acceptable in orphan/rare disease. However, the FDA expressed ethical concerns with a placebo-controlled study design due to the existence of an available treatment for this serious disease and recommended an active controlled design against mepolizumab. The Division (Pulmonary, Allergy and Rheumatology Products) also expressed concern with the proposed dosing regimen (60 mg first dose followed by 30 mg Q8W) due to a lack of initial intensive dosing (i.e., 30 mg Q4W x 3) and at minimum recommended the asthma approved dose and dosing regimen in the EGPA study.
- The objective of the meeting was to gain FDA's agreement on 1) the revised Phase III activecontrolled, NI study design, 2) the selected NI margin and statistical approach, and 3) the plans for registration upon completion of the DB treatment period.
- In the preliminary meeting comments, FDA confirmed agreement with the NI study design, primary and secondary endpoints, and the 30 mg Q4W dosing regimen. It was suggested there may be some flexibility in the sample size and NI margin if the applicant could provide adequate

<div style=\"page-break-after: always\"></div>

justification in the setting of a rare disease, a well conducted study, and inclusion of indirect comparison to the placebo rate seen in the mepolizumab study (MIRRA).

- The applicant requested clarification on methods for comparing benralizumab remission rate to the placebo remission rate seen in the mepolizumab study. As this is a novel approach, the FDA responded that validity needs to be established and demonstrated to support the indirect comparison. The FDA suggested the applicant to provide a detailed justification in the protocol and submit the SAP proposal for FDA review.
- The SAP and detailed justification for the selection of NI margin and historical comparison were submitted to the FDA on 3 Sep 2019.

## 2.1.4. General comments on compliance with GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH. The MAH has also provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Benralizumab is a humanized, afucosylated, monoclonal antibody of relative molecular weight 150 kilodaltons. As per the ERA Guideline (EMEA/CHMP/SWP/4447/00 Rev1, 2006), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids are exempt from ERA study requirements because by their nature they are unlikely to result in significant risk to the environment.

## 2.2.2. Conclusion on the non-clinical aspects

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of benralizumab. Considering the above data, benralizumab is not expected to pose a risk to the environment

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trial D3253C00001 (Mandara) was performed in accordance with GCP as claimed by the MAH. The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

Table 1. Tabular overview of clinical studies

| Type of study               | Study identifier            | Location of study report in Module 5   | Objectives of the study                                                                                                                          | Study design and type of control                                | Test products, Dosage regimen, Route of administration                                                                                         | No. of subjects rand/treated           | Healthy subjects or diagnosis of patients   | Duration of treatment                                                                           | Study status; type of report                                                  |
|-----------------------------|-----------------------------|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Controlled Clinical Studies | Controlled Clinical Studies | Controlled Clinical Studies            | Controlled Clinical Studies                                                                                                                      | Controlled Clinical Studies                                     | Controlled Clinical Studies                                                                                                                    | Controlled Clinical Studies            | Controlled Clinical Studies                 | Controlled Clinical Studies                                                                     | Controlled Clinical Studies                                                   |
| Efficacy and safety         | D3253C00001 (MANDARA)       | 5.3.5.1                                | Evaluate the efficacy and safety of benralizumab compared to mepolizumab in the treatment of EGPA in patients receiving standard of care therapy | Randomised, DB, active- controlled, parallel group, multicentre | 1 x benralizumab 30 mg plus 3 placebo to mepolizumab SC injections Q4W 3 x mepolizumab 100 mg plus 1 placebo to benralizumab SC injections Q4W | Benralizumab: 70/70 Mepolizumab: 70/70 | Adults with relapsing or refractory EGPA    | 52 weeks of randomised treatment (DB period) followed by optional OLE period of at least 1 year | DB period complete, OLE period ongoing; Full report for primary database lock |

DB = double-blind; EGPA = eosinophilic granulomatosis with polyangiitis; No. = number; OLE = open-label extension; Q4W = every 4 weeks; rand = randomised; SC = subcutaneous

## 2.3.2. Pharmacokinetics

Data from the pivotal MANDARA study were used for the evaluation of PK, PD and immunogenicity profile of benralizumab in EGPA:

Table 2. Overview of Benralizumab Clinical Studies with PK, PD and Immunogenicity Assessments

| Study Name (Study Number)   | Study Type and Design                                                                                           | Study Population                                                                                                                                                       | Dosing Regimen                                                                                                                                                                                                      | Overall Objectives                                                                                                                                                                                                                          | PD Markers                | PK, PD, and ADA Assessment Points                                                                                                                                                                                                                   |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MANDARA (D3253C00001)       | Phase III, randomised, active- controlled, parallel group, multicentre, 52-week double- blind study with an OLE | Patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy; Atotal of 140 eligible patients were randomised | DB period: 1 x benralizumab 30 mg plus 3 placebo to mepolizumab by SC injections Q4Wor 3 x mepolizumab 100 mg plus 1 placebo to benralizumab by SC injections Q4W OLE period: benralizumab 30mg by SC injection Q4W | To compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by SC injection Q4Win patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy | Blood (serum) eosinophils | DB period: PK: Pre-dose at Weeks 0, 4, 12, 24, 36, 48, and 52; post-dose at Weeks 1 and 25 ADA/nAb: Pre- dose at Weeks 0, 12, 24, 36, 48, and 52 PD: Pre-dose at Screening and Weeks 0, 1, 4, 8, 12, 16, 20, 24, 25, 28, 32, 36, 40, 44, 48, and 52 |

ADA = anti-drug antibody; DB = double-blind; EGPA = eosinophilic granulomatosis with polyangiitis; nAb = neutralising antibody; OLE = openlabel extension; PD = pharmacodynamics; PK = pharmacokinetics; Q4W = every 4 weeks; SC = subcutaneous

No new biopharmaceutical studies were conducted in support of the proposed EGPA indication.

<div style=\"page-break-after: always\"></div>

Serum  samples  for  the  assessment  of  benralizumab  concentrations,  Anti-drug  antibodies  (ADA)  and neutralizing activity of ADA from patients with EGPA who enrolled in the MANDARA study were collected according  to  the  schedule  of  activities  described  in  the  clinical  protocol  of  the  study.  Benralizumab concentrations  were  measured  using  a  validated  Electrochemiluminescence  (ECL)  immunoassay  which utilises  a  sandwich  format  with  capture  and  detection  mAbs  recognizing  2  distinct  epitopes  on  the benralizumab molecule. The assay was initially validated by MedImmune in both human plasma and serum and subsequently transferred to PPD where it was partially validated for use in EGPA patient serum. The results of the partial validation of the immunoassay (assay performance: accuracy and precision, electivity, and specificity) supported the validity of the method to quantify benralizumab accurately and precisely in EGPA patient serum, with an LLOQ of 3.86 ng/mL, quantitative range of 3.86 to 1250 ng/mL, and MRD of 1:50.

Assessment of Anti-Drug Antibodies to Benralizumab -Assessment of Neutralising Activity of Anti-Drug Antibody Responses: Assessment of ADA responses to benralizumab followed a 3-tiered testing approach, which consisted of validated assays for detection (screening assay), specificity (confirmatory assay), and semi-quantification (titre assay). Confirmed ADA positive samples from the Phase III study were subsequently tested for in vitro neutralising activity, as assessed by a ligand-binding nAb assay. ADA screening and ligand-binding neutralizing antibody assays were validated at PPD. Sensitivity and drug tolerance were estimated for both assays. Selectivity and specificity were also investigated in EGPA patient sera. The performance of both assays was shown to be stable and reliable when monitored during the MANDARA study.

In general, bioanalytical methods used have been appropriately described and validated, and deemed fit for purpose, as commented by the CHMP.

Pharmacokinetic analysis was performed only on samples from EGPA patients who received benralizumab 30 mg Q4W during the 52-week DB period. Geometric mean benralizumab trough serum concentrations reached steady state by Week 12 (1797.94 ng/mL) during the DB period (Table 3). Serum samples from week 1 and 25 were collected following benralizumab administration.

<div style=\"page-break-after: always\"></div>

Table 3. Benralizumab Serum Concentration (ng/mL) (PK Analysis Set)

<!-- image -->

| Time point   | Statistic              | Benralizumab 30 mg (N = 67)   |
|--------------|------------------------|-------------------------------|
| Baseline     | n                      | 65                            |
|              | n<LLOQ                 | 9                             |
|              | Geometric mean (CV[%]) | 6.09 (NC)                     |
|              | Median                 | 0                             |
|              | Minimum, Maximum       | 0, 6.09                       |
| Week 1       | n                      | 63                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 2154.93 (33.60)               |
|              | Median                 | 2182.65                       |
|              | Minimum, Maximum       | 989.91, 4094.65               |
| Week 4       | n                      | 67                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 1118.88 (48.82)               |
|              | Median                 | 1140.58                       |
|              | Minimum, Maximum       | 419.65,6999.28                |
| Week 12      | n                      | 66                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 1797.94 (50.33)               |
|              | Median                 | 1996.48                       |
|              | Minimum, Maximum       | 676.03,4268.72                |

<div style=\"page-break-after: always\"></div>

All&lt;LLOQvalueswere substituted with thevalueof O.

<!-- image -->

| Time point   | Statistic              | Benralizumab 30 mg (N = 67)   |
|--------------|------------------------|-------------------------------|
| Week 24      |                        | 53                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 2009.30 (63.63)               |
|              | Median                 | 2019.7                        |
|              | Minimum,Maximum        | 383.36, 6961.92               |
| Week 25      | n                      | 60                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 2992.87 (59.00)               |
|              | Median                 | 3222.53                       |
|              | Minimum,Maximum        | 623.14, 6897.36               |
| Week 36      | n                      | 66                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 1829.28 (67.35)               |
|              | Median                 | 2094.4                        |
|              | Minimum, Maximum       | 212.22,6512.35                |
| Week 48      | n                      | 63                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 1868.93 (59.34)               |
|              | Median                 | 1792.87                       |
|              | Minimum,Maximum        | 322.46, 5124.64               |
| Week 52      |                        | 62                            |
|              | n<LLOQ                 | 0                             |
|              | Geometric mean (CV[%]) | 1837.16 (58.46)               |
|              | Median                 | 1933.985                      |
|              | Minimum, Maximum       | 339.97,5608.26                |

Baseline is the last non-missing value prior to administration of the first dose of study treatment.

CV = coefficient of variation; LLOQ = lower limit of quantification (3.86 ng/mL); N = number of patients in treatment group; n =number of patients in analysis; PK =pharmacokinetics

Source:Table 14.2.4.1

Population Pharmacokinetic Analyses : Population PK modelling was conducted to characterise the PK properties of benralizumab in patients with EGPA. The benralizumab PK analysis data set consisted of 67 subjects and 516 benralizumab PK observations. Previously established two-compartment model (legacy model) with first-order absorption and elimination developed during the severe asthma clinical development programme for adult and adolescent patients was used to establish the PK profile of benralizumab in EGPA patients (final model) by comparing the PK parameter estimates from the MANDARA study with the population pharmacokinetic (PPK) estimates from the legacy model. The starting point model was originally proposed to be the model developed for the eosinophilic esophagitis (EoE) population, which was itself a model derived based on the priors of the asthma indication. It was considered more appropriate to use the model developed in the asthma indication as a starting point, for which there were extensive rich and sparse data from nine clinical trials available. Associated interindividual variability (IIV) and residual unexplained variability (RUV) were included in the PPK analysis (Table 4):

<div style=\"page-break-after: always\"></div>

Table 4. Comparison of the Parameter Estimates Between the Final Benralizumab PK Model and the Legacy Benralizumab PK Model

|                                                | Final Model                                    | Final Model                                    | Legacy Model                                   | Legacy Model                                   |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Parameter                                      | Value                                          | RSE (%)                                        | Value                                          | RSE (%)                                        |
| PK Parameter's                                 | PK Parameter's                                 | PK Parameter's                                 | PK Parameter's                                 | PK Parameter's                                 |
| CL (L/day)                                     | 0.218                                          | 4.29                                           | 0.289                                          | 2.25                                           |
| Vc(L)                                          | 3.14                                           | 3.22                                           | 3.13                                           | 3.22                                           |
| Q (L/day)                                      | 0.739                                          | 5.28                                           | 0.739                                          | 5.09                                           |
| Vp (L)                                         | 2.50                                           | 4.27                                           | 2.52                                           | 4.44                                           |
| Ka t1/2abs (day)                               | 3.26                                           | 6.19                                           | 3.56                                           | 7.22                                           |
| F                                              | 0.589                                          | (FIX)                                          | 0.589                                          | 2.51                                           |
| CovariateEffectonPKParameter's                 | CovariateEffectonPKParameter's                 | CovariateEffectonPKParameter's                 | CovariateEffectonPKParameter's                 | CovariateEffectonPKParameter's                 |
| WT on CL                                       | 0.799                                          | 4.19                                           | 0.807                                          | 4.24                                           |
| ADA on CL                                      | 1.25                                           | 8.28                                           | 2.24                                           | 1.52                                           |
| Injection location \"thigh' on F                | 1.25                                           | 3.30                                           | NA                                             | NA                                             |
| WT on Ve                                       | 0.789                                          | 13.3                                           | 0.803                                          | 13.3                                           |
| WT on Vp                                       | 0.518                                          | 20.5                                           | 0.528                                          | 20.5                                           |
| Inter-Individual Variability of PK Parameter's | Inter-Individual Variability of PK Parameter's | Inter-Individual Variability of PK Parameter's | Inter-Individual Variability of PK Parameter's | Inter-Individual Variability of PK Parameter's |
| IIV CL (CV)                                    | 0.300                                          | 9.55                                           | 0.242                                          | 3.73                                           |
| IIV V. (CV)                                    | 0.239                                          | 8.02                                           | 0.244                                          | 8.40                                           |
| IIV Q (CV)                                     | 0.0894                                         | (FIX)                                          | 0.0894                                         | (FIX)                                          |
| IIV V, (CV)                                    | 0.439                                          | 5.22                                           | 0.447                                          | 5.42                                           |
| IIV k, (CV)                                    | 0.796                                          | 5.42                                           | 0.831                                          | 5.33                                           |
| IIV F (CV)                                     | 0.171                                          | (FIX)                                          | 0.171                                          | 11.3                                           |
| RUV (CV)                                       | 0.175                                          | 11.7                                           | 0.250                                          | 2.76                                           |

Due to rounding, the values for the legacy model in this table might be slightly different from the values reported in the publication from Yan et al 2019.

The RSE for IIV and RUV parameters were reported on the approximate SD scale.

ADA = anti-drug antibody; CL = clearance; CV = coefficient of variation; F = bioavailability; IIV = inter- individual variability; k, = first-order absorption rate constant; NA = not applicable; PK = pharmacokinetic(s);

Q = inter-compartmental clearance; RSE = relative standard error; RUV = residual unexplained variability;

SD = standard deviation; ti/2 = half-life; Ve= central volume of distribution; Vp = peripheral volume of distribution; WT = weight

Source: Table A3-2, D3253C00001 PPK Report, Module 5.3.3.5

In line with the legacy model data, body weight was a significant covariate on CL, Vc, and Vp, ADA was a significant covariate on CL and injection location was a significant covariate on F (1.25, RSE: 3.30). This finding is consistent with results from the AMES study where exposure after administration in the thigh was approximately 15% to 30% higher compared to abdomen and upper arm. No other covariate-parameter relationships  were  identified.  Overall,  the  parameter  estimates  were  similar  between  the  two  models, however Clearance (CL) was predicted to be approximately 25% lower in patients with EGPA, compared to patients with asthma/severe asthma.

Exposure  metrics  of  benralizumab  were  compared  between  the  2  models:  simulated  benralizumab concentrations resulting from current final PK model compared with simulated benralizumab concentrations from the legacy model and sampled population (n = 1000). For both simulations 30 mg Q4W dosing was assumed, and subjects were assumed to be ADA negative and to have received the administered dose in any  other  location  than  the  thigh.  Based  on  the  summary  statistics  of  the  exposure  metrics  from  the models/populations, the simulated benralizumab concentrations and exposure metrics for the final model

<div style=\"page-break-after: always\"></div>

are higher compared to those simulated for the legacy model. This is attributed to the lower clearance estimated for the current final model. In addition, the variability in exposure metrics and benralizumab concentrations simulated with the current final model is higher compared to the legacy model. However, the results of these simulations should be considered with caution, in light of the relatively high shrinkage observed for the empirical Bayes estimates (EBEs) from both the current final model and legacy model, especially when evaluating the outer percentiles of the data.

The final population PK model for benralizumab in adult patients with EGPA provided a good description of the observed data overall and in ADA status and body weight (WT) subgroups.

- While the estimated parameter values were similar between the two patient populations, CL was found to be lower in patients with EGPA compared to patients with asthma.
- The final model included the covariate effects of ADA status on CL, injection location on F, and WT on CL,  Vc  and  Vp.  CL  was  approximately  25%  higher  when  ADA  status  was  positive,  compared  to  a negative  ADA  status,  F  was  also  around  25%  higher  when  doses  were  administered  in  the  thigh compared to other injection locations, and CL, Vc and Vp increased with increasing WT. No additional covariate-parameter relationships were identified.
- Model simulations demonstrated higher benralizumab concentrations and a decreased WT adjusted CL when simulated with the current final model or simulated using the legacy model. As a result, the exposure parameters t1/2, Cmin,ss, Cav,ss, Cmax,ss, and AUCt,ss were moderately increased (22-37%) for the current final model compared to the legacy model. These results should be considered with care, in light of the relatively high shrinkage observed for the EBEs from both the current final model and legacy model, especially when evaluating the outer percentiles of the data.

Assumptions directly related to the final results and conclusions of the current analysis are listed in Table 5:

Table 5. Important assumptions related to the final results and conclusions

| Assumption                                                                                                                                     | Reasons for the assumption                                                                                                                             | Justification                                                                                                                           | Limitations/Risk mitigation                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| The PK characteristics of benralizumab are similar in adolescents/adults with asthma/- severe asthma and in patients with EGPA (current data). | The structure of the legacy model as well as priors were built based on the parameter estimates from the legacy model were used for model development. | Available data in the MANDARA study was limited and sparse.                                                                             | A different model might be obtained when developing from scratch based on rich data in patients with EGPA.            |
| Omitting observations below the LLOQ has no impact on the parameter estimates of the final model.                                              | A number of observations were below the LLOQ.                                                                                                          | Omitting a small number of BLQ observations usually does not impact the parameter estimates of the final model and is a common practice | The conclusions of the analysis are not dependent on this assumption.                                                 |
| The predictions of the individual parameters can be used to generate individual exposure metrics even if the                                   | Shrinkage is a property of the data and not of the model, implying that model modifications will                                                       | Without additional knowledge to inform the estimation of the EBEs, the individual estimates cannot be estimated with                    | A high shrinkage may complicate the detection of a possible exposure- response relationship. In the exposure-response |

<div style=\"page-break-after: always\"></div>

| associated shrinkages are above what is usually considered as a high threshold (30%).   | not have a large effect on shrinkage   | less shrinkage. However, the population parameters are not affected by the shrinkage and no modeling decision was taken based on EBE-based diagnostics.   | analysis this may be tested by estimating individual PK parameters simultaneously with the pharmacodynamic (PD) model.   |
|-----------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|

## Absorption and Distribution

In patients with EGPA, the estimated Vc and Vp of benralizumab were 3.14 L (RSE%: 3.22) and 2.50 L (RSE% 4.27), respectively. The IIV on Vc and Vp (%CV) were 23.9% and 43.9%, respectively.

## Elimination

The estimated CL of benralizumab was 0.218 L/day (RSE%: 4.29), and IIV on CL (%CV) was 30.0% (Table 2) in patients with EGPA. CL was predicted to be approximately 25% lower in patients with EGPA compared to patients with severe asthma.

Since from the current PopPK model it cannot be concluded that the PK findings in EGPA patients are consistent with that of asthma. The interpretation of the model results is hampered due to the mainly sparse sampling data included in the model and high shrinkage values. Although, the individual estimates of exposure metrics are hampered by the high shrinkage, population parameters are not affected. Thus, the applicant included the lower CL in EGPA patients of 0.22 L/day from the final model in section 5.2 of the  SmPC.  Furthermore,  the  Applicant  should  remove  the  phrase  that  findings  in  EGPA  patients  were consistent with those in asthma (see comment on SmPC 5.2).

## Special populations

The effect of race, sex, age, and baseline eosinophil count on benralizumab CL were evaluated.

|                            | Overall N=67   |
|----------------------------|----------------|
| Sex                        |                |
| Male                       | 25 (37%)       |
| Female                     | 42 (63%)       |
| Race                       |                |
| Asian                      | 9 (13%)        |
| White                      | 50 (75%)       |
| Multiple or other          | 3 (4.5%)       |
| (Missing)                  | 5 (7.5%)       |
| ADA status                 |                |
| ADA negative               | 61 (91%)       |
| ADA positive               | 6 (9.0%)       |
| Concomitantparacetamoluse  |                |
| No concomitant paracetamol | 51 (76%)       |
| Concomitant paracetamol    | 16 (24%)       |
| Concomitant PPI use        |                |
| No concomitant PPI         | 34 (51%)       |
| Concomitant PPI            | 33 (49%)       |

Numbers represent the number of subjects in each category; percentages represent the corresponding percentage of total number of subjects, specified in the column header.

<div style=\"page-break-after: always\"></div>

Body weight: Body weight was identified as a relevant covariate, with significant effects on CL, Vc, and Vp

ADA status: Clearance was predicted to be approximately 25% higher when patients were ADA positive (allometric coefficient: 1.25)

Injection Location: Administering the benralizumab doses in the thigh resulted in an approximately 25% increase in F compared to other injection locations (arm or abdominal wall).

## Pharmacokinetics using human biomaterials

In  previous  severe  asthma  studies,  human  biomaterial  studies  showed  that  benralizumab  binds  to the interleukin-5 receptor alpha subunit with high affinity on the surface of human eosinophils and basophils and binds selectively to eosinophils in a mixed leucocyte population.

## 2.3.3. Pharmacodynamics

## Mechanism of action

The mechanism of action of benralizumab involves depletion of eosinophils through enhanced antibodydependent cellular cytotoxicity (ADCC). Benralizumab binds to IL-5Rα on eosinophils and basophils. The absence of fucose in the Fc domain of benralizumab results in high affinity for FcγRIIIa, the main activating FcγR expressed on the immune effector cells, NK cells, and macrophages. The higher affinity for FcγRIIIa results in the recruitment and activation of NK cells and macrophages leading to apoptosis of eosinophils and basophils through enhanced ADCC. Depletion of blood eosinophils with benralizumab is rapid, with a 50% reduction in 1.7 ± 0.7h (mean ± SD, following a single dose, near complete, and sustained depletion of eosinophils in blood and in tissue, including airways, bone marrow, and gastrointestinal tract.

## Primary and secondary pharmacology

Changes in Blood Eosinophils Over Time: A reduction in blood eosinophil count from baseline was observed in  both  treatment  groups  from  Week  1,  the  first  time  point  assessed,  through  Week  52,  with  greater reductions in benralizumab group compared with mepolizumab group at all time points (Figure 1).  The proportion of patients with a ≥ 90% reduction in blood eosinophil count from baseline and those with an absolute blood eosinophil count of ≤ 30 cells/μL at Week 1 was higher in the benralizumab group compared with the mepolizumab group (51.5% vs 12.1%) with differences maintained through Week 52.

<div style=\"page-break-after: always\"></div>

Figure 1. Absolute Eosinophil Count, Least Square Mean Change from Baseline by Timepoint, Line Plot (Full Analysis Set)

<!-- image -->

The absolute eosinophil count is log-transformed. Where a result of 0 was recorded, a small value (ie, minimum of all non-missing results/2) was added prior to logtransformation.

The error bars are the upper bounds and the lower bounds of the 95%CIs.

CI=confidence interval

Source: Figure 14.2.1.14.2

The proportion of patients with an absolute eosinophil count ≤ 30 cells/μL at Week 1 was higher in the benralizumab  group  compared  with  the  mepolizumab  group  (adjusted  rates  of  51.5% vs 12.1%,  p  &lt; 0.0001). This difference was maintained through Week 52 (adjusted rates at Week 52 of 69.4% vs 16.5%, p &lt; 0.0001).

Greater reduction for benralizumab compared to mepolizumab was also demonstrated across all time points based on the 90% reduction threshold (p &lt; 0.001), and at Week 1 only (p = 0.001) based on the &lt; 150 cells/μL threshold.

Benralizumab Immunogenicity: Immunogenicity variables were summarized over DB period for all patients in the safety analysis set with at least one available ADA result. The following immunogenicity conclusions were made from MANDARA study:

In benralizumab group, both the prevalence and the incidence of ADA was 9.0% (6/67 patients). All ADA responses were treatment-induced with half of the ADA positive  patients (3/67) being transiently ADA positive and the other half being persistently ADA positive (3/67). One of the persistently positive patients was also nAb positive (1/67).

Regarding  the  kinetics  of  ADA  response,  the  percentage  of  ADA  positive  patients  observed  over  time generally  increased  through  Week  36  and  then  remained  relatively  constant  through  Week  52. Seroconversion generally occurred by Week 36. There was one nAb positive patient with positive results detected at Weeks 36 and Week 48.

In patients with positive ADA results, the median ADA titre increased until Week 48; however, because 3 out of 6 patients were transiently ADA positive, the number of ADA positive patients at each time point only ranged from 1 to 3. There was one nAb positive patient. This patient was consistently ADA positive from Week 24 through Week 52 with in  vitro neutralising  activity  detected  at  Weeks  36  and  Week 48. The detection of in vitro neutralizing activity coincided with the measurement of the highest titre at Week 36 and was still detectable at Week 48 although the ADA titre had decreased.

<div style=\"page-break-after: always\"></div>

No consistent effect of ADA on mean trough benralizumab serum concentrations was observed. There was one transiently ADA positive patient with trough serum concentrations consistently (Weeks 24 to 52) below the minimum of ADA negative patients; however, the low serum concentrations occurred for this patient during  time  points  of  either  ADA  positive  or  ADA  negative  results.  Thus,  the  data  do  not  suggest  an association between the low serum concentrations and ADA detection.

## 2.3.4. Discussion on clinical pharmacology

The interpretation of the PPK model results is hampered due to the mainly sparse sampling data included in  the  model  and  high  shrinkage  values.  Although,  the  individual  estimates  of  exposure  metrics  are hampered by the high shrinkage, population parameters are not affected. As the legacy model, the final benralizumab PK model was a two-compartment model with first-order absorption from the dosing site and first-order elimination from the central compartment. Both the legacy and the final benralizumab PK model included the effect of WT on CL, Vc and Vp, as well as the effect of ADA on CL. Overall, the parameter estimates were similar between the two models, although CL was predicted to be approximately 25% lower in  patients  with  EGPA,  compared  to  patients  with  asthma/severe  asthma.  This  observation  may  be attributed to more frequent benralizumab dosing regimen in EGPA patients (Q4W) versus patients with severe asthma (Q4W for the first 3 doses followed by Q8W thereafter). Thus, the lower CL in EGPA patients of 0.22 L/day from the final model was included in section 5.2 of the SmPC. Furthermore, the Applicant removed the phrase that findings in EGPA patients were consistent with those in asthma. This is agreed.

Depletion of eosinophils in peripheral blood is an important marker of biological activity of benralizumab. The PD effect of benralizumab in patients with EGPA was consistent with its effect observed in patients with severe asthma, showing rapid and near complete depletion of blood eosinophils.

In benralizumab group, the percentage of patients with positive ADA result at any time and the percentage of patients who were treatment-emergent ADA positive was 9% (6/67 patients). All ADA responses were treatment-induced. Half of the patients were transiently ADA positive, and the other half were persistently ADA positive. One of the persistently ADA positive patients was also nAb positive. No consistent effect of ADA on PK, efficacy, PD and safety was observed.

## 2.3.5. Conclusions on clinical pharmacology

Geometric mean benralizumab trough serum concentrations reached steady state by Week 12 (1797.94 ng/mL)  during  the  DB  period.  From  the  PPK  modelling  it  cannot  be  concluded  that  PK  findings  for benralizumab in EGPA (30 mg Q4W) is overall consistent with the benralizumab PK properties in severe asthma (30 mg Q4W for the first 3 doses followed by Q8W thereafter). Based on the assessment of changes in blood eosinophil count over time and proportion of patients who reached certain thresholds of eosinophil count reduction over time, PD effect of benralizumab in patients with EGPA was consistent with its effect observed in patients with severe asthma, showing rapid and near complete depletion of blood eosinophils. The clinical pharmacology profile of benralizumab was sufficiently described and there are no outstanding issues.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No  formal  dose-response  studies  have  been  performed  because  of  the  rarity  of  EGPA.  The  currently approved dosing regimen of benralizumab in severe asthma is 30 mg administered SC Q4W for the first 3

<div style=\"page-break-after: always\"></div>

doses and Q8W thereafter. According to the applicant's justification, a more frequent dosing regimen (30 mg SC Q4W) was selected for benralizumab in EGPA following discussions with FDA on: 1) the severity of the disease, 2) the extensive database of benralizumab from asthma studies, and 3) the approval of a higher dose of mepolizumab in EGPA compared with its approved dose in asthma (MIRRA). EGPA is a more severe disease than asthma often with vasculitic involvement of other organs, and the eosinophil load in patients with EGPA is often higher than in patients with asthma with an eosinophilic phenotype. In addition, clinical trial in Hypereosinophilic syndrome (HES) described in the literature also supported the use of Q4W dosing regimen of benralizumab in EGPA on the grounds that eosinophil burden in EGPA is similar to that observed in HES, with both diseases also sharing some clinical and histological feature. Benralizumab 30 mg Q4W was well tolerated and was effective in reducing blood and tissue eosinophilia in patients with several clinical subtypes of HES.

Nevertheless, while the severity of EGPA disease and approval of a higher dose of mepolizumab in EGPA compared with asthma (MIRRA) is noted by the CHMP , the applicant's decision to use the Q4W dosing regimen for benralizumab in EGPA is not driven by data specific for the proposed indication. In the responses to the CHMP's request, information on patients with EGPA controlled during the first 3 months of treatment with the loading dose of Q4W and uncontrolled disease when moved to the Q8W maintenance dose was provided, which justified the proposed dosing regimen.

## 2.4.2. Main study

## Title of Study

MANDARA  study: A  Randomised,  Double-blind,  Active-controlled  52-week  Study  with  an  Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy.

## Methods

MANDARA study included a 52-week DB period in which the efficacy and safety of benralizumab were compared with an active comparator, mepolizumab (Figure 2). Eligible patients were randomized 1:1 at baseline (Visit 2) to receive benralizumab 30 mg every 4 weeks (Q4W) or mepolizumab 300 mg Q4W. The study has an ongoing Open label extension (OLE) period to assess long-term safety and tolerability of benralizumab.

Figure 2. Flow Chart of Study Design

<div style=\"page-break-after: always\"></div>

<!-- image -->

BVAS = Birmingham Vasculitis Activity Score; EoT = End of treatment; OCS = oral corticosteroids; OLE = open-label extension; Q4W = every 4 weeks; SC = subcutaneous; V = Visit (number).

The rationale for using the Full Analysis Set (FAS) as primary analysis is that all patient data is used in this rare  disease  setting  and  the  approach  allows  comparability  with  the  previous  mepolizumab  placebocontrolled study in patients with EGPA. The analysis of safety endpoints was based on the safety analysis set. The analysis of the primary and secondary efficacy endpoints, as well as, secondary safety endpoints included  all  data  captured  during  the  52-week  DB  treatment  period,  defined  as  the  period  after administration of randomised IP at Visit 2 (Week 0) and the conclusion of Visit 17 (Week 52), inclusive.

The primary database lock occurred after all randomised patients were followed up for the 52-week DB period. The study remained blinded until the primary database lock. Data from the DB period of the study (intention-to-treat approach) were included in the primary analysis. Furthermore, exposure and Adverse Event (AE) data from the OLE period available at the time of the primary database lock were also reported. Additional analyses may be performed after the primary database lock to analyze the data that were not available in the primary analysis. The final database lock occurs after the last patient has completed at least one year in the OLE period and the end of the study has been declared.

## Study participants

## Inclusion criteria

- Provision of signed and dated, written Informed consent form (ICF) prior to any mandatory study specific procedures, sampling, and analyses.
- Patients: males and females 18 years of age and older at the time of signing the ICF.
- Patients who have been diagnosed with EGPA for at least 6 months before screening visit (Visit 1) date based on the history or presence of: asthma plus documented eosinophilia (&gt; 1.0 × 10 9 /L and/or &gt; 10% of leukocytes) plus documentation of at least 2 of the following additional features of EGPA:
- (a)  A  biopsy  showing  histopathological  evidence  of  eosinophilic  vasculitis,  OR  perivascular  eosinophilic infiltration, OR eosinophil-rich granulomatous inflammation
- (b) Neuropathy, mono or poly (motor deficit or nerve conduction abnormality)

<div style=\"page-break-after: always\"></div>

- (c) Pulmonary infiltrates, non-fixed
- (d) Sino-nasal abnormality
- (e) Cardiomyopathy (established by echocardiography or magnetic resonance imaging)
- (f) Glomerulonephritis (hematuria, red cell casts, proteinuria)
- (g) Alveolar hemorrhage (by bronchoalveolar lavage)
- (h) Palpable purpura
- (i) Positive test for ANCA immunofluorescence and/or positive test for MPO and/or PR3 antibodies
- History of relapsing OR refractory disease defined as:

Relapsing disease: Patients should have a history of at least one confirmed EGPA relapse (i.e., requiring increase in investigator-initiated oral corticosteroids (OCS) dose, initiation/increased dose of immunosuppressive therapy or hospitalization) within the past 2 years which occurred at least 12 weeks prior to screening (Visit 1) while receiving a dose of prednisolone (or equivalent) of ≥ 7.5 milligram per day (mg/day).

Japan-only  definition  of  relapsing  disease: patients  should  have  a  past  history  of  at  least  one confirmed EGPA relapse (i.e. requiring increase in investigator-initiated OCS dose, initiation of IV prednisolone [or equivalent], initiation/increased dose of immunosuppressive therapy, initiation/increased dose of IV Ig or hospitalization), within the past 2 years which occurred at least 12 weeks prior to screening (Visit 1) while receiving a dose of prednisolone (or equivalent) of ≥ 7.5 mg/day.

Refractory disease:

EITHER: Failure to attain remission within the 6 months prior to Visit 1 (BVAS [scale 0-63] = 0 and OCS dose ≤ 7.5 mg/day prednisolone or equivalent) following induction treatment with a standard regimen, administered for at least 3 months; OR: Within 6 months prior to screening (Visit 1), recurrence of symptoms of EGPA (not necessarily meeting the protocol definition of relapse) while tapering OCS, occurring at any dose level ≥ 7.5 mg/day prednisolone or equivalent.

- Therapy with corticosteroids: The prescribed dose of oral prednisolone or prednisone had to be stable (i.e., no adjustment of the dose), ≥ 7.5 mg/day but not &gt; 50 mg/day) for at least 4 weeks prior to baseline (Visit 2). Stable doses of OCS other than prednisolone or prednisone could be acceptable but should be discussed with the applicant's study physician.
- Immunosuppressive therapy: If receiving immunosuppressive therapy (excluding CYC), the dosage should  have  been  stable  for  the  4  weeks  prior  to  baseline  (Visit  2).  Note:  The  dose  of immunosuppressive therapy should not exceed the maximal doses used in clinical practice.
- ECG evaluation at screening (Visit 1): QTcF &lt; 450 msec or QTcF &lt; 480 msec for patients with bundle branch block.

## Reproduction

- Negative serum pregnancy test for women of childbearing potential (WOCBP) at screening (Visit 1)
- WOCBP must agree to use a highly effective method of birth control (confirmed by the Investigator) from randomization throughout the study duration and for at least 12 weeks after last dose of Investigational product (IP). Highly effective forms of birth control (those that can achieve a failure rate of less than 1% per year when used consistently and correctly).
- Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal.

<div style=\"page-break-after: always\"></div>

Women will be considered postmenopausal if they have been amenorrhoeic for ≥ 12 months prior to the planned date of randomization without an alternative medical cause.

## Exclusion criteria

- Granulomatosis with polyangiitis (previously known as Wegener's granulomatosis) or microscopic polyangiitis.
- Organ-threatening EGPA: organ-threatening EGPA as per the European League against Rheumatism criteria (Yates et al 2016), i.e., organ failure due to active vasculitis, creatinine &gt; 5.8 mg/dL (&gt; 513 μmol/L) within 3 months prior to screening (Visit 1) and through randomization (Visit 2).
- Life-threatening EGPA: imminently life-threatening EGPA disease defined as any of the following within 3 months prior to screening (Visit 1) and through randomization (Visit 2).
- -Intensive care required
- -Severe alveolar haemorrhage  or haemoptysis requiring transfusion or ventilation or haemoglobin &lt; 8 g/dL (&lt; 80 g/L) or drop in haemoglobin &gt; 2 g/dL (&gt; 20 g/L) over a 48-hour period due to alveolar haemorrhage
- -Rapidly progressive glomerulonephritis with creatinine &gt; 2.5 mg/dL (&gt; 221 μmol/L) or rise in creatinine  &gt;  2  mg/dL  (&gt;  177  μmol/L)  over  a  48-hour  period  Severe  gastrointestinal involvement, for example, gangrene, bleeding requiring surgery
- -Severe central nervous system involvement
- -Severe cardiac involvement, for example, life-threatening arrhythmia, cardiac failure: ejection fraction &lt; 20%, NYHA Class III/IV (NYHA 2012), acute myocardial infarction.
- Malignancy: current malignancy, or history of malignancy, except:
- -Patients who have had basal cell carcinoma, localised squamous cell carcinoma of the skin or in  situ  carcinoma  of  the  cervix  were  eligible  provided  that  the  patient  is  in  remission  and curative therapy was completed at least 12 months prior to screening (Visit 1).
- -Patients with other malignancies were eligible provided that the patient is in remission and curative  therapy  was  completed  at  least  5  years  prior  to  the  date  informed  consent  was obtained
- Liver disease: unstable liver disease, cirrhosis, and known biliary abnormalities
- Cardiovascular: patients who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment including but not limited to:
- -Known ejection fraction &lt; 30%, OR
- -Severe heart failure that meets NYHA Class IV (NYHA 2012), OR
- -Hospitalized in the 12 months prior to screening (Visit 1) for severe heart failure meeting NYHA Class III (NYHA 2012), OR
- -Angina diagnosed within 3 months prior to screening (Visit 1) and through randomisation (Visit 2).
- Infectious disease, Parasitic infection, Hepatitis status, Immunodeficiency History of known allergy, intolerance, or anaphylaxis to any biologic therapy or vaccine, known history of allergy or reaction to  any  component  of  the  IP  formulation,  or  other  specific  concurrent  medical  conditions  or prior/concomitant/prohibited therapy or laboratory findings .

<div style=\"page-break-after: always\"></div>

## Treatments

Table 6 summarises the treatments used in the clinical study.

Table 6. Study Treatments

|                         | Treatment 1                                                                                                                                                   | Treatment 1                                                                                                                                                     | Treatment 2                                                                                                                                                                                        | Treatment 2                                                                                                        |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Study treatment name    | Benralizumab                                                                                                                                                  | Placebo to mepolizumab a,b (0.9% sodium chloride)                                                                                                               | Mepolizumab ab                                                                                                                                                                                     | Placebo to benralizumab                                                                                            |
| Dosage formulation      | 30 mg/mL solution for injection in APFS; 1 mL fill volume                                                                                                     | Matching placebo: solutions for injection in 1 mL polypropylene syringes (3 syringes were used on each dosing occasion). Injection volume per syringe was 1 mL. | 3 x 100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL polypropylene syringes for administration on each dosing occasion. Injection volume per syringe was 1 mL. | Matching placebo solution for injection in APFS; 1 mL fill volume.                                                 |
| Route of administration | SC injection                                                                                                                                                  | SC injection                                                                                                                                                    | SC injection                                                                                                                                                                                       | SC injection                                                                                                       |
| Dosing instructions     | Benralizumab active solution was administered to patients by healthcare professionals, patients, or their caregivers SC using an APFS in this clinical study. | Placebo solution was administered to patients by healthcare professionals SC using a syringe in this clinical study.                                            | Mepolizumab active solution was administered to patients by healthcare professionals SC using a syrmge m this clinical study.                                                                      | Placebo solution was administered to patients by healthcare professionals SC using an APFS in this clinical study. |
| Packaging and labelling | Refer to pharmacy manual                                                                                                                                      | Refer to pharmacy manual                                                                                                                                        | Refer to pharmacy manual                                                                                                                                                                           | Refer to pharmacy manual                                                                                           |
| Provider                | Sponsor                                                                                                                                                       | Study site                                                                                                                                                      | Sponsor                                                                                                                                                                                            | Sponsor                                                                                                            |

APFS = accessorised pre-filled syringe; SC = subcutaneous(ly).

## Objectives

## Primary objective:

- To assess the durability of response to treatment with benralizumab compared with mepolizumab in patients with relapsing or refractory EGPA who were receiving standard of care therapy, assessed by the proportion of patients in remission at both Weeks 36 and 48.

## Secondary objectives:

<div style=\"page-break-after: always\"></div>

- To  assess  the  efficacy  of  benralizumab  compared  with  mepolizumab  on  duration  of  clinical remission, defined as accrued duration in weeks where a patient achieved remission.
- To assess the efficacy of benralizumab compared with mepolizumab on time to first relapse
- To assess the effect of benralizumab on corticosteroid dose required during Week 48 through Week 52 compared to mepolizumab.
- To assess the clinical benefit of benralizumab compared to mepolizumab.
- To assess the annualised relapse rate in patients receiving benralizumab compared to mepolizumab.
- To assess the proportion of patients who achieved remission within the first 24 weeks and remained in  remission  for  the  remainder  of  the  double-blind  treatment  period  in  patients  receiving benralizumab compared to mepolizumab.
- To assess additional measures of the efficacy and health status/health-related quality of life in patients receiving benralizumab compared to mepolizumab.
- To assess the safety and tolerability of benralizumab compared to mepolizumab.
- To assess the pharmacokinetics and immunogenicity of benralizumab.

## Exploratory objectives:

- To  assess  the  cumulative  OCS  use  in  response  to  treatment  with  benralizumab  compared  to mepolizumab.
- To evaluate the effect of benralizumab compared to mepolizumab on healthcare resource utilisation due to EGPA.
- To evaluate the effect of benralizumab compared to mepolizumab on biomarkers of inflammation a
- To evaluate the effect of benralizumab compared to mepolizumab on biomarkers related to the MoA, eosinophilic inflammation, and EGPA disease pathogenesis, as well as baseline predictors of response to benralizumab or mepolizumab  a
- To characterise the patient-reported experience and treatment benefits of benralizumab compared with mepolizumab through patient interviews a .
- a The following endpoints (except for CRP/ESR and IgE) related to the objective above will be reported outside of the clinical study report: biomarkers of inflammation; exploratory biomarkers in serum, nasal secretions, tissue biopsies and  sputum  (Mechanistic  sub-study  only);  patient  interviews  to  characterize  patient-reported  experience  and treatment benefits (sub-study).

## Outcomes/endpoints

Primary endpoint: Proportion of patients with relapsing or refractory EGPA, achieving remission defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Weeks 36 and 48.

Supportive endpoint: Proportion of patients who have achieved remission defined by BVAS = 0 and OCS dose ≤ 7.5 mg/day (supportive remission definition) at both Weeks 36 and 48.

## Secondary endpoints:

- Total accrued duration of remission for the following categories: 0 wk, &gt; 0 to &lt; 12 wk, 12 to &lt; 24 wk, 24 to &lt; 36 wk, ≥ 36 wk. Analysis was repeated based on main and supportive remission definitions.
- Time from randomisation to first EGPA relapse, where relapse was defined as any of the following:
- o Active vasculitis (BVAS &gt; 0); OR
- o Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR
- o Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sinonasal symptom questions;

warranting any of the following:

- -An increased dose of OCS therapy to 4 mg/day prednisolone total daily dose; OR
- -An increased dose or addition of immunosuppressive therapy; OR
- -Hospitalisation related to EGPA worsening.
- Based on the average daily OCS dose during Week 48 through Week 52:
- o Proportion of patients in each category: 0 mg; &gt; 0 to ≤ 4 mg; &gt; 4 to ≤ 7.5 mg and &gt; 7.5 mg

<div style=\"page-break-after: always\"></div>

- o Proportion  of  patients  in  each  category  of  percent  reduction  from  baseline:  no  reduction  or withdrawal  from  treatment;  &lt;  25%  reduction;  25%  to  &lt;  50%  reduction;  50%  to  &lt;  75% reduction; 75% to &lt; 100% reduction; 100% reduction
- o Proportion of patients with ≥ 50% reduction from baseline
- o Proportion of patients with 100% reduction from baseline
- o Proportion of patients with ≤ 4 mg in average daily dose
- Proportion of patients who had achieved any clinical benefit when meeting any of the criteria below.
- Proportion of patients who had achieved complete response when meeting all of the criteria below.
- o Remission (defined as BVAS = 0 and OCS dose ≤ 4 mg/day) at any time during the double-blind treatment period
- o ≥ 50% reduction in average daily OCS dose during Weeks 48 through 52
- o EGPA relapse free during the double-blind treatment period.

Analysis was repeated for the supportive remission definition.

- Annualised relapse rate.
- Proportion of patients who had achieved remission within the first 24 weeks and remained in remission for  remainder  of  the  double-blind  treatment  period.  Analysis  was  repeated  based  on  main  and supportive remission definitions.
- BVAS, VDI, pulmonary function testing, asthma symptoms (ACQ-6), sino-nasal symptoms (including SNOT 22 questionnaire), health-related quality of life (SF-36v2), PGIS, WPAI-GH and blood eosinophil counts were assessed as change from Baseline over the 52-week double-blind treatment period.

PGIC was assessed as response proportions at each weekly assessment between Visits 2 and 4.

- Safety and tolerability were evaluated based on AEs, vital signs, physical exam, clinical laboratory, and ECG.
- Serum benralizumab concentrations
- Anti-benralizumab antibodies and neutralizing antibodies.

## Exploratory Endpoints:

- Cumulative  OCS  use,  as  measured  by  AUC  for  daily  OCS  dose,  over  the  52-week  double-blind treatment period.
- Number of EGPA-related hospitalizations; length of hospital stay; ICU days; number of EGPA-related ER visits; number of EGPA-related outpatient visits (by type); number of EGPA-related procedures/tests (by specific procedure/test)
- o Biomarkers of inflammation, e.g., CRP and ESR, Exploratory biomarkers
- o Patient  interviews  to  characterise  patient-reported  experience  and  treatment  benefits  (substudy).

ACQ-6 = Asthma Control Questionnaire (6-item version); AE(s) = adverse event(s); AUC = area under the curve; BVAS =  Birmingham  Vasculitis  Activity  Score;  CRP  =  C-reactive  protein;  ECG  =  electrocardiogram;  EGPA  =  eosinophilic granulomatosis with polyangiitis; ER = emergency room; ESR = erythrocyte sedimentation rate; ICU = intensive care unit;  IP  =  investigational  product;  MoA  =  mechanism  of  action;  OCS  =  oral  corticosteroid;  PGIC  =  Patient  Global Impression of Change; PGIS = Patient Global Impression of Severity; SF- 36v2 = Short Form 36-Item Health Survey (version 2, acute recall); SNOT-22 = Sino-nasal Outcome Test-22; VDI = Vasculitis Damage Index; wk = week(s); WPAI-GH = Work Productivity and Activity Impairment Questionnaire (general health version 2.0).

<div style=\"page-break-after: always\"></div>

## Sample size

The sample size and the feasibility of completing the study were considered in the determination of the NI margin for MANDARA. Substantial evidence of mepolizumab efficacy in EGPA was demonstrated in MIRRA study  with  22/68  patients  (32%)  treated  with  mepolizumab  achieving  remission  compared  with  2/68 patients (3%) on placebo. Based on the above historical evidence, the assumption was that benralizumab and mepolizumab each have a remission rate of 32%; 140 patients provide approximately 90% power to demonstrate NI with a margin of -25% at the 5% 2-sided significance level (equivalent to a 2.5% onesided significance level). For the study to be positive, the lower 95% confidence limit for the difference between benralizumab and mepolizumab needs to be higher than the NI margin of -25%.

## Randomisation

Randomisation was stratified by region. Approximately 25% of patients were expected to participate in a mechanistic sub-study to explore the PD response and MoA of benralizumab compared to mepolizumab. The aim of the sub-study was the identification of biomarkers of eosinophil recruitment, activation, and survival, investigation of inflammation and immunological mechanisms related to EGPA, and identification of  baseline  biomarkers  predicting  response  to  benralizumab  or  mepolizumab.  The  number  of  enrolled patients with ANCA-positive status or an eosinophil count &lt; 150 cells/μL (&lt; 0.15 × 10 9 /L) at screening was restricted to approximately 10% and 40%, respectively, of the total number of randomized patients.

In order to limit the total number of ANCA-positive patients and the patients with eosinophil count of &lt; 150 cells/μL (&lt; 0.15 × 10 9 /L), after approximately 10% and 40% respectively of the total number of randomized patients was reached, further ANCA-positive and patients with eosinophil count of &lt; 150 cells/μL were not randomized into the study and were considered screen failures

## Blinding (masking)

During the first 52 weeks of this study - the DB design - the applicant's staff involved in the study, the patients and the Investigators involved in the treatment or clinical evaluation and patient monitoring were not aware of the treatment allocation. Placebo to benralizumab and placebo to mepolizumab solutions were visually matched with benralizumab and mepolizumab solutions, respectively. All packaging and labelling of the IP were prepared in such way as to ensure blinding for all applicant and investigational site staff. Placebo to mepolizumab (0.9% sodium chloride) was prepared and dispensed by the study site using labels provided by the unblinded site pharmacist.

## Statistical methods

The analysis of the primary and secondary efficacy endpoints included all data captured during the 52-week DB period. The primary analysis of exposure and AEs included data captured during both the DB period and OLE period at the time of database lock. A primary estimand was applied to the analysis of the primary endpoint whereby all data up to the end of the DB period were included, regardless of whether a patient remained on blinded IP or not, with a similar strategy used for the secondary endpoints. All hypothesis testing was reported using 2-sided tests and all p-values were nominal. Summary data presentation and the calculation of absolute change from baseline is described in the SAP.

Efficacy endpoints were analysed using the Full Analysis Set (for definitions of analysis sets, see below Numbers Analysed ). Patients were analysed according to their randomized treatment. The rationale for

<div style=\"page-break-after: always\"></div>

using the FAS as primary is that all patient data is used in this rare disease setting and the approach allows comparability with the previous mepolizumab placebo-controlled study in patients with EGPA. The analysis of safety endpoints will be based on the safety analysis set. The analysis of the primary and secondary efficacy endpoints and secondary safety endpoints would include all data captured during the 52-week DB treatment period, defined as the period after administration of randomised IP at Visit 2 (Week 0) and the conclusion of Visit 17 (Week 52), inclusive.

## Results

## Participant flow

Patient disposition shown in Table 7 was generally balanced between the benralizumab and mepolizumab groups. The proportions of patients who discontinued product administration or the study during the DB period were low and similar between groups.

<div style=\"page-break-after: always\"></div>

Table 7. Patient Disposition (Enrolled Analysis Set)

|                                                         | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   |
|---------------------------------------------------------|---------------------------|---------------------------|---------------------------|
|                                                         | Benralizumab 30 mg        | Mepolizumab 300 mg        | Total                     |
| Patients emolled*                                       | NA                        | NA                        | 157                       |
| Patients randomised                                     | 70 (100)                  | 70 (100)                  | 140 (100)                 |
| Patients emrolled but not randomised                    | NA                        | NA                        | 17                        |
| Screen failure                                          | NA                        | NA                        | 10                        |
| Withdrawal by patient                                   | NA                        | NA                        | 3                         |
| Adverse event                                           | NA                        | NA                        | 1                         |
| Other                                                   | NA                        | NA                        | 3                         |
| Patients randomised and received treatment              | 70 (100)                  | 70 (100)                  | 140 (100)                 |
| Patients who completed DB IP b c                        | 69 (98.6)                 | 67 (95.7)                 | 136 (97.1)                |
| Patients who discontinued IP in DB period b             | 1(1.4)                    | 3 (4.3)                   | 4 (2.9)                   |
| Withdrawal by patient                                   | 1(1.4)                    | 2 (2.9)                   | 3 (2.1)                   |
| Adverse event                                           | 0 (0.0)                   | 1 (1.4)                   | 1 (0.7)                   |
| Patients who completed DB period b d                    | 69 (98.6)                 | 67 (95.7)                 | 136 (97.1)                |
| Patients who completed DB IP and DB period              | 69 (98.6)                 | 67 (95.7)                 | 136 (97.1)                |
| Patients who discontimued DB IP but completed DB period | 0 (0.0)                   | 0 (0.0)                   | 0 (0.0)                   |
| Patients who withdrew firom DB period b                 | 1(1.4)                    | 3 (4.3)                   | 4 (2.9)                   |
| Adverse event                                           | 0 (0.0)                   | 1 (1.4)                   | 1 (0.7)                   |
| Withdrawal by patient                                   | 0 (0.0)                   | 1 (1.4)                   | 1 (0.7)                   |
| Other                                                   | 0 (0.0)                   | 1 (1.4)                   | 1 (0.7)                   |
| Due to COVID-19 pandemic                                | 1(1.4)                    | 0 (0.0)                   | 1 (0.7)                   |
| Patients who emrolled in OLE period b                   | 66 (94.3)                 | 62 (88.6)                 | 128 (91.4)                |
| Patients who discontinued IP in OLE period              | 6 (8.6)                   | 5 (7.1)                   | 11 (7.9)                  |
| Withdrawal by patient                                   | 3 (4.3)                   | 0 (0.0)                   | 3 (2.1)                   |
| Adverse event                                           | 2 (2.9)                   | 2 (2.9)                   | 4 (2.9)                   |
| Lack of therapeutic response                            | 1(1.4)                    | 3 (4.3)                   | 4 (2.9)                   |
| Patients who withdrew from OLE period b                 | 6 (8.6)                   | 5 (7.1)                   | 11 (7.9)                  |
| Adverse event                                           | 1 (1.4)                   | 1 (1.4)                   | 2 (1.4)                   |
| Death                                                   | 0 (0.0)                   | 1 (1.4)                   | 1 (0.7)                   |
| Lack of efficacy                                        | 2 (2.9)                   | 2 (2.9)                   | 4 (2.9)                   |
| Withdrawal by patient                                   | 2 (2.9)                   | 0 (0.0)                   | 2 (1.4)                   |
| Other                                                   | 1 (1.4)                   | 1 (1.4)                   | 2 (1.4)                   |

Three patients were emrolled but withdrew consent due to COVID-19, therefore not randomised.

COVID-19 = coronavinus disease 2019; DB = double-blind; IP = investigational product; NA = not applicable: OLE = open-label extension

<div style=\"page-break-after: always\"></div>

|                       | Number (%6) of patients   | Number (%6) of patients   | Number (%6) of patients   |
|-----------------------|---------------------------|---------------------------|---------------------------|
|                       | Bemralizumab 30 mg        | Mepolizumab 300 mg        | Total                     |
| Withdrawal by patient | 2 (2.9)                   | 0 (0.0)                   | 2 (1.4)                   |
| Other                 | 1 (1.4)                   | 1 (1.4)                   | 2 (1.4)                   |

- Completion of DB IP was based upon the muumber of patients completing treatment with IP up to and including Week 48 (Visit 16).
- Includes patients who discontimued IP but attended all study visits in DB period.

Three patients were enrolled but withdrew consent due to COVID-19, therefore not randomised.

COVID-19 = coronavinus disease 2019; DB = double-blind; IP = investigational product; NA = not applicable; OLE =open-label extension

## Recruitment

This study was conducted at 50 centers in 9 countries with a total of 157 enrolled subjects. The majority of participants were enrolled in France (33 subjects, 23.6%), followed by Canada (19 subjects, 13.6%), Italy, United Kingdom (18 subjects, 12.9%) and Germany (17 subjects, 12.1%). Enrolment from United States (13 subjects, 9.3%), Israel (10 subjects, 7.1%), Japan (8 subjects, 5.7%) and Belgium (4 subjects, 2.9%) was of a slightly smaller scale. The first patient enrolled on 29 October 2019; the last patient last visit in the DB period of the study was on 10 August 2023. The primary clinical data cut-off date was 10 August 2023.

## Conduct of the study

There were 4 amendments in the original MANDARA clinical study protocol and all were approved by the applicant before being submitted to a regulatory authority and/or an IRB/IEC. None of the amendments had an impact on the analysis of the primary endpoint or affected the integrity of the trial. Substantial changes in the conduct of the study that were implemented by protocol amendments are summarized in Table 8.

<div style=\"page-break-after: always\"></div>

Table 8. Protocol Amendments Related to Changes in Study Conduct

| Amendment Number/Date                                  | Key details of Amendment                                                                                                                                                                                                                                                                                                                                                                                                | Main reason(s) for Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendments made after the start of patient recruitment | Amendments made after the start of patient recruitment                                                                                                                                                                                                                                                                                                                                                                  | Amendments made after the start of patient recruitment                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (Version 2.0) 27 March 2020                            | This was a non-substantial amendment.                                                                                                                                                                                                                                                                                                                                                                                   | The protocol was amended to coirect and/or clarify inclusion/exclusion criteria. clarify that nasal secretions will be collected from selected sites.                                                                                                                                                                                                                                                                                                                                                                           |
| 2 (Version 3.0) 04 August 2020                         | New wording was added which would give guidance on how the study could continue in the event of a serious disnuption with details of mitigations that could be employed to ensuure study continuity.                                                                                                                                                                                                                    | The impact of COVID-19 has highlighted the risk to contimuity of clinical tials duuing times of study disnuption, whether by civil crisis, natual disaster or public health crisis. This section details the measures that may be implemented if a patient is not able to visit a study site to ensue that the clinmical tial can continue whilst minimizing risk to the patient, maintaining compliance with GCP, and minimizing risks to study integrity. These changes will only be imitiated at a time of shudy disnuption. |
|                                                        | Reduced the fequency of spiromety assessments to 12 week intervals (Visit 2, 6, 9, 13, 16, 17 ) in the Double-blind teatment period Spirometry is no longer required at IPD/EOT visit.                                                                                                                                                                                                                                  | To decrease patient and HCP exposuure to potential pathogens given COVID-19 pandemic.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                        | Added a bullet to Exclusion Criterion no 14: \"- Receipt of any other marketed or investigational biologic products within 4 months or 5 half lives prior to screening. whichever is longer? Modified Exclusion Criterion no 22: \"Other investigational non-biologic product: receipt of any investigational non-biologic product hrug within 30 days or 5 half-lives prior to screening (Visit 1) whichever is longer.\" | These changes were implemented to align with updated safety recommendations based on accumulated safety data                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Amendment Number/Date            | Key details of Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                      | Main reason(s) for Amendment                                                                                                                                                           |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  | Section 8.4.2.1: Modifed text, \"If a patient becomes pregiant dhuing the course of the shudy, IP should be discontimued immediately temporariy withheld and a conversation between the Investigator and a Study Physician has to take place to determine whether continuation on IP or discontinuation of IP is in the best interest of the patient\" Section 7.1 Patients will be discontimued from IP in the following situations: Removed bullet \"Pregnancy | These changes were implemented to follow cuurent sponsor safety recommendations in studies with bemralizumab                                                                           |
| 3 (Version 4.0) 24 Febnuary 2021 | This was a non-substantial amendment.                                                                                                                                                                                                                                                                                                                                                                                                                         | The protocol was amended to introduce the possibility of self/at-home administration of bemalizumab duing the OLE period of the study.                                                 |
| 4 (Version 5.0) 11 April 2023    | Added a new Schedule of Assessments presenting the assessments to be perfonmed dhuing Year 4 onwards in the OLE period.                                                                                                                                                                                                                                                                                                                                       | To ensture contimity of treatment for patients who would end Year 3 of the OLE period before all patients have been allowed at least one year of treatment with open-label bemalizmab. |
|                                  | Changed one secondary objective and clarified one corresponding secondaury endpoint and added corresponding secondary endpoints.                                                                                                                                                                                                                                                                                                                              | To assess the steroid sparing effect of treatment.                                                                                                                                     |
|                                  | Added a secondary objective.                                                                                                                                                                                                                                                                                                                                                                                                                                  | To combine ciurent endpoints to assess clinical benefit in a clinically relevant way.                                                                                                  |
|                                  | Added derivation of the new endpoints.                                                                                                                                                                                                                                                                                                                                                                                                                        | To present how the new endpoints will be derived.                                                                                                                                      |

HCP = healthcare provider; IP = investigational product; IPD = investigational product discontimuation;

COVID-19 = coronavinus disease 2019; EOT = end of treatment; GCP = Good Climical Practice;

OLE = Open-Label Extension

Changes to planned analysis related to protocol amendments were applied before unblinding of the study data and this is acceptable.

## Baseline data

EGPA disease history and baseline characteristics (Table 9) were summarized for each treatment group using descriptive statistics on FAS. Median age of subjects was 55 years. The majority of participants were between 18-65 years old. Gender representation was equally distributed between treatment groups.

<div style=\"page-break-after: always\"></div>

Table 9. EGPA Disease History and Baseline Characteristics

## EGPA Disease History and Baseline Characteristics (Full Analysis Set)

<!-- image -->

| Characteristics                                         | Statistics or category   | Benralizumab 30 mg (N= 70)   | Mepolizumab 300 mg (N= 70)   | Total (N =140)   |
|---------------------------------------------------------|--------------------------|------------------------------|------------------------------|------------------|
| EGPA disease history                                    |                          |                              |                              |                  |
| EGPA disease characteristics                            |                          |                              |                              |                  |
| Asthma, n (%)                                           | Yes                      | 70 (100.0)                   | 70 (100.0)                   | 140 (100.0)      |
|                                                         | No                       | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)          |
| Eosinophilia, n (%)                                     | Yes                      | 70 (100.0)                   | 70 (100.0)                   | 140 (100.0)      |
|                                                         | No                       | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)          |
| Biopsy Evidence of EOS Vasculitis/Inflammation, n (%) “ | Yes                      | 20 (28.6)                    | 33 (47.1)                    | 53 (37.9)        |
|                                                         | No                       | 50 (71.4)                    | 37 (52.9)                    | 87 (62.1)        |
| Neuropathy, n (%) b                                     | Yes                      | 38 (54.3)                    | 45 (64.3)                    | 83 (59.3)        |
|                                                         | No                       | 32 (45.7)                    | 25 (35.7)                    | 57 (40.7)        |
| Nonfixed pulmonary infiltrates, n (%)                   | Yes                      | 49 (70.0)                    | 43 (61.4)                    | 92 (65.7)        |
|                                                         | No                       | 21 (30.0)                    | 27 (38.6)                    | 48 (34.3)        |
| Sino-nasal abnommality, n (%)                           | Yes                      | 63 (90.0)                    | 66 (94.3)                    | 129 (92.1)       |
|                                                         | No                       | 7 (10.0)                     | 4 (5.7)                      | 11 (7.9)         |
| Cardiomyopathy (ECG/MRI), n (%) *                       | Yes                      | 17 (24.3)                    | 13 (18.6)                    | 30 (21.4)        |
|                                                         | No                       | 53 (75.7)                    | 57 (81.4)                    | 110 (78.6)       |
| Glomenlonephritis, n (%)                                | Yes                      | 4 (5.7)                      | 2 (2.9)                      | 6 (4.3)          |
|                                                         | No                       | 66 (94.3)                    | 68 (97.1)                    | 134 (95.7)       |
| Alveolar haemonhage, n (%)                              | Yes                      | 2 (2.9)                      | 2 (2.9)                      | 4 (2.9)          |
|                                                         | No                       | 68 (97.1)                    | 68 (97.1)                    | 136 (97.1)       |
| Palpable pupura, n (%)                                  | Yes                      | 7 (10.0)                     | 10 (14.3)                    | 17 (12.1)        |
|                                                         | No                       | 63 (90.0)                    | 60 (85.7)                    | 123 (87.9)       |
| Historical ANCA-positive, n (%)                         | Yes                      | 16 (22.9)                    | 20 (28.6)                    | 36 (25.7)        |
|                                                         | No                       | 54 (77.1)                    | 50 (71.4)                    | 104 (74.3)       |
| EGPA disease type                                       |                          |                              |                              |                  |
| Relapsing disease, n (%)                                | Yes                      | 45 (64.3)                    | 48 (68.6)                    | 93 (66.4)        |
|                                                         | No                       | 25 (35.7)                    | 22 (31.4)                    | 47 (33.6)        |

<div style=\"page-break-after: always\"></div>

## EGPADiseaseHistory andBaseline Characteristics(Full AnalysisSet)

<!-- image -->

| Characteristics                                 | Statisties or category   | Benralizumab 30mg (N=70)   | Mepolizumab 300mg (N=70)   | Total (N=140)   |
|-------------------------------------------------|--------------------------|----------------------------|----------------------------|-----------------|
| Reffactory disease,n(%)                         | s                        | 42 (60.0)                  | 42 (60.0)                  | 84 (60.0)       |
|                                                 | No                       | 28 (40.0)                  | 28 (40.0)                  | 56 (40.0)       |
| BothrelapsingandrefractoryEGPA, (%)u            | Yes                      | 18 (25.7)                  | 20 (28.6)                  | 38 (27.1)       |
|                                                 | No                       | 52 (74.3)                  | 50 (71.4)                  | 102 (72.9)      |
| Time since diagnosis of EGPA (year)             | n                        | 70                         | 70                         | 140             |
|                                                 | Mean (SD)                | 5.39 (5.378)               | 4.93 (5.919)               | 5.16 (5.639)    |
|                                                 | Median (min, max)        | 3.02 (0.6, 24.0)           | 2.18 (0.1,38.0)            | 2.84 (0.1,38.0) |
|                                                 | ≤4 yearsn (%)            | 37 (52.9)                  | 42 (60.0)                  | 79 (56.4)       |
|                                                 | 4 years n (%)            | 33 (47.1)                  | 28 (40.0)                  | 61 (43.6)       |
| Numberofrelapsesoverpast 2years                 | 0                        | 12 (17.1)                  | 13 (18.6)                  | 25 (17.9)       |
|                                                 | 1                        | 24 (34.3)                  | 20 (28.6)                  | 44 (31.4)       |
|                                                 | 2                        | 17 (24.3)                  | 17 (24.3)                  | 34 (24.3)       |
|                                                 | 3-5                      | 12 (17.1)                  | 16 (22.9)                  | 28 (20.0)       |
|                                                 | >S                       | 2 (2.9)                    | 2 (2.9)                    | 4 (2.9)         |
|                                                 | Not known                | 3 (4.3)                    | 2 (2.9)                    | 5 (3.6)         |
| Immumosuppressivetherapysince diagnosis, n (%)  | s                        | 41 (58.6)                  | 42 (60.0)                  | 83 (59.3)       |
|                                                 | No                       | 26 (37.1)                  | 27 (38.6)                  | 53 (37.9)       |
|                                                 | Not known                | 2 (2.9)                    | 1 (1.4)                    | 3 (2.1)         |
|                                                 | Missing                  | 1 (1.4)                    | 0 (0.0)                    | 1 (0.7)         |
| EGPAbaselinecharacteristics                     |                          |                            |                            |                 |
| Absolute eosinophil couut atbaseline (cells/uL) | n                        | 70                         | 70                         | 140             |
|                                                 | Mean (SD)                | 306.0 (225.02)             | 384.9 (563.60)             | 345.4 (429.39)  |
|                                                 | Median (min, max)        | 240.0 (30,920)             | 225.0(0,3830)              | 230.0 (0,3830)  |
|                                                 | <150n(%)                 | 20 (28.6)                  | 20 (28.6)                  | 40 (28.6)       |
|                                                 | ≥150n(%)                 | 50 (71.4)                  | 50 (71.4)                  | 100 (71.4)      |
| ANCA-positive at screening,n(%)                 | Yes                      | 7 (10.0)                   | 7 (10.0)                   | 14 (10.0)       |
|                                                 | No                       | 63 (90.0)                  | 63 (90.0)                  | 126 (90.0)      |
| Prednisolone or prednisone dose (mg/day)        | n                        | 70                         | 70                         | 140             |
|                                                 | Mean (SD)                | 11.09 (4.577)              | 10.95 (5.885)              | 11.02 (5.253)   |

<div style=\"page-break-after: always\"></div>

EGPA Disease History and Baseline Characteristics (Full Analysis Set)

<!-- image -->

| Characteristics                            | Statisties or category   | Benralizumab 30 mg (N= 70)   | Mepolizumab 300 mg (N = 70)      | Total (N=140)   |
|--------------------------------------------|--------------------------|------------------------------|----------------------------------|-----------------|
|                                            | Median (min, max)        | 10.00 (5.0,30.0)             | 10.00 (7.5,40.0)10.00 (5.0,40.0) |                 |
|                                            | c12mg/day                | 52 (74.3)                    | 56 (80.0)                        | 108 (77.1)      |
|                                            | ≥12mg/day                | 18 (25.7)                    | 14 (20.0)                        | 32 (22.9)       |
| Immmosuppressive therapy at baseline n (%) | Yes                      | 26 (37.1)                    | 24 (34.3)                        | 50 (35.7)       |
|                                            | No                       | 44 (62.9)                    | 46 (65.7)                        | 90 (64.3)       |
| BVAS                                       | n                        | 70                           | 70                               | 140             |
|                                            | Mean (SD)                | 2.3 (3.49)                   | 1.9 (2.92)                       | 2.1 (3.21)      |
|                                            | Median (min, max)        | 0.0 (0, 18)                  | 0.0 (0, 15)                      | 0.0 (0, 18)     |
|                                            | >0n(%)                   | 34 (48.6)                    | 33 (47.1)                        | 67 (47.9)       |
|                                            | = 0n(%)                  | 36 (51.4)                    | 37 (52.9)                        | 73 (52.1)       |
| VDI                                        | n                        | 70                           | 70                               | 140             |
|                                            | Mean (SD)                | 4.0 (1.80)                   | 4.0 (1.78)                       | 4.0 (1.78)      |
|                                            | Median (min, max)        | 4.0 (1, 9)                   | 4.0 (0, 10)                      | 4.0 (0, 10)     |
|                                            | ≥5n (%)                  | 23 (32.9)                    | 21 (30.0)                        | 44 (31.4)       |
|                                            | ≤5n(%)                   | 47 (67.1)                    | 49 (70.0)                        | 96 (68.6)       |
| ACQ-6                                      | n                        | 70                           | 70                               | 140             |
|                                            | Mean (SD)                | 1.35 (1.168)                 | 1.18 (1.083)                     | 1.26 (1.126)    |
|                                            | Median (min, max)        | 1.17 (0.0,4.5)               | 1.00 (0.0, 5.3)                  | 1.17 (0.0, 5.3) |
|                                            | ≤1.5 n (%)               | 39 (55.7)                    | 42 (60.0)                        | 81 (57.9)       |
|                                            | ≥1.5 n (%)               | 31 (44.3)                    | 28 (40.0)                        | 59 (42.1)       |
| SNOT-22 total score                        | n                        | 70                           | 70                               | 140             |
|                                            | Mean (SD)                | 32.7 (21.83)                 | 30.4 (21.32)                     | 31.6 (21.53)    |
|                                            | Median (min, max)        | 31.0 (0, 103)                | 25.0 (0, 89)                     | 29.0 (0, 103)   |
| IgE (mgL)                                  | n                        | 69                           | 68                               | 137             |
|                                            | Mean (SD)                | 0.36 (0.578)                 | 0.39 (0.521)                     | 0.38 (0.548)    |
|                                            | Median (min, max)        | 0.18 (0.0, 3.2)              | 0.19 (0.0, 2.4)                  | 0.18 (0.0, 3.2) |

Time since diagnosis of EGPA (year) = (Date of randomisation - EGPA first diagnosed date + 1)/365.25.

Percentages were based upon all patients in the Full Analysis Set.

Baseline was defined as the last measurement on or prior to the date of randomisation.

ACQ-6 = Asthma Control Questionnaire (6-item version); ANCA = anti-neutrophil cytoplasmic antibodies;

BVAS = Birmingham Vasculitis Activity Score; ECG = electrocardiogram; EGPA = eosinophilic granulomatosis with polyangiitis; EOS = eosinophil; IgE = immunoglobulin E; max = maximum; min = minimum;

MRI = magnetic resonance imaging; N = number of patients in treatment group; n = number of patients in analysis; SD = standard deviation; SNOT-22 = Sino-nasal Outcome Test-22; VDI = Vasculitis Damage Index

<div style=\"page-break-after: always\"></div>

The  majority  of  EGPA  disease  characteristics  were  comparable  between  the  two  treatment  arms.  The proportions of patients who discontinued IP or the study during the DB period were low and similar between groups. Of note, there was a marked difference in the number of patients with Biopsy Evidence of EOS Vasculitis/Inflammation at  baseline,  between  the  mepolizumab  group:  33  (47.1%)  compared  with  the benralizumab group 20 (28.6%). Based on a cross-study comparison with MIRRA, which is of equal size with MANDARA, the number of patients with Biopsy Evidence of EOS Vasculitis/Inflammation at baseline in the  mepolizumab  group  was  also  higher  [25(37%)],  compared  with  the  number  of  patients  in  the benralizumab group in MANDARA .

Regarding EGPA baseline characteristics, max value for Absolute eosinophil count at baseline (cells/uL ) for the mepolizumab group is significantly higher compared with the respective value for the benralizumab group, despite patients being equally balanced in the eosinophil count subgroups [&lt; 150 n (%) and ≥ 150 n (%)].Median (min, max):  Benralizumab: 240 .0 cells/μl (30, 920)] vs Mepolizumab: 225.0 cells/μl (0, 3830). Mean (SD):  Benralizumab: 306.0 cells/μl (225.02) vs Mepolizumab: 384.9 cells/μl (563.60) . Similar differences were also noted for Absolute eosinophil count at screening (cells/uL), where max value for the mepolizumab group reached 2650 cells/μl vs 960 cells/μl for the benralizumab group.

The above observations indicate imbalances in disease burden between the groups at baseline -imbalances that could benefit the benralizumab group. The Applicant was asked by the CHMP to provide an additional analysis  of  the  primary  endpoint  (remission  at  both  weeks  36  and  48).  In  this  analysis,  the  logistic regression model should be adjusted for Biopsy Evidence of EOS Vasculitis/Inflammation at baseline and max value  för  absolute  eosinophil  count,  in  addition  to  the  variables  included  in  the  primary  analysis (treatment arm, baseline dose of prednisone, baseline BVAS, region) (see discussion below).

## Numbers analysed

## Description of the populations used for analyses

The Enrolled  Analysis  Set :  all  patients  who  signed  the  informed  consent  form.  Patient  disposition  was analysed using the Enrolled Analysis Set.

The Full analysis set (FAS): All patients randomized and receiving at least one (1) dose of IP, irrespective of their protocol adherence and continued participation in the study. Patients were analyzed according to their randomized treatment irrespective of whether or not they have prematurely discontinued, according to the ITT principle. Patients who withdraw consent to participate in the study were included up to the date of their study termination. All efficacy analyses and demographics were analyzed using the Full Analysis Set.

The Per Protocol Analysis Set : subset of FAS consisting of all patients who were randomised and received treatment excluding any patients with protocol deviations affecting the primary efficacy endpoint

The Safety Analysis Set : all patients who received at least one dose of IP. Erroneously treated patients (e.g., those randomised to treatment A but actually given treatment B) are accounted for in the treatment group of the treatment they actually received (a patient who has on one or several occasions received benralizumab is classified as benralizumab).

The Pharmacokinetic analysis set: all patients who received benralizumab and from whom PK blood samples are assumed not to be affected by factors such as protocol violations and who had at least one quantifiable serum PK observation post first dose will be included in the PK analysis dataset. All PK summaries were based on this analysis set.

The OLE analysis set : all patients who enter the OLE part of the study and who received at least 1 dose of IP during the OLE treatment period.

<div style=\"page-break-after: always\"></div>

The Enrolled Analysis Set included a total of 140 patients and the Full Analysis Set included a total of 70 patients in each of the two treatment groups (Table 10):

## Table 10. Analysis Sets

|                                                  | Number of patients   | Number of patients   | Number of patients   |
|--------------------------------------------------|----------------------|----------------------|----------------------|
|                                                  | Benralizumab 30 mg   | Mepolizumab 300 mg   | Total                |
| Patients randomised                              | 70                   | 70                   | 140                  |
| Patients included in safety analysis set b       | 70                   | 70                   | 140                  |
| Patients excluded from safety analysis set       | 0                    | 0                    | 0                    |
| Patients included in FAS c                       | 70                   | 70                   | 140                  |
| Patients excluded from FAS                       | 0                    | 0                    | 0                    |
| Patients included in per protocol analysis set d | 63                   | 64                   | 127                  |
| Patients excluded from per protocol analysis set | 7                    | 6                    | 13                   |
| Patients included in PK analysis set e           | 67                   | 0                    | 67                   |
| Patients excluded from PK analysis set           | 3                    | 70                   | 73                   |
| Patients included in OLE amalysis set t          | 66                   | 62                   | 128                  |
| Patients excluded from OLE analysis set          | t                    | 8                    | 12                   |

- All patients who received at least one dose of IP were included in the safety analysis set.
- All patients randomised who received any IP were included in the FAS.
- All patients randomised and who received IP, excluding any patients with protocol deviations affecting the primary efficacy endpoint as noted in SAP Section 2.2.1, are included in the per protocol analysis set.
- All patients who received IP and from whom PK blood samples were obtained were assumed not to be affected by factors such as protocol violations and who had at least one quantifiable senum PK observation post first dose were inchuded in the PK amalysis dataset.
- All patients who entered the OLE part of the study and who received at least 1 dose of IP duing the OLE treahment period.

FAS = Full Analysis Set; ICF = Infommed Consent Formr; IP = investigational product; PK = phamacokinetic(s); SAP = Statistical Analysis Plam; OLE = Open-label extension

## Outcomes and estimation

## Primary endpoint

Proportion of Patients who Achieved Main Remission at Both Weeks 36 and 48

Benralizumab was NI to mepolizumab as demonstrated by the lower bound of 95% CI falling well above the prespecified clinical NI margin of -25% for the difference in main remission rate only at both Weeks 36 and 48 (Table 11). More than half of patients achieved main remission at both Weeks 36 and 48 in the benralizumab group and in the mepolizumab group.

Table 11. Proportion of Patient who Achieved Main Remission at both Week 36 and 48, Treatment Comparison, Logistic Regression Using Marginal Standardisation Method (Full Analysis Set)

<div style=\"page-break-after: always\"></div>

Tablel ProportionofPatientswhoAchievedMfainRemissionatbothWeeks36 and48.TreatmentComparison,LogisticRegressionUsingMarginal StandardisationMfethod(FullAnalysisSet)

<!-- image -->

|                 |                          |                                            |                            | Comparisonbetveengroups           | Comparisonbetveengroups   | Comparisonbetveengroups   |
|-----------------|--------------------------|--------------------------------------------|----------------------------|-----------------------------------|---------------------------|---------------------------|
| Remiccion       | Treatmentgroup           | Number(%) ofpatients whoachiered reinision | Adjusted remision rate(%)) | Difference in remiscion rates(%)- | 10%696                    | P-ralue\"                  |
| Main remission  | Benralizumab 30mg(N=70)  | 40 (67.1)                                  | 67.7                       | 1.21                              | -14.11,16.53              | 0.8773                    |
|                 | Mepolizumab 300 mg(N=70) | 40(57.1)                                   | 56.5                       |                                   |                           |                           |
| OCSdose 4mg/day | Benralizumab 30mg(N=70）  | 42(60.0)                                   | 60.6                       | 2.64                              | -12.67,17.95              | 0.7354                    |
|                 | Mepolizumab 300 mg(N=70) | 41(58.6)                                   | 58.0d                      |                                   |                           |                           |
| BVAS=0          | Benralizumab 30mg(N=70)  | 58(82.9)                                   | 83.0                       | -1.17                             | -13.27,10.94              | 0.8502                    |
|                 | Mepolizumab 300 mg(N=70) | 59(84.3)                                   | 84.2                       |                                   |                           |                           |

- 2-sided p-value testing differences between treatument goups(equivalent to a l-sided 0.025 level).

Adjusted remissionrate in mepolizumabpoup changed due to the change in dataset fitted to the model Mainremissionwas defined a:BVAS=O and OCS dose≤4 mg/day(in the eventapatient had achieved remission and at any subsequent visit had a BVAS=l which did not require an increase in OCS dose above

4mg/day,orany other signifieantclinical intervention orinvestigation,thepatientwasconsidered to be in continuedremission)

BVAS=Bimingham Vasculitis Aetivity Score;CI=confidence interval; N=number ofpatient in treatment group:NI=non-infenority,OCS=onlcorticosteroids.

Source:Table14.2.1.1.1

A significantly higher proportion of patients who received benralizumab achieved remission at both Weeks 36 and 48 compared with the historical placebo control from the MIRRA study (Table 12):

Table 12. Proportion of Patient who Achieved Main Remission at both Week 36 and 48, Comparison with Historical Placebo, 2 Sample Test (Full Analysis Set)

|                           |                                                    | Comparison between groups         | Comparison between groups   | Comparison between groups   |
|---------------------------|----------------------------------------------------|-----------------------------------|-----------------------------|-----------------------------|
| Treatment group [a]       | Number (%) of patients who achieved main remission | Difference in remission rates (%) | 95% CI                      | P-value                     |
| Benralizumab 30 mg (N=70) | 40 (57.1)                                          | 54.2                              | 41.93, 66.47                | < 0.0001                    |
| Historical Placebo (N=68) | 2 (2.9)                                            | -                                 | -                           | -                           |
|                           | 40 (57.1)                                          | 24.8                              | 8.73, 40.85                 | 0.0034                      |

<div style=\"page-break-after: always\"></div>

| Mepolizumab 300 mg (N=70)             |           |    |    |    |
|---------------------------------------|-----------|----|----|----|
| Historical Mepolizumab 300 mg (N= 68) | 22 (32.4) | -  | -  | -  |

CI Confidence Interval. N Number of subjects in treatment group. n Number of subjects in analysis. BVAS Birmingham Vasculitis Activity Score. OCS Oral corticosteroids.

Main remission is defined as BVAS=0 and OCS dose &lt;= 4 mg/day (in the event a subject has achieved remission and at any subsequent visit has a BVAS=1 which does not require an

increase in OCS dose above 4 mg/day, or any other significant clinical intervention or investigation, the subject will be considered to be in continued remission).

The historical placebo remission rate and historical mepolizumab remission rate are gathered from subjects observed within the phase 3 trial, MIRRA (Wechsler et al 2017).

[a] The p-value is evaluated with a 2-sample test for binomial proportions using a one-sided test of Benralizumab having an improved rate over placebo with a 2.5% significance level.

Performance of Mepolizumab Comparator Arm with regards to remission rate in MANDARA was higher compared to that observed in MIRRA study (57.1% vs 32.4%, 95% CI [8.73, 40.85]; P = 0.0034)

For the justification of the difference in performance of Mepolizumab Comparator Arm on the proportion of patients who achieved remission at both Weeks 36 and 48 in MANDARA, in comparison with the historical placebo control from MIRRA study, the applicant summarized data from 2 real-world studies. In these studies (N=203, remission definition: BVAS = 0 and OCS ≤ 4 mg/day; N=51 patients remission definition: BVAS = 0 and OCS ≤ 5 mg/day) highly variable remission rates of 31-76% and 37-82% were observed for treatment with 100 mg and 300 mg doses of mepolizumab, respectively. Furthermore, higher treatment effects are generally observed in active comparator trials compared with the placebo-controlled trials.

A tipping point analysis was also conducted to assess the robustness of the indirect comparison to historic placebo (Figure 3). In the analysis, the number of patients meeting the remission endpoint were updated under varying assumptions for the different treatment groups independently. For any given number of patients meeting remission in the benralizumab group, non-responders in the historic placebo arm (66/68 patients) were converted to responder status one at a time. In each scenario evaluated, the superiority of benralizumab over the historic placebo was evaluated at the 2-sided 0.05 level to identify the point at which the result tipped from significant (p &lt; 0.05) to non-significant (p ≥ 0.05).

<div style=\"page-break-after: always\"></div>

Figure 3. Sensitivity Analysis: Proportion Of Subjects Who Achieved Main Remission At Both Weeks 36 And 48, Treatment Comparison, Two Sample Test, Tipping Point Analysis (Full Analysis Set)

0

<!-- image -->

Main remission at both weeks 36 and 48 is defined as BVAS=0 and OCS dose &lt;= 4 mg/day (in the event a subject has achieved remission and at any subsequent visit has a BVAS=1 which does not require an increase in OCS dose above 4 mg/day, or any other significant clinical intervention or investigation, the subject will be considered to be in continued remission). The historical placebo remission rate is gathered from subjects observed within the phase 3 trial. For any given number of subjects meeting remission in the benralizumab group, non-responders in the historical placebo arm (66/68 patients) are converted to responder status one at a time. In each scenario evaluated, the superiority of benralizumab over the historical placebo is evaluated at the 2-sided 5% level to identify the point at which the result tips from significant to non-significant. The dots are presenting the results: filled = p-value &lt;0.05 (significant), open = p-value &gt;=0.05 (non-significant).

With the observed benralizumab remission rate in MANDARA, it would require 26 additional patients in the placebo group to tip the result of the primary endpoint from significance to non-significance, which is more than 10 times the number of patients who achieved remission on placebo in MIRRA.

Similar response rates were observed between benralizumab and mepolizumab groups for the proportion of patients who achieved main remission at both Weeks 36 and 48 when using the supportive remission definition (defined as BVAS = 0 and OCS ≤ 7.5 mg/day), see Table 13.

<div style=\"page-break-after: always\"></div>

Table 13. Proportion Of Subjects Who Achieved Remission (Main Remission And Supportive Remission) At Both Week 36 And 48, Treatment Completion, Logistic Regression Using Marginal Standardisation Method (Full Analysis Set)

|                      |                           |                                 |                    | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   | Comparison between groups   |
|----------------------|---------------------------|---------------------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                      |                           | Number (&) of subjects achieved | Adjusted remission | Adjusted remission          | Difference                  | Difference                  | in remission                | in remission                | in remission                |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| Remission            | Treatment group           | remission                       | rate (8）[a]        |                             |                             | rates                       | (8） [a]                     | 958 CI [b]                  | P-value [c]                 |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| Supportive remission | Benralizumab 30 mg (N=70) | 55 (78.6)                       | 79.0               |                             |                             | 5.44                        |                             | (-7.46, 18.34)              | 0.4085                      |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                      | Mepolizumab 300 mg (N=70) | 52 (74.3)                       | 73.6               |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| oCSdose<= 7.5 mg/day | Benralizumab 30mg (N=70)  | 61 (87.1)                       | 87.0               |                             |                             | 7.25                        |                             | (-4.22,18.72)               | 0.2153                      |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                      | Mepolizumab 300 mg (N=70) | 56 (80.0)                       | 79.8               |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |

Consistent with the main analysis outcome are the results from sensitivity analyses using the per-protocol population [subjects who were randomised and received treatment excluding subjects (n=13) with protocol deviations affecting the primary efficacy endpoint] shown in Table 14:

<div style=\"page-break-after: always\"></div>

Table 14. Sensitivity Analysis: Proportion Of Subjects Who Achieved Remission At Both Week 36 And 48, Treatment Comparison, Logistic Regression Using Marginal Standardisation Method (Per Protocol Population)

|                        |                           |                                                |                                 | Comparisonbetweengroups           | Comparisonbetweengroups   | Comparisonbetweengroups   |
|------------------------|---------------------------|------------------------------------------------|---------------------------------|-----------------------------------|---------------------------|---------------------------|
| Remission              | Treatmentgroup            | Number (%) of subjects achieved main remission | Adjusted remission rate (%) [a] | Difference in remission rates [a] | 95%CI[b]                  | P-value [c]               |
| Main remission         | Benralizumab 30 mg (N=63) | 36 (57.1)                                      | 57.1                            | -2.40                             | (-18.25, 13.45)           | 0.7663                    |
|                        | Mepolizumab 300 mg (N=64) | 38 (59.4)                                      | 59.5                            |                                   |                           |                           |
| OCS dose <= 4 mg/day   | Benralizumab30 mg(N=63)   | 38 (60.3)                                      | 60.3                            | -0.56                             | (-16.39, 15.27)           | 0.9447                    |
|                        | Mepolizumab 300 mg (N=64) | 39 (60.9)                                      | 60.9                            |                                   |                           |                           |
| BVAS=0                 | Benralizumab 30 mg (N=63) | 54 (85.7)                                      | 85.5                            | -3.75                             | (-15.03, 7.54)            | 0.5152                    |
|                        | Mepolizumab 300 mg (N=64) | 57 (89.1)                                      | 89.3                            |                                   |                           |                           |
| Supportive remission   | Benralizumab 30 mg (N=63) | 49 (77.8)                                      | 77.9                            | 1.44                              | (-11.81, 14.69)           | 0.8308                    |
|                        | Mepolizumab300mg(N=64)    | 49 (76.6)                                      | 76.4                            |                                   |                           |                           |
| OCS dose <= 7.5 mg/day | Benralizumab 30 mg (N=63) | 54 (85.7)                                      | 85.6                            | 4.54                              | (-7.35, 16.44)            | 0.4542                    |
|                        | Mepolizumab 300 mg (N=64) | 52 (81.3)                                      | 81.1                            |                                   |                           |                           |

egression model. The covariates in the model include treatment arm, baseline dlose of prednisone, baseline BVAS and region (North

a] The remission rates and the difference (Beoralizumak - Mepolizumab) are estimated using marginal standardization method in a logistic

America, Western Europe, and Japan). Baseline is defined as the last measurement on or prior to the date of randomization.

b] Non-inferiority test is assessed using a Nl margin of -25%. The lower 95% confidence limit for the absolute difference between Beoralizuwwek and Mepolizumab remission rates needs to be above the NI margin of -25%.

c] This is the p-value for superiority test.

Per-protocol population is defined as subjects who were randlomised and received treatment excluding any subjects with protocol deviations affecting the primary efficacy endpoint as noted in SAP Section 2.2.1.

Additional analysis of remission response over time demonstrated that in both treatment groups, remission response rates increased similarly over time up to Week 36 and remained consistent for the end of the DB period/Week 52 (Line Plot Figure 4):

Figure 4. Proportion Of Patients Who Achieved Main Remission By Timepoint - Line Plot (Full Analysis Set)

<!-- image -->

## Secondary Endpoints

<div style=\"page-break-after: always\"></div>

Superiority of benralizumab compared to mepolizumab was tested using the same logistic regression model at the 2-sided 0.05 level per the statistical analysis plan of the study.

## Total Accrued Duration of Remission

Total  accrued  duration  of  main  remission  was  similar  in  the  benralizumab  group  compared  with  the mepolizumab group (table 15). A total of 61 patients (87.1%) and 55 patients (78.5%) in the benralizumab and mepolizumab groups, respectively, achieved remission at any time during the DB period, 1 of the 3 components included in the clinical benefit endpoint.

Table 15. Total Accrued Duration (Weeks) of Remission, Treatment Comparison, Proportional Odds Model (Full Analysis Set)

|                     |                             |           |                   |                  |                  |            | Comparison between groups a   | Comparison between groups a   | Comparison between groups a   |
|---------------------|-----------------------------|-----------|-------------------|------------------|------------------|------------|-------------------------------|-------------------------------|-------------------------------|
| Remission           | Treatment group             | 0 Weeks   | > 0 to < 12 Weeks | 12 to < 24 Weeks | 24 to < 36 Weeks | ≥ 36 Weeks | Odds ratio                    | 95% CI                        | P-value                       |
| Main remission      | Benralizumab 30 mg (N = 70) | 9 (12.9)  | 13 (18.6)         | 8 (11.4)         | 20 (28.6)        | 20 (28.6)  | 1.32                          | 0.72, 2.40                    | 0.3653                        |
| Main remission      | Mepolizumab 300 mg (N = 70) | 15 (21.4) | 10 (14.3)         | 8 (11.4)         | 19 (27.1)        | 18 (25.7)  | -                             | -                             | -                             |
| OCS dose ≤ 4 mg/day | Benralizumab 30 mg (N = 70) | 9 (12.9)  | 11 (15.7)         | 9 (12.9)         | 19 (27.1)        | 22 (31.4)  | 1.27                          | 0.70, 2.31                    | 0.4371                        |
| OCS dose ≤ 4 mg/day | Mepolizumab 300 mg (N = 70) | 12 (17.1) | 12 (17.1)         | 8 (11.4)         | 18 (25.7)        | 20 (28.6)  | -                             | -                             | -                             |
| BVAS = 0            | Benralizumab 30 mg (N = 70) | 0         | 0                 | 2 (2.9)          | 6 (8.6)          | 62 (88.6)  | 1.50                          | 0.54, 4.15                    | 0.4312                        |
| BVAS = 0            | Mepolizumab 300 mg (N = 70) | 0         | 2 (2.9)           | 2 (2.9)          | 7 (10.0)         | 59 (84.3)  | -                             | -                             | -                             |

a The odds ratio (benralizumab vs mepolizumab) and its 95% CI were estimated with a proportional odds model. The covariates in the model included treatment arm, baseline dose of prednisone, baseline BVAS and region. A &gt; 1 odds ratio means benralizumab is favoured.

Main remission was defined as BVAS = 0 and OCS dose ≤ 4 mg/day (in the event a patient had achieved remission and at any subsequent visit had a BVAS = 1 which did not require an increase in OCS dose above 4 mg/day, or any other significant clinical intervention or investigation, the patient was considered to be in continued remission).

BVAS = Birmingham Vasculitis Activity Score; CI = confidence interval; N = number of patients in treatment group; OCS = oral corticosteroid

Source: Table 14.2.1.2.1

Results for total accrued duration of remission using the supportive remission definition of BVAS = 0 and OCS ≤ 7.5 mg/day for the benralizumab group compared with the mepolizumab group were consistent with those of the main remission definition.

<div style=\"page-break-after: always\"></div>

Total duration of sustained remission is defined as the longest uninterrupted period of weeks where BVAS=0 plus OCS dose of prednisolone/prednisone ≤4 mg/day over the 52-week study treatment period. The results from the supportive analysis of total duration of sustained (uninterrupted) remission during the DB period were comparable between the two treatment groups [95% CI]: 1.34 [0.74, 2.44]) (Table 16).

Table 16. Total Accrued Duration (Weeks) Of Sustained Remission (Main Remission And Supportive Remission) During DB Treatment Period, Proportional Odds Model (Full Analysis Set)

|                                              |                                              | Number (%) of subjects   | Number (%) of subjects   | Number (%) of subjects   | Number (%) of subjects   | Number (%) of subjects   | Comparisonbetweengroups[a]   | Comparisonbetweengroups[a]   | Comparisonbetweengroups[a]   |
|----------------------------------------------|----------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------------|------------------------------|------------------------------|
| Remission                                    | Treatmentgroup                               | 0 weelcs                 | >0 to <12 weeks          | 12 to ≤24 weeks          | 24 to =36 weeks          | >=36 weelks              | Odds ratio                   | 95%CI                        | P-value                      |
| Main remission                               | Benralizumab 30 mg (N=70)                    | 9 (12.9)                 | 15 (21.4)                | 11 (15.7)                | 16 (22.9)                | 19 (27.1)                | 1.34                         | (0.74, 2.44)                 | 0.3330                       |
|                                              | Mepolizumab 300 mg (N=70)                    | 15 (21.4)                | 13 (18.6)                | 8 (11.4)                 | 18 (25.7)                | 16 (22.9)                |                              |                              |                              |
| Supportive remissionBenralizumab30 mg (N=70) | Supportive remissionBenralizumab30 mg (N=70) | 2 (2.9)                  | 5 (7.1)                  | 8 (11.4)                 | 18 (25.7)                | 37 (52.9)                | 1.23                         | (0.64, 2.34)                 | 0.5318                       |
| Mepolizumab 300 mg (N=70)                    | Mepolizumab 300 mg (N=70)                    | 4 (5.7)                  | 6 (8.6)                  | 10 (14.3)                | 14 (20.0)                | 36 (51.4)                |                              |                              |                              |

CI Confidence Interval. N Number of subjects in treatment group. n Number of subjects in analysis. BVAS Bimingham Vasculitis Activity Score. OCS Oral corticosteroids.

[a] The odds ratio (Benralizumab vs. Mepolizumab) for 24 or more iveeks of accruedl duration of remission and its 95% CI are estimated with a proportional odds model. The covariates in the model include treatment armm, baseline dose of prednisone, baseline BVAS and region.

The total duration of sustained main remission main remission definition) is dlefined as the longest uminterrupted period of weeks where BVAS=0 and OCS dose of prednisolone/prednisone &lt;= 4 mg/day over the 52-week treatment period (in the event a subject has achieved remission and at any subsequent visit has a BVAS=1 which does not require an increase in OCS dose above 4 Kep/au or any other significant clinical intervention or investigation, the subject will be considered to be in continued remission).

The total duration of sustained supportive remission is defined as the longest uminterrupted period of weeks where BVAS=0 and OCS dose of prednisolone/prednisone &lt;= 7.5mg/day over the 52-week treatment period (in the event a subject has achieved remission and at any subsequent visit has a BVAS=1 which does not require an increase in OCS dose above 7.5 mg/day, or any other significant clinical intervention or investigation, the subject will be considered to be in continued remission).

Baseline is defined as the last measurement on or prior to the date of randlomisation.

A sensitivity analysis performed on the patient population that was administered OCS for only treating EGPA demonstrated that the percentage of patients achieving a total accrued duration of remission was similar between the mepolizumab and benralizumab groups.

## Time to First Relapse

The time to first relapse was similar in patients in the benralizumab group compared with the mepolizumab group  (Table  17  and  Figure  5).  Major  relapse  occurred  during  the  DB  period  in  0  patients  in  the benralizumab group and 3 patients (4.3%) in the mepolizumab group.

<div style=\"page-break-after: always\"></div>

Figure 5. Time to First Relapse - Kaplan Meier Plot (Full Analysis Set)

<!-- image -->

The time to relapse = start date of relapse - date of randomisation + 1. If a patient did not experience a relapse by Week 52, their time to relapse was right-censored at the last available assessment time. The relapse was defined as worsening or persistence of active disease characterized by: active vasculitis (BVAS &gt; 0); or active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; or active nasal and/or sinus disease, with a corresponding worsening in at least 1 of the sino-nasal symptom questions; warranting: an increase of OCS therapy; or an increased dose or addition of an immunosuppressive agent or hospitalization related to EGPA worsening.

1 patient had first relapse after Week 52.

The lower bound and upper bound of the 95% CI of the estimated proportion of patients with relapse by Week 16, Week 32 and Week 52 are marked on the lines.

ACQ-6 = Asthma Control Questionnaire (6-item version); BVAS = Birmingham Vasculitis Activity Score; CI = confidence interval; EGPA = eosinophilic granulomatosis with polyangiitis; HR = hazard ratio; N = Number of patients in treatment group; OCS = oral corticosteroids

Source: Figure 14.2.1.3

<div style=\"page-break-after: always\"></div>

Table 17. Time to First Relapse and Time to First Major Relapse, Cox-proportional hazard model (Full analysis set)

<!-- image -->

|               |                                                        | Benralizumab 30 mg (N=70)   | Mepolizumab 300 mg (N=70)   |
|---------------|--------------------------------------------------------|-----------------------------|-----------------------------|
| Relapse       | Number (&) of subjects with relapse                    | 21 (30.0)                   | 21 (30.0)                   |
|               | Time to first relapse (weeks) (95s CI) [a]             |                             |                             |
|               | 1st quartile                                           | 40.43 (23.14,NE)            | 38.57 (24.14, NE)           |
|               | Median                                                 | NE (NE,NE)                  | NE (NE，NE)                  |
|               | 3rd quartile                                           | NE (NE, NE)                 | NE (NE，NE)                  |
|               | Percent subject with at least one relapse (95& CI) [a] |                             |                             |
|               | By Week 16                                             | 5.71 (2.18, 14.51)          | 4.29 (1.40,12.70)           |
|               | By Week 32                                             | 17.14 (10.12, 28.21)        | 20.24 (12.52,31.77)         |
|               | By Week 52                                             | 30.00 (20.71，42.21)         | 29.10 (19.85, 41.40)        |
|               | P-value for unstratified log-rank test                 | 0.9466                      |                             |
|               | Hazard ratio （95 CI)[b]                                | 0.98 (0.53, 1.82)           |                             |
| Major Relapse | Number (8) of subjects with major relapse              | 0                           | 3 (4.3)                     |
|               | Time to first relapse (weeks) (95 CI) [a]              |                             |                             |
|               | 1st quartile                                           | NE  (NE, NE)                | NE (53.00, NE)              |
|               | Median                                                 | NE (NE, NE)                 | NE (NE, NE)                 |
|               | 3rd quartile                                           | NE (NE, NE)                 | NE (NE, NE)                 |
|               | Percent subjectwith at least one relapse (95g CI)[a]   |                             |                             |
|               | By Week 16                                             | 0.00 (0.00，0.00)            | 0.00 (0.00,0.00)            |
|               | By Week 32                                             | 0.00 (0.00,0.00)            | 0.00 (0.00,0.00)            |
|               | By Week 52                                             | 0.00 (0.00,0.00)            | 2.94 (0.74, 11.25)          |
|               | P-value for unstratified log-rank test                 | 0.0784                      |                             |
|               | Hazard ratio (958 CI)[b]                               | Not calculable              |                             |

## Annualised Relapse Rate

Relapse was defined as worsening or persistence of active disease characterised by: active vasculitis (BVAS &gt; 0); or active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; or active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions; warranting: an increase of OCS  therapy; or an increased dose or addition of an immunosuppressive agent or hospitalisation related to EGPA worsening. Major relapse was a subset of the total relapse events and was defined as any organ or life-threatening EGPA event, BVAS ≥ 6, an asthma relapse requiring hospitalisation, or sino-nasal relapse requiring hospitalisation. During the DB period, the number  of  EGPA  relapses  reported  for  patients  treated  with  benralizumab  (n=34)  was  slightly  higher compared to the respective number (n=30) reported for patients treated with mepolizumab. The annualised relapse rate was similar in the benralizumab group compared with the mepolizumab group. The rate ratio is 1.03 (95% CI: [0.56, 1.90], p=0.9282). The types of relapses (vasculitis, asthma, and sino-nasal) were similar for both patient treatment groups. Major relapse occurred during the DB period in 0 patients in the benralizumab group and 3 patients (4.3%) in the mepolizumab group.

## Average Daily Dose of OCS

<div style=\"page-break-after: always\"></div>

During  Weeks  48  to  52,  a  higher  proportion  of  patients  treated  with  benralizumab  compared  with mepolizumab had a 100% reduction in OCS. Reductions of at least 50% in the average daily dose of OCS were  observed  in  numerically  higher  proportions  of  patients  receiving  benralizumab  compared  with mepolizumab, 1 of the 3 components included in the clinical benefit endpoint.

Interestingly, a similar proportion of patients achieved an average daily OCS dose of ≤ 4 mg/day in the two treatment groups (48 patients [68.6%] in the benralizumab group vs 49 [70%] in the mepolizumab group), and similar proportions of patients achieved OCS dose ≤ 7.5 mg/day (63 patients [90.0%] in the benralizumab group and 62 patients [88.6%] in mepolizumab group).

Reduction  in  average  daily  dose  of  OCS  from  baseline  was  possible  in  a  majority  of  patients  in  both treatment  groups  as  shown  in  Table  22;  only  3  patients  in  benralizumab  group  and  7  patients  in mepolizumab group had no reduction in OCS or withdrew from IP before Week 48. A similar reduction in mean average daily OCS dose from baseline was observed in patients treated with benralizumab compared with mepolizumab starting at Weeks 5 to 8 through the DB period (Figure 6).

Figure 6. Mean Average Daily Dose of Prednisolone/Prednisone by Timepoint, Line Plot (Full Analysis Set)

<!-- image -->

Consistent findings were obtained in a sensitivity analysis on the patient population who achieved remission at weeks 36 and 48 using OCS only for treating oEGPA.

## Remission within the First 24 Weeks and Remaining in Remission for the Remainder of the Double-Blind Period

Similar proportions of patients in the benralizumab group compared with the mepolizumab group achieved remission within the first 24 weeks of treatment and remained in remission through Week 52. Results for total accrued duration of remission using the supportive remission definition of BVAS = 0 and OCS ≤ 7.5 mg/day for the benralizumab group compared with the mepolizumab group were consistent with those of the main remission definition.

## Clinical benefit

<div style=\"page-break-after: always\"></div>

The proportions of patients who achieved any clinical benefit were high and similar in both treatment groups (Table 18). Similar proportions of patients in the benralizumab group compared with the mepolizumab group achieved complete response.

Table 18. Proportion Of Patients Who Achieved Any Clinical Benefit And Patient Who Achieved Complete Response, Logistic Regression Using Marginal Standardisation Method (Full Analysis Set)

|                      |                           |                                              |                            | Comparison betveen groups a      | Comparison betveen groups a   | Comparison betveen groups a   |
|----------------------|---------------------------|----------------------------------------------|----------------------------|----------------------------------|-------------------------------|-------------------------------|
|                      | Treatment group           | Number (%) of patients who achieved response | Adjusted response rate (%) | Difference in response rates (%) | 10%96                         | P-value                       |
| Any clinical benefit | Benralizmab 30 mg (N=70)  | 66 (94.3)                                    | 94.4                       | 4.60                             | -4.22, 13.41                  | 0.3068                        |
|                      | Mepolizumab 300 mg (N=70) | 63 (90.0)                                    | 89.8                       |                                  |                               |                               |
| Complete response    | Benralizmab 30 mg (N=70)  | 43 (61.4)                                    | 62.5                       | 7.90                             | -7.32, 23.12                  | 0.3088                        |
| Complete response    | Mepolizumab 300 mg (N=70) | 39 (55.7)                                    | 54.6                       |                                  |                               |                               |

- 。 Main remission (defined as BVAS = 0 and OCS dose ≤ 4 mg/day) at any time duing the double-blind treatment period
- ≥ 50% reduction in average daily OCS dose during Weeks 48 through 52
- EGPA relapse free during the double-blind treatment period.

Complete response was defined as meeting all the criteria above.

BVAS=BiminghamVasculitis ActivityScore;CI=confidence interval;EGPA =eosinophilicgranulomatosis with polyangiitis.N=mumber ofpatients in treatment group; OCS =oral corticosteroid

The results from the analysis for the supportive remission definition were consistent with those based on the main remission definition.

## Secondary Endpoints for the assessment of additional measures of efficacy and health status/health-related quality of life

BVAS: Similar decreases from baseline LS mean BVAS were observed in the benralizumab and mepolizumab groups over the 52-week DB period.

VDI: VDI documents features of vasculitis due to persistent damage, without disease activity. Damage is defined as the presence of nonhealing scars. VDI has a range of 0 to 64. A score of 0 indicates no damage. Similar and small increases were observed in LS mean change from baseline VDI in the benralizumab and mepolizumab groups at Week 52 (0.13 vs 0.10, respectively). The LS mean difference between treatment groups was 0.03 (95% CI: [-0.10, 0.16], p = 0.6799).

## Patient reported outcome endpoints

ACQ-6: Similar improvements in mean ACQ-6 score from baseline to Weeks 48 through 52 were observed in  the  benralizumab  group  (-0.57)  and  the  mepolizumab  group  (-0.61),  both  of  which  were  clinically meaningful. The LS mean difference between treatment groups was 0.05 (95% CI: [-0.18, 0.27], p = 0.6730). Similar proportions of patients in the benralizumab and mepolizumab groups achieved ACQ-6 response (defined as a decrease in score from baseline of at least 0.5) to Weeks 48 through 52 (41.8% and 48.0%, respectively). The difference in response rates was -6.16% (95% CI: [-18.52, 6.21], p = 0.3290).

SF-36v2: Similar changes from baseline at Week 52 were observed in the benralizumab and mepolizumab groups in LS mean SF-36v2 MCS (1.13 and 2.19, respectively) and LS mean SF-36v2 PCS (0.29 and 2.45, respectively). Similar proportions of patients in the benralizumab and mepolizumab groups achieved SF36v2 MCS response at Week 52 (37.1% vs 28.6%, respectively). The difference in response rates was 6.43% (95% CI: [-7.09, 19.96], p = 0.3513). Similar proportions of patients in the benralizumab and

<div style=\"page-break-after: always\"></div>

mepolizumab groups achieved SF-36v2 PCS response at Week 52 (24.3% vs 37.1%, respectively). The difference in response rates was -11.77% (95% CI: [-26.21, 2.67], p = 0.1102).

SNOT-22: Similar reductions from baseline SNOT-22 were observed in the benralizumab and mepolizumab groups over the 52-week DB period. Though a minimal clinically important difference in SNOT-22 score has not been established in EGPA, neither group met the thresholds established in previous research in chronic rhinosinusitis.

SSQ: Similar  minimal  changes  from  baseline  in  SSQ  scores  were  observed  in  the  benralizumab  and mepolizumab groups over the 52-week DB period.

PGIS and PGIC: Similar changes from baseline PGIS were observed in the benralizumab and mepolizumab groups over the 52-week DB period. A greater proportion of patients provided a response in the milder categories (mild, very mild, and no symptoms) at Week 52 than at baseline in both treatment groups. The most common category at baseline was 'moderate' for both groups, while at Week 52 the most common response was 'very mild' for both groups. By Week 4, patients in the benralizumab and mepolizumab groups were reporting similar levels of improvement in health status measured by PGIC from baseline (most common response  for  both  groups  was  'about  the  same'  at  Week  4),  without  discernible  pattern  of difference.

WPAI-GH: Similar changes from baseline were observed in WPAI-GH total score in the benralizumab and mepolizumab groups over the 52-week DB period. Similar improvements in change from baseline mean WPAI-GH activity impairment scores were also observed in the benralizumab and mepolizumab groups at Week 52 (-3.28 and -7.78, respectively).

Spirometry: Similar  changes  from  baseline  FEV1  and  FVC  were  observed  in  the  benralizumab  and mepolizumab groups over the 52-week DB period.

## Ancillary analyses

The Forest Plot in Figure 7 shows the analysis of the primary endpoint in prespecified subgroup populations accounting for eleven patient characteristics (blood eosinophil count at baseline, BMI, OCS dose at baseline, gender age group, region, time since EGPA diagnosis, immunosuppressive therapy at baseline, VDI score, race, ANCA -positive status). Two nominal interactions with Pvalue &lt; 0.05 were observed for the subgroups of immunosuppressant use at baseline and for baseline VDI score. In the benralizumab group, the remission rates for immunosuppressant use at baseline subgroups were consistent with the overall remission rate.

<div style=\"page-break-after: always\"></div>

Figure 7. : Subgroup Analysis: Proportion of Patients Who Achieved Main Remission at Both Weeks 36 and 48, Treatment Comparison by Subgroups, Logistic Regression Using Marginal Standardisation Method - Forest Plot (Full Analysis Set)

<!-- image -->

|                         | Benra 30mg N, n(%)   | Mepo 300mg N, n(%)   |                          | Difference in remission rate (95% CI)   |
|-------------------------|----------------------|----------------------|--------------------------|-----------------------------------------|
| Overall                 | 70,40 (57.1)         | 70,40 (57.1)         |                          | 1.21 (-14.11, 16.53)                    |
| Blood eosi nophil count |                      |                      |                          |                                         |
| <150 cells/uL           | 20,12 (60.0)         | 20,12 (60.0)         |                          | 1.30 (-26.54, 29.14)                    |
| >=150 cells/uL          | 50,28 (56.0)         | 50,28 (56.0)         |                          | 1.43 (-16.71, 19.57)                    |
| Body mass index         |                      |                      |                          |                                         |
| <=30 kgm2               | 58,34 (58.6)         | 51,31 (60.8)         |                          | -2.72 (-19.57, 14.12)                   |
| >30 kg/m2               | 12,6 (50.0)          | 19.9 (47.4)          |                          | 11.80 (-23.13, 46.73)                   |
| OCSuse atbaseline       |                      |                      |                          |                                         |
| <12 mg/day              | 52,36 (69.2)         | 56,34 (60.7)         |                          | 8.43 (-9.01, 25.87)                     |
| >=12 mg/day             | 18,4 (22.2)          | 14.6 (42.9)          |                          | -18.14 (-49.57, 13.29)                  |
| Gender                  |                      |                      |                          |                                         |
| Male                    | 25,11 (44.0)         | 31,17 (54.8)         |                          | -6.25 (-29.85, 17.35)                   |
| Female                  | 45,29 (64.4)         | 39,23 (59.0)         |                          | 5.76 (-14.33, 25.84)                    |
| Age group               |                      |                      |                          |                                         |
| >=18 to<=65             | 57,33 (57.9)         | 59,33 (55.9)         |                          | 1.09 (-16.03, 18.21)                    |
| >65                     | 13,7 (53.8)          | 11.7 (63.6)          | FavoursMepoiFavoursBenra | 0.64 (-32.77, 34.05)                    |

-90-70-50-30 -10 10 30 50 70 90

## Differenceinremission rates(BenraMepo)

<!-- image -->

-90-70-50-30-1010305070 90

Differenceinremissionrates(Benra-

Mepo)

<div style=\"page-break-after: always\"></div>

Mainremissionwasdefined asBVAS=0andOCSdose≤4mg/day(intheevent apatienthadachievedremissionand at anysubsequent visit had aBVAS=1 whichdidnotrequire anincrease inOCSdoseabove4mg/day,or any othersignificant clinicalinterventionorinvestigation,thepatient wasconsidered tobein continuedremission).

Theremissionratesandthedifference(benralizumab-mepolizumab)wereestimatedusingmarginalstandardisationmethodinalogisticregressionmodel.The the subgroup(treatment arm*subgroup)

Thep-valueforeachinteractiontermisestimatedfromlogisticregressionwithout usingmarginal standardizationmethod.

Baselinewasdefinedasthelastmeasurementonorpriortothedateofrandomisation.

Missing race was included in the category 'Other'.

PositiveANCAstatuswaseitherbaselinepositiveorhistoricalpositive.

ANCA = anti-neutrophil cytoplasmic antibody(ies);Benra =benralizumab;BVAS=BirminghamVasculitis Activity Score; CI=confidence interval; EGPA = eosinophilic granulomatosis with polyangiitis; Mepo = mepolizumab; N = number of patients in treatment group; OCS = oral corticosteroids; VDI=VasculitisDamageIndex

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 19. Summary of Efficacy for MANDARA trial

| Title: A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy ( MANDARA Study )   | Title: A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy ( MANDARA Study )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Title: A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy ( MANDARA Study )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                        | D3253C00001, MANDARA, EudraCT Number 2019-001832-77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | D3253C00001, MANDARA, EudraCT Number 2019-001832-77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                                                                                                  | This Phase III study in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy included a 52-week double- blind (DB) period in which the efficacy and safety of benralizumab was compared with an active comparator, mepolizumab. Eligible patients were randomised 1:1 at baseline to receive benralizumab 30 mg Q4W or mepolizumab 300 mg Q4W. The study also includes an ongoing open label extension (OLE) period that intends to allow each patient at least one additional year of treatment with open-label benralizumab 30 mg Q4W, to assess long-term safety and tolerability of benralizumab in this patient population. At the time of this submission, the primary analysis (including all data collected from patients in the during the DB phase and safety data (exposure and AE/SAE) data from the OLE) is completed. | This Phase III study in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy included a 52-week double- blind (DB) period in which the efficacy and safety of benralizumab was compared with an active comparator, mepolizumab. Eligible patients were randomised 1:1 at baseline to receive benralizumab 30 mg Q4W or mepolizumab 300 mg Q4W. The study also includes an ongoing open label extension (OLE) period that intends to allow each patient at least one additional year of treatment with open-label benralizumab 30 mg Q4W, to assess long-term safety and tolerability of benralizumab in this patient population. At the time of this submission, the primary analysis (including all data collected from patients in the during the DB phase and safety data (exposure and AE/SAE) data from the OLE) is completed. |
| Design                                                                                                                                                                                                                                                                                                                  | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 52 weeks DB active-controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                                                                                  | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 1-4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                                                                                  | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | At least 1-year OLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                                                                                                                              | Non-inferiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Non-inferiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                                                                                                                       | Benralizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1 x 30 mg plus 3 placebo to mepolizumab SC Q4W, 70 randomised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Treatments groups                                                                                                                                                                                                                                                                                                       | Mepolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 3 × 100 mg plus 1 placebo to benralizumab SC Q4W, 70 randomised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions during the double-blind period   | Primary endpoint    | Remission at both Week 36 and 48                        | Proportion of patients achieving main remission, defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Week 36 and Week 48.                                                                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------------------------------------|---------------------|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions during the double-blind period   | Secondary endpoints | Total duration of remission during DB period            | Total accrued duration of remission for the following categories: 0 wk, > 0 to < 12 wk, 12 to < 24 wk, 24 to < 36 wk, ≥ 36 wk.                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Endpoints and definitions during the double-blind period   | Secondary endpoints | Relapse during DB period                                | Time from randomisation to first EGPA relapse, where relapse was defined as any of the following: Active vasculitis (BVAS > 0); OR Active asthma symptoms and/or signs with a corresponding worsening in ACQ- 6 score; OR Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions; Warranting any of the following: An increased dose of OCS therapy to > 4 mg/day prednisolone total daily dose; OR An increased dose or addition of immunosuppressive therapy; OR Hospitalisation related to EGPA worsening. |
| Endpoints and definitions during the double-blind period   | Secondary endpoints | Corticosteroid dose required during Weeks 48 through 52 | Annualized relapse rate Based on the average daily prednisolone/prednisone dose during Week 48 through Week 52: • Proportion of patients in each category: 0 mg; > 0 to ≤ 4 mg; > 4 to ≤ 7.5 mg, and > 7.5 mg. • Proportion of patients in each category of percent reduction from baseline: no reduction or withdrawal from treatment; < 25% reduction; 25 to < 50% reduction; 50 to < 75% reduction; 75 to < 100% reduction; 100% reduction. • Proportion of patients with ≥ 50% reduction from baseline. • Proportion of patients with 100% reduction from baseline.      |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                               | Clinical benefit during DB period                                                                                                                                                                                                                                                                                                                                                                                                                 | Proportion of patients who had achieved any clinical benefit when meeting any of the criteria below. Proportion of patients who had achieved complete response when meeting all of the criteria below. Remission (defined as BVAS = 0 and prednisolone/prednisone dose ≤ 4 mg/day) at any time during the double- blind treatment period. ≥ 50% reduction in average daily prednisolone/prednisone dose during Weeks 48 through 52. EGPA relapse free during the double- blind treatment period.   |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                               | Remission during DB period                                                                                                                                                                                                                                                                                                                                                                                                                        | Proportion of patients who had achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period.                                                                                                                                                                                                                                                                                                                                          |
| Primary Database lock                           | 05 September 2023                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05 September 2023                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05 September 2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Results and Analysis: MANDARA                   | Results and Analysis: MANDARA                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis: MANDARA                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis: MANDARA                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis population and time point description  | The primary analysis is to demonstrate NI of benralizumab versus mepolizumab based on the primary endpoint of main remission at both Weeks 36 and 48. All subjects in the Full Analysis Set who were randomised and received at least one dose of IP were used for primary analysis. Subjects were analysed according to their randomised treatment irrespective of whether or not they prematurely discontinued, according to the ITT principle. | The primary analysis is to demonstrate NI of benralizumab versus mepolizumab based on the primary endpoint of main remission at both Weeks 36 and 48. All subjects in the Full Analysis Set who were randomised and received at least one dose of IP were used for primary analysis. Subjects were analysed according to their randomised treatment irrespective of whether or not they prematurely discontinued, according to the ITT principle. | The primary analysis is to demonstrate NI of benralizumab versus mepolizumab based on the primary endpoint of main remission at both Weeks 36 and 48. All subjects in the Full Analysis Set who were randomised and received at least one dose of IP were used for primary analysis. Subjects were analysed according to their randomised treatment irrespective of whether or not they prematurely discontinued, according to the ITT principle.                                                  |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                   | Benralizumab                                                                                                                                                                                                                                                                                                                                                                                                                                      | Mepolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                | 70                                                                                                                                                                                                                                                                                                                                                                                                                                                | 70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Subjects with main remission (Primary endpoint) at both Week 36 and 48 n (%)                                                                                                                                                                                                                                                                                                                                                                      | 40 (57.1)                                                                                                                                                                                                                                                                                                                                                                                                                                         | 40 (57.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Subjects with main remission (Primary endpoint) at both Week 36 and 48 n (% 1 )                                                                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                 | Benralizumab - Mepolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                  | Subjects with main remission (Primary endpoint) at both Week 36 and 48 n (% 1 )                                                                                                                                                                                                                                                                                                                                                                   | Difference between group                                                                                                                                                                                                                                                                                                                                                                                                                          | 1.21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Subjects with main remission (Primary endpoint) at both Week 36 and 48 n (% 1 )                                                                                                                                                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                            | -14.11, 16.53                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | Subjects with main remission (Primary endpoint) at both Week 36 and 48 n (% 1 )                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.8773                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Notes                                           | Patient disposition: All randomised subjects in MANDARA study were dosed, and 97.1% of the randomised subjects completed the 52-week DB period. A total of 4 patients discontinued IP during the DB period, and discontinuation from IP was similar between treatment groups. The primary reason for discontinuation from IP was withdrawal by patient (3 patients [2.1%])   | Patient disposition: All randomised subjects in MANDARA study were dosed, and 97.1% of the randomised subjects completed the 52-week DB period. A total of 4 patients discontinued IP during the DB period, and discontinuation from IP was similar between treatment groups. The primary reason for discontinuation from IP was withdrawal by patient (3 patients [2.1%])   | Patient disposition: All randomised subjects in MANDARA study were dosed, and 97.1% of the randomised subjects completed the 52-week DB period. A total of 4 patients discontinued IP during the DB period, and discontinuation from IP was similar between treatment groups. The primary reason for discontinuation from IP was withdrawal by patient (3 patients [2.1%])   |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                            | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                           | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                           | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                              | Benralizumab                                                                                                                                                                                                                                                                                                                                                                 | Mepolizumab                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                           | 70                                                                                                                                                                                                                                                                                                                                                                           | 70                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Subjects with total accrued duration of remission during DB period n (%) 0 weeks > 0 to < 12 weeks 12 to < 24 weeks 24 to < 36 weeks ≥ 36 weeks Subjects who achieved main remission within                                                                                                                                                                                  | 9 (12.9) 13 (18.6) 8 (11.4) 20 (28.6) 20 (28.6)                                                                                                                                                                                                                                                                                                                              | 15 (21.4) 10 (14.3) 8 (11.4) 19 (27.1) 18 (25.7)                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | the first 24 Weeks and remained in remission for the remainder of the double-blind period n (% 1 )                                                                                                                                                                                                                                                                           | 28 (42.1)                                                                                                                                                                                                                                                                                                                                                                    | 27 (36.5)                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Time to first relapse Subject with relapse n (%)                                                                                                                                                                                                                                                                                                                             | 21 (30.0)                                                                                                                                                                                                                                                                                                                                                                    | 21 (30.0)                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability |                                                                                                                                                                                                                                                                                                                                                                              | 0.50                                                                                                                                                                                                                                                                                                                                                                         | 0.49                                                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Annualized relapse rate Subjects with average daily dose of prednisolone/prednisone during Week 48 through 52 n (%) 0 > 0 to ≤ 4.0 mg > 4.0 to ≤ 7.5 mg                                                                                                                                                                                                                      | 29 (41.4) 19 (27.1) 15 (21.4)                                                                                                                                                                                                                                                                                                                                                | 19 (27.1) 30 (42.9) 13 (18.6) 8 (11.4)                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | > 7.5 mg Subjects with ≥ 50% OCS reduction during Weeks 48 and 52 n (% 1 )                                                                                                                                                                                                                                                                                                   | 7 (10.0) 59 (84.7)                                                                                                                                                                                                                                                                                                                                                           | 52 (73.9)                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Subjects with 100% OCS                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | reduction during weeks 48 to 52 n (% 1 )                                                                                                                                                                                                                                                                                                                                     | 29 (41.4)                                                                                                                                                                                                                                                                                                                                                                    | 18 (25.8)                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                | Subjects with complete response (main remission) n (% 1 )                                                                                                | 43 (62.5)                | 39 (54.6)                    |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|------------------------------|
| Effect estimate per comparison | Secondary endpoint: Subject with total accrued duration of remission during DB period                                                                    | Comparison groups        | Benralizumab vs. Mepolizumab |
| Effect estimate per comparison | Secondary endpoint: Subject with total accrued duration of remission during DB period                                                                    | Odds ratio               | 1.32                         |
| Effect estimate per comparison | Secondary endpoint: Subject with total accrued duration of remission during DB period                                                                    | 95% CI                   | 0.72, 2.40                   |
| Effect estimate per comparison | Secondary endpoint: Subject with total accrued duration of remission during DB period                                                                    | P-value                  | 0.3653                       |
| Effect estimate per comparison | Secondary endpoint: Subject who achieved main remission within the first 24 Weeks and remained in remission for the remainder of the double-blind period | Comparison groups        | Benralizumab - Mepolizumab   |
| Effect estimate per comparison | Secondary endpoint: Subject who achieved main remission within the first 24 Weeks and remained in remission for the remainder of the double-blind period | Difference               | 5.54                         |
| Effect estimate per comparison | Secondary endpoint: Subject who achieved main remission within the first 24 Weeks and remained in remission for the remainder of the double-blind period | 95% CI                   | -9.30, 20.37                 |
| Effect estimate per comparison | Secondary endpoint: Subject who achieved main remission within the first 24 Weeks and remained in remission for the remainder of the double-blind period | P-value                  | 0.4643                       |
| Effect estimate per comparison | Secondary endpoint: Time to first relapse                                                                                                                | Comparison groups        | Benralizumab vs. Mepolizumab |
| Effect estimate per comparison | Secondary endpoint: Time to first relapse                                                                                                                | Hazard ratio             | 0.98                         |
| Effect estimate per comparison | Secondary endpoint: Time to first relapse                                                                                                                | 95% CI                   | 0.53, 1.82                   |
| Effect estimate per comparison | Secondary endpoint: Time to first relapse                                                                                                                | P-value                  | 0.9466                       |
| Effect estimate per comparison | Secondary endpoint: Annualized relapse rate                                                                                                              | Comparison groups        | Benralizumab vs. Mepolizumab |
| Effect estimate per comparison | Secondary endpoint: Annualized relapse rate                                                                                                              | Rate ratio               | 1.03                         |
| Effect estimate per comparison | Secondary endpoint: Annualized relapse rate                                                                                                              | 95% CI                   | 0.56, 1.90                   |
| Effect estimate per comparison | Secondary endpoint: Annualized relapse rate                                                                                                              | P-value                  | 0.9282                       |
| Effect estimate per comparison | Secondary endpoint: Subjects with average daily dose of prednisolone/prednisone during Week 48 through 52                                                | Comparison groups        | Benralizumab vs. Mepolizumab |
| Effect estimate per comparison | Secondary endpoint: Subjects with average daily dose of prednisolone/prednisone during Week 48 through 52                                                | Odds ratio               | 1.38                         |
| Effect estimate per comparison | Secondary endpoint: Subjects with average daily dose of prednisolone/prednisone during Week 48 through 52                                                | 95% CI                   | 0.75, 2.54                   |
| Effect estimate per comparison | Secondary endpoint: Subjects with average daily dose of prednisolone/prednisone during Week 48 through 52                                                | P-value                  | 0.3062                       |
|                                | Secondary endpoint: Subjects with ≥ 50% OCS reduction during Weeks 48 and 52                                                                             | Comparison groups        | Benralizumab - Mepolizumab   |
|                                | Secondary endpoint: Subjects with ≥ 50% OCS reduction during Weeks 48 and 52                                                                             | Difference between group | 10.79                        |
|                                | Secondary endpoint: Subjects with ≥ 50% OCS reduction during Weeks 48 and 52                                                                             | 95% CI                   | -2.25, 23.83                 |
|                                | Secondary endpoint: Subjects with ≥ 50% OCS reduction during Weeks 48 and 52                                                                             | P-value                  | 0.1047                       |
|                                | Secondary endpoint: Subjects with 100% OCS reduction during weeks 48 to 52                                                                               | Comparison groups        | Benralizumab - Mepolizumab   |
|                                | Secondary endpoint: Subjects with 100% OCS reduction during weeks 48 to 52                                                                               | Difference between group | 15.69                        |
|                                | Secondary endpoint: Subjects with 100% OCS reduction during weeks 48 to 52                                                                               | 95% CI                   | 0.67, 30.71                  |

<div style=\"page-break-after: always\"></div>

|       |                                                                         | P-value                          | 0.0406                           |
|-------|-------------------------------------------------------------------------|----------------------------------|----------------------------------|
|       | Secondary endpoint: Subjects with any clinical benefit (main remission) | Comparison groups                | Benralizumab - Mepolizumab       |
|       | Secondary endpoint: Subjects with any clinical benefit (main remission) | Difference between group         | 4.60                             |
|       | Secondary endpoint: Subjects with any clinical benefit (main remission) | 95% CI                           | -4.22, 13.41                     |
|       | Secondary endpoint: Subjects with any clinical benefit (main remission) | P-value                          | 0.3068                           |
|       | Secondary endpoint: Subjects with complete response (main remission)    | Comparison groups                | Benralizumab - Mepolizumab       |
|       | Secondary endpoint: Subjects with complete response (main remission)    | Difference between group         | 7.90                             |
|       | Secondary endpoint: Subjects with complete response (main remission)    | 95% CI                           | -7.32, 23.12                     |
|       | Secondary endpoint: Subjects with complete response (main remission)    | P-value                          | 0.3088                           |
| Notes | See notes under primary endpoint                                        | See notes under primary endpoint | See notes under primary endpoint |

## 2.4.3. Discussion on clinical efficacy

The key benralizumab EGPA clinical trial was Phase III MANDARA study and the product is developed for the new indication for the treatment of EGPA in adult patients with a dose of 30 mg Q4W by SC injection.

## Design and conduct of clinical studies

MANDARA was a randomised, double blind, active-controlled non-inferiority study to evaluate the efficacy and safety of Benralizumab compared to Mepolizumab in the treatment of EGPA in patients, receiving Standard of Care. The study included a 52-week DB, active-controlled treatment period in which the efficacy and safety of 30 mg benralizumab administered SC Q4W was compared with 3x100 mg mepolizumab administered SC Q4W and an ongoing OLE period that intends to allow each patient at least one additional year of treatment with open-label benralizumab to assess long-term safety and tolerability of benralizumab in this patient population. IP was administered Q4W from baseline until week 48 in a double-blind fashion. Those  patients  that  completed  the  double-blind  treatment  period  on  IP,  would  receive  open-label benralizumab administered Q4W from week 52 onwards. Tapering of daily oral prednisolone/prednisone dose was allowed from Week 4 onwards to a target of ≤ 4 mg/day. The primary endpoint of the study was the 'proportions of patients who achieved remission at both Weeks 36 and 48 using a NI margin of -25%'. Additional analysis was conducted using a supportive remission definition of BVAS = 0 and OCS dose ≤ 7.5 mg/day. Overall, the study design and determination of NI margin followed the principles described in the 'Guideline on the Choice of the Non-Inferiority Margin' EMEA/CPMP/EWP/2158/99 and the ICH guideline: 'E10 Choice of Control Group in Clinical Trials'. The target population of the study was adult female or male patients aged 18 years and above with documented EGPA diagnosis and a history of relapsing or refractory disease and documentation of at least 2 additional features of EGPA.

Despite that the main inclusion criteria were generally acceptable and aligned with the respective criteria of MIRRA study (asthma), the target population of the 'adult female or male patients aged 18 years and above documented EGPA diagnosis and a history of relapsing or refractory disease and documentation of

<div style=\"page-break-after: always\"></div>

at  least  2  additional  features  of  EGPA' was  not  reflected  in  the  originally  proposed  indication  by  the applicant: ' Fasenra is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis '.  Consequently,  on  request  of  the  CHMP,  a  warning  that  Fasenra  has  not  been  studied  in patients with active organ threatening or life-threatening manifestations of EGPA was added to section 4.4, as well as the relevant information on posology in these patients to sections 4.2 of the SmPC.

The applicant justified the absence of dose-response studies as a result of the rarity of EGPA. The use of a more  frequent  dosing  regimen  (30  mg  SC  Q4W)  was  selected  for  benralizumab  in  EGPA  following discussions with FDA on: 1) the severity of the disease, 2) the extensive database of benralizumab from asthma studies, and 3) the approval of a higher dose of mepolizumab in EGPA compared with its approved dose in asthma (MIRRA). The currently approved dosing regimen of benralizumab in severe asthma is 30 mg administered SC Q4W for the first 3 doses and Q8W thereafter. The applicant's argument that the Q4W frequency is further supported by the long-term pivotal studies in asthma exacerbations and severe asthma, SIROCCO and CALIMA can be supported.

## Efficacy data and additional analyses

The primary objective of MANDARA was to assess the durability of response to treatment with benralizumab compared with mepolizumab in patients with relapsing or refractory EGPA who are receiving standard of care therapy, assessed by the proportion of patients in remission at both Weeks 36 and 48. A total of 140 patients were randomized. The primary endpoint proportion of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Weeks 36 and 48 was met. This was supported by the results from the analysis of the supportive endpoint, sensitivity analysis on the proportion of patients with relapsing or refractory EGPA. To compensate for the absence of placebo in the current study, the applicant performed an indirect comparison of benralizumab and historic placebo from MIRRA on remission rate, using a 2-sided test with a 0.05 significance level. A significantly higher proportion of patients who received benralizumab achieved remission at both Weeks 36 and 48 compared with the historical placebo control from MIRRA study. According to FDA guidance 'Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry' (FDA 2016), the lower bound of the 95% confidence interval (M1) for difference in remission rates between mepolizumab and placebo in MIRRA study, ie, -18%, provided a conservative basis of the NI margin for an active-controlled study, taking into account the variability of the data in MIRRA. Given the rarity of the disease and the goal of recruiting mepolizumab and benralizumab naïve participants in a reasonable timeframe, AZ proposed a recruitment goal of 140 subjects with EGPA and a -25% NI margin. According to the MAH, the potential difference of 10% in remission rates is not considered to be clinically meaningful by the clinical experts. Considering that the lower bound of the CI for the difference in remission rates was 14.1% (close to 10% and also lower than 18%), there is no concern anymore.

Following the results from the primary analysis for demonstration of benralizumab non-inferiority, compared with mepolizumab, the same logistic regression model was used to test superiority of benralizumab over mepolizumab at the 2-sided 5% significance level (equivalent to a 1-sided test at 2.5% significance level).  The results from the analysis of secondary endpoints were overall supportive of the results from primary analysis, albeit with limited statistical significance. Benralizumab effect was comparable to mepolizumab for the majority of secondary objectives assessed:

- -total accrued duration of main remission was similar in the benralizumab group compared with the mepolizumab group, the odds ratio is 1.32 (95% CI: [0.72, 2.40], p=0.3653) (table 19 &amp; 27).
- -time  to  first  relapse  was  similar  in  patients  in  the  benralizumab  group  compared  with  the mepolizumab  group  with  0  major  relapses  occurred  during  the  DB  period  in  patients  in  the benralizumab group and 3 patients (4.3%) in the mepolizumab group

<div style=\"page-break-after: always\"></div>

- -composite endpoint of any clinical benefit from treatment (defined as any of: Remission at any time during the double-blind treatment period, ≥ 50% reduction in average daily OCS dose during Weeks 48 through 52 &amp; EGPA relapse free during the double-blind treatment period), the proportions of patients  were  high  and  similar  in  both  treatment  groups  (94.3%  and  90.0%,  respectively). Complete response was also similar between groups (61.4% and 55.7%, respectively).
- -annualised relapse rate, was similar in patients treated with benralizumab compared with those treated with mepolizumab (rate ratio [95% CI]: 1.03 [0.56, 1.90]).
- -The proportion of patients who achieved an average daily OCS dose of ≤ 4 mg/day was similar in the  two  treatment  groups  (48  patients  [68.6%]  in  benralizumab  vs  49  [70%]  in  mepolizumab group), and similar proportions of patients achieved ≤ 7.5 mg/day (63 patients [90.0%] in the benralizumab group and 62 patients [88.6%] in mepolizumab group).
- -proportion of patients who achieved remission within the first 24 weeks and remained in remission for the remainder of the DB period, similar results were obtained for benralizumab and mepolizumab groups (40.0% vs 38.6%, respectively) (p = 0.4643).
- -additional  measures of  efficacy  in  asthma  (ACQ-6)  Sino-nasal  (SNOT-22  and  SSQ),  spirometry results (FEV1 and FVC) and health status/health-related quality of life assessments (SF-36v2, PGIS, PGIC, and WPAI-GH) were similar in the benralizumab and mepolizumab groups at Week 52.

A marked difference was only observed between benralizumab and mepolizumab groups on the OCS use during Week 48 through Week 52 where, 100% reduction in average daily dose of OCS was observed in a statistically significant percentage of patients receiving benralizumab compared with mepolizumab (41.4% vs 25.7%, respectively; nominal p = 0.0406). In addition, reductions of at least 50% in the average daily dose of OCS were observed in numerically higher proportions of patients receiving benralizumab compared with mepolizumab (84.3% vs 74.3%, respectively; nominal p = 0.1047).

Measurement of disease activity by BVAS was similar in the benralizumab and mepolizumab groups over the 52-week DB period.

VDI records organ damage due to vasculitis, treatment or unrelated, that has occurred at least three months prior to recording and therefore it is a measure of the cumulative burden of disease. The damage index score can only remain stable or deteriorate as time progresses. In the current study, VDI results presented as estimation of the mean change from baseline at weeks 24 and 52 in the benralizumab and mepolizumab group showed minimal increases in LS mean change from baseline in both treatment groups at Week 52. Of note, statistically non-significant differences on VDI have also been reported between mepolizumab and placebo in MIRRA study (mepolizumab had a similar baseline VDI score and was administered under the same dosing scheme as in MANDARA).

In addition, similar values were reported for the majority of the exploratory variables: Cumulative OCS use, Number of EGPA-related hospitalizations; length of hospital stay; ICU days; number of EGPA-related ER visits; number of EGPA-related outpatient visits (by type); number of EGPA-related procedures/tests (by specific procedure/test). It is noted, however, that the results for certain variables (although of exploratory nature) related to EGPA healthcare resource utilization i.e., the number of general care hospitalization days, hospital  admissions  or  emergency  department  &gt;  24  hours,  number  of  subjects  having  spirometry assessments &amp; number of subjects with emergency room visits were slightly increased for the benralizumab group compared to the mepolizumab group.

The  pivotal  study,  MANDARA,  evaluated  the  efficacy  and  safety  of  benralizumab  compared  with mepolizumab, as active comparator, in the treatment of patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. The applicant's decision to use

<div style=\"page-break-after: always\"></div>

the Q4W dosing regimen for the proposed indication of benralizumab in EGPA is considered sufficiently justified.

The MAH has applied for the following indication: 'Fasenra is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.'

As outlined in  the  inclusion  criteria  of  MANDARA,  the  study  participants  were  required  to  have  a  prior diagnosis of refractory or relapsing EGPA on corticosteroid therapy with or without stable immunosuppressive  therapy.  Hence,  the  originally  targeted  indication  was  not  representative  of  the population studied in MANDARA. The applicant was asked to modify the proposed indication, so it reflects the enrolled patients' disease characteristics. Hence, the indication wording modified and the following is agreed by the CHMP:

'Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (see section 5.1).'

Section 4.1 of the SmPC has been updated accordingly.

The  applicant  informed  EMA  on  28  August  2024  of  findings  from  study  monitoring  which  resulted  in correction of source data for one of the patients in benralizumab group. Due to this correction, the patient no  longer  fulfils  the  criteria  for  main  remission.  Minor  changes  were  introduced  to  data  on  remission, accrued duration of remission and oral corticosteroid dose. Additional on-site source data verification for primary endpoint data at the site involved, did not identify additional critical issues. Following re-run of the efficacy  analyses  impacted  by  this  error  it  is  considered  that  the  changes  in  efficacy  results  are  nonsignificant and do not affect the overall efficacy conclusions of the study.

## 2.4.4. Conclusions on the clinical efficacy

The  efficacy  of  benralizumab  in  EGPA  is  dependent  on  its  ability  to  provide  clinically  meaningful improvements for patients with EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. In this setting, benralizumab was found to be non-inferior to mepolizumab. The analysis of the primary endpoint was further supported by the treatment comparison in pre-specified subgroups of patients (blood eosinophil count at baseline, BMI, OCS dose at baseline, gender age group, region, time since EGPA diagnosis, immunosuppressive therapy at baseline, VDI score, race, ANCA -positive status) who achieved main remission at weeks 36 and 48.

## 2.5. Clinical safety

The safety profile of benralizumab in patients with EGPA is primarily supported by the data from MANDARA. Additional  data  from  long-term  pivotal  studies  in  asthma  populations  i.e.  SIROCCO  (D3250C00017), CALIMA (D3250C00018), and BORA (D3250C00021), further support the safety profile of benralizumab, in particular regarding the Q4W dosing regimen.

## Patient exposure

The total number of patients enrolled in MANDARA study, was 157 patients. All 140 randomized patients received at least one dose of IP during the DB period as follows: 70 patients received benralizumab and 70 patients received mepolizumab. All randomized patients were included in the Safety Analysis Set.  Up to the primary database lock, 128 patients received at least 52 weeks of benralizumab 30 mg Q4W and 128 patients received at least one dose of IP in the OLE period and were included in the OLE Analysis Set.

<div style=\"page-break-after: always\"></div>

The mean duration of IP administration was longer during the ongoing OLE period compared with the DB period  in  both  the  benralizumab  and  the  mepolizumab/benralizumab  groups  consistent  with  the  study design. No new safety concerns regarding duration of IP administration were identified.

## Adverse events

Overall,  no  new  safety  concerns  regarding  AEs  were  identified  during  the  MANDARA  study.  The  most common AEs reported during the DB period were COVID-19 (21.4% patients), headache (17.1% patients), and arthralgia (17.1% patients) in the benralizumab group compared with COVID-19 (27.1% patients), headache (15.7% patients), and nasopharyngitis (14.3% patients) in the mepolizumab group. Most AEs were transient in nature and of mild or moderate intensity. No events of helminth infection were reported. A total of 3 malignant neoplasm events including 2 prostate cancer AEs in the mepolizumab group and 1 marginal zone lymphoma AE in the benralizumab group were reported during the DB period. No new notable trends were observed during the OLE period of the study compared with the DB period. The most common AEs during the DB period were defined as those with a PT frequency of &gt; 3% in either treatment group. The below AE summaries (Table 20 (DB) and 21 (OLE)) included all patients on benralizumab at any time as the total while on benralizumab 30 mg group, and it is referred to as the total benralizumab group .

Table 20. Adverse Events in Any Category - DB Period (Safety Analysis Set)

|                                             | Number (%) of patients         | Number (%) of patients       |
|---------------------------------------------|--------------------------------|------------------------------|
| AE category                                 | Benralizumab 30 mg a* (N = 70) | Mepolizumab 300mg a (N = 70) |
| Any AE                                      | 63 (90.0)                      | 67 (95.7)                    |
| Any AE with outcome of death                | 0                              | 0                            |
| AnySAE(includingeventswithoutcome of death) | 4 (5.7)                        | 9 (12.9)                     |
| Any AE leading to discontinuation of IP     | 0                              | 2 (2.9)                      |

An AE during the DB period was defined as an AE with an onset date on or after day of the first dose of study DB treatment and prior to the first dose of open-label benralizumab (up to end of study for patients who did not roll over to the OLE period).

Adverse events were coded using MedDRA version 26.0.

AE = adverse event; DB = double-blind; IP = investigational product; MedDRA = Medical Dictionary for Regulatory Activities; N = number of patients in treatment group; OLE = open-label extension; SAE = serious adverse event

<div style=\"page-break-after: always\"></div>

Table 21. Adverse Events in Any Category - OLE Period (OLE Analysis Set)

|                                                  | Number (%) of patients     | Number (%) of patients                        |
|--------------------------------------------------|----------------------------|-----------------------------------------------|
| AE category                                      | Benralizumab30 mg (N = 66) | Mepolizumabswitched to Benralizumaba (N = 62) |
| Any AE                                           | 54 (81.8)                  | 57 (91.9)                                     |
| Any AE with outcome of death                     | 0                          | 1 (1.6)                                       |
| Any SAE (including events with outcome of death) | 10 (15.2)                  | 13 (21.0)                                     |
| Any AE leading to discontinuation of IP          | 2 (3.0)                    | 1 (1.6)                                       |

Percentages were calculated using the number of patients in each treatment group (N) as denominator.

Only events that started during the OLE period were counted.

Adverse events were coded using MedDRA version 26.0.

AE = adverse event; IP = investigational product; MedDRA = Medical Dictionary for Regulatory Activities;

N = number of patients in treatment group; OLE = open-label extension; SAE = serious adverse event

## Adverse Events by System Organ Class and Preferred Term

Small  numerical  differences  were  observed  between  treatment  groups  for  the  most  common  AEs  (PT frequency of &gt; 3% in either group), during the DB period without identification of specific trends or pattern. The most frequent (PT frequency &gt; 3%) reported Adverse Events (by PT) are listed in Table 22. The most frequently reported common AE was COVID-19; 15 patients (21.4%) in the benralizumab group and 19 patients  (27.1%) in  the mepolizumab group were identified with COVID-19 AEs during the DB period. Despite two of the events (one in each treatment group) being serious, both resolved.

<div style=\"page-break-after: always\"></div>

Table 22. Most Common AEs - DB Period (PT Frequency &gt;3%) (Safety Analysis Set)

<!-- image -->

|                                         | Benralizumab 30 mg (N =70) (Exp = 70.2 years) a   | Benralizumab 30 mg (N =70) (Exp = 70.2 years) a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years) a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years) a   |
|-----------------------------------------|---------------------------------------------------|---------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| PT                                      | Number (%) of patients b                          | Event rate (per 100 PY)°                          | Number (%) of patients b                           | Event rate (per 100 PY)°                           |
| Anymostcommon (frequency of > 3%) AE    | 51 (72.9)                                         | 72.65                                             | 61 (87.1)                                          | 86.77                                              |
| COVID-19                                | 15 (21.4)                                         | 21.37                                             | 19 (27.1)                                          | 27.03                                              |
| Headache                                | 12 (17.1)                                         | 17.09                                             | 11 (15.7)                                          | 15.65                                              |
| Arthralgia                              | 12 (17.1)                                         | 17.09                                             | 8 (11.4)                                           | 11.38                                              |
| Nasopharyngitis                         | 6 (8.6)                                           | 8.55                                              | 10 (14.3)                                          | 14.22                                              |
| Sinusitis                               | 5 (7.1)                                           | 7.12                                              | 8 (11.4)                                           | 11.38                                              |
| Fatigue                                 | 5 (7.1)                                           | 7.12                                              | 6 (8.6)                                            | 8.53                                               |
| Bronchitis                              | 5 (7.1)                                           | 7.12                                              | 5 (7.1)                                            | 7.11                                               |
| Sinusitis bacterial                     | 5 (7.1)                                           | 7.12                                              | 3 (4.3)                                            | 4.27                                               |
| Upperrespiratorytract infection         | 4 (5.7)                                           | 5.70                                              | 4 (5.7)                                            | 5.69                                               |
| Influenza like illness                  | 4 (5.7)                                           | 5.70                                              | 3 (4.3)                                            | 4.27                                               |
| Nausea                                  | 1 (1.4)                                           | 1.42                                              | 6 (8.6)                                            | 8.53                                               |
| Viral upper respiratory tract infection | 1 (1.4)                                           | 1.42                                              | 6 (8.6)                                            | 8.53                                               |
| Asthenia                                | 6 (8.6)                                           | 8.55                                              | 0                                                  | 0                                                  |
| Hypertension                            | 1 (1.4)                                           | 1.42                                              | 5 (7.1)                                            | 7.11                                               |
| Injection site bruising                 | 2 (2.9)                                           | 2.85                                              | 4 (5.7)                                            | 5.69                                               |
| Injection site pain                     | 3 (4.3)                                           | 4.27                                              | 3 (4.3)                                            | 4.27                                               |
| Oral candidiasis                        | 2 (2.9)                                           | 2.85                                              | 4 (5.7)                                            | 5.69                                               |
| Rash                                    | 4 (5.7)                                           | 5.70                                              | 2 (2.9)                                            | 2.84                                               |
| Urinary tract infection                 | 5 (7.1)                                           | 7.12                                              | 1 (1.4)                                            | 1.42                                               |
| Back pain                               | 2 (2.9)                                           | 2.85                                              | 3 (4.3)                                            | 4.27                                               |
| Diarrhoea                               | 2 (2.9)                                           | 2.85                                              | 3 (4.3)                                            | 4.27                                               |
| Myalgia                                 | 4 (5.7)                                           | 5.70                                              | 1 (1.4)                                            | 1.42                                               |
| Skin laceration                         | 1 (1.4)                                           | 1.42                                              | 4 (5.7)                                            | 5.69                                               |
| Tooth infection                         | 3 (4.3)                                           | 4.27                                              | 2 (2.9)                                            | 2.84                                               |
| Abdominal pain                          | 0                                                 | 0                                                 | 4 (5.7)                                            | 5.69                                               |

<div style=\"page-break-after: always\"></div>

|                       | Benralizumab 30 mg (N = 70) (Exp = 70.2 years) a   | Benralizumab 30 mg (N = 70) (Exp = 70.2 years) a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years) a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years) a   |
|-----------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| PT                    | Number (%) of patients b                           | Event rate (per 100 PY)°                           | Number (%) of patients b                           | Event rate (per 100 PY)                            |
| Adrenal insufficiency | 1 (1.4)                                            | 1.42                                               | 3 (4.3)                                            | 4.27                                               |
| Asthma                | 1 (1.4)                                            | 1.42                                               | 3 (4.3)                                            | 4.27                                               |
| Contusion             | 1 (1.4)                                            | 1.42                                               | 3 (4.3)                                            | 4.27                                               |
| Muscle spasms         | 3 (4.3)                                            | 4.27                                               | 1 (1.4)                                            | 1.42                                               |
| Pain in extremity     | 0                                                  | 0                                                  | 4 (5.7)                                            | 5.69                                               |
| Rhinitis              | 1 (1.4)                                            | 1.42                                               | 3 (4.3)                                            | 4.27                                               |
| Vomiting              | 1 (1.4)                                            | 1.42                                               | 3 (4.3)                                            | 4.27                                               |
| Constipation          | 3 (4.3)                                            | 4.27                                               | 0                                                  | 0                                                  |
| Herpes zoster         | 0                                                  | 0                                                  | 3 (4.3)                                            | 4.27                                               |
| Osteopenia            | 0                                                  | 0                                                  | 3 (4.3)                                            | 4.27                                               |

- Number (%) of patients with AEs, sorted on descending frequency for PT according to total frequency. Patients with multiple events in the same PT are counted only once for that PT. Patients with events in more than one PT are counted once in each of those PTs. Percentages are based upon number of patients in each treatment group within the Safety Analysis Set.
- The event rate per 10o PY was defined as the number of patients with an AE divided by the total PY multiplied by 100.

An AE during the DB period was defined as an AE with an onset date on or after day of the first dose of study DB treatment and prior to the first dose of open-label benralizumab (up to end of study for patients who did not roll over to the OLE period).

Most common is defined as a total frequency of &gt; 3% in any treatment group.

Adverse events were coded using MedDRA version 26.0.

AE = adverse event; DB = double blind; Exp = exposure; MedDRA = Medical Dictionary for Regulatory Activities; N = number of patients in treatment group; OLE = open-label extension; PT = preferred term; PY = patient-years

Relatedness was recorded for each AE by response to a prompt if there was a reasonable possibility the AE was caused by the IP; therefore, relatedness is referred to as possibly related or not possibly related .

The majority of AEs during the DB period were assessed as not possibly related to IP by the Investigator. No clinically meaningful difference was observed between treatment groups during the DB period in the proportion of patients with AEs possibly related to IP . D uring the DB period, AEs related to benralizumab treatment i.e. headache (7.1%) and fatigue (2.9%) were reported with higher frequency in MANDARA study compared with the Phase III asthma studies.

No significant difference in the proportion of patients with severe AEs during the DB period between the two groups was observed: 5 severe adverse events were reported in the benralizumab group (COVID-19, headache, syncope, neuropathy peripheral, and anosmia) and 6 severe adverse events in the mepolizumab group  (prostate  cancer  [2  events],  acute  respiratory  failure,  cholangitis,  infusion  related  reaction,  and wound infection). Similarly to the DB period safety observations, no clinically meaningful differences were seen between benralizumab and mepolizumab/benralizumab groups in the OLE period.

## Serious adverse event/deaths/other significant events

During the DB period, 4 SAEs were reported in the benralizumab group and 9 SAEs in the mepolizumab group. One of three SAEs reported in the mepolizumab group was assessed as possibly related to IP, and 2  SAEs  led  to  discontinuation  of  IP.  All  patients  in  the  benralizumab  group  and  most  patients  in  the mepolizumab group recovered from SAEs reported during the DB period. No hypersensitivity AEs were

<div style=\"page-break-after: always\"></div>

serious, and no events of anaphylactic reactions were reported. The proportions of patients with injection site reaction AEs were low and similar in the benralizumab group an in the mepolizumab group.

During  the  OLE  period,  10  and  13  SAEs  were  reported  in  the  benralizumab  group  and  in  the mepolizumab/benralizumab group, respectively. One of the SAEs in the mepolizumab/benralizumab group was assessed by the Investigator as possibly related to IP, 2 SAEs led to discontinuation of IP, and most SAEs had resolved at the time of data cut-off. No death was reported in the DB period in any of the two treatment groups.

One death from pulmonary embolism occurred during the OLE period in the mepolizumab/benralizumab group. This event was assessed as not possibly related to the IP by the Investigator. Based on information from the patient narrative, a patient who was in remission from EGPA developed an AE with outcome of death from pulmonary embolism. It was noted by the CHMP that the event of pulmonary embolism occurred two months after treatment with benralizumab in a patient from the mepolizumab switched to benralizumab group.  Taking  into  consideration  that  pulmonary  embolism  was  one  of  the  fatal  AEs  reported  in  the benralizumab Phase III exacerbation studies, the Investigator assessment of the fatal event in MANDARA as ' not possibly related to the IP ' based on the patient's underlying conditions, was questioned and the MAH was asked to discuss further this fatal event (see discussion below).

## Serious Adverse Events (SAEs)

DB Period: There were no clinically meaningful differences in the frequency and event rate of SAEs between the benralizumab and mepolizumab groups during the DB period (Table 23). All but one of the SAEs were assessed as having no causal relationship to the IP; most events resolved.

<div style=\"page-break-after: always\"></div>

Table 23. SAE - DB Period (Safety Analysis Set)

|                                                                     | Benralizumab 30 mg (N = 70) (Exp = 70.2 years) a   | Benralizumab 30 mg (N = 70) (Exp = 70.2 years) a   | Mepolizumab 300mg (N = 70) (Exp = 70.3 years)a   | Mepolizumab 300mg (N = 70) (Exp = 70.3 years)a   |
|---------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| SOC PT                                                              | Number (%) of patients b                           | Event rate (per 100 PY)                            | Number (%) of patients                           | Event rate (per 100 PY)                          |
| Patients with anySAE                                                | 4 (5.7)                                            | 5.70                                               | 9 (12.9)                                         | 12.80                                            |
| Infections and infestations                                         | 2 (2.9)                                            | 2.85                                               | 4 (5.7)                                          | 5.69                                             |
| COVID-19                                                            | 1 (1.4)                                            | 1.42                                               | 1 (1.4)                                          | 1.42                                             |
| Appendicitis                                                        | 0                                                  | 0                                                  | 1 (1.4)                                          | 1.42                                             |
| Bronchitis                                                          | 1 (1.4)                                            | 1.42                                               | 0                                                | 0                                                |
| Streptococcal urinary tract infection                               | 0                                                  | 0                                                  | 1 (1.4)                                          | 1.42                                             |
| Wound infection                                                     | 0                                                  | 0                                                  | 1 (1.4)                                          | 1.42                                             |
| Hepatobiliary disorders                                             | 0                                                  | 0                                                  | 2 (2.9)                                          | 2.84                                             |
| Cholangitis                                                         | 0                                                  | 0                                                  | 1 (1.4)                                          | 1.42                                             |
| Hepaticinfiltration eosinophilic                                    | 0                                                  | 0                                                  | 1 (1.4)                                          | 1.42                                             |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0                                                  | 0                                                  | 2 (2.9)                                          | 2.84                                             |
| Prostate cancer                                                     | 0                                                  | 0                                                  | 2 (2.9)                                          | 2.84                                             |
| Nervous system disorders                                            | 2 (2.9)                                            | 2.85                                               | 0                                                | 0                                                |
| Neuropathy peripheral                                               | 1 (1.4)                                            | 1.42                                               | 0                                                | 0                                                |
| Syncope                                                             | 1 (1.4)                                            | 1.42                                               | 0                                                | 0                                                |
| Respiratory, thoracic and mediastinal disorders                     | 0                                                  | 0                                                  | 1 (1.4)                                          | 1.42                                             |
| Acute respiratory failure                                           | 0                                                  | 0                                                  | 1 (1.4)                                          | 1.42                                             |

- The event rate per 100 PY was defined as the number of patients with an SAE divided by the total PY multiplied by 100.

An SAE during the DB period was defined as a SAE with an onset date on or after day of the first dose of study roll over to the OLE period).

Serious AEs were coded using MedDRA version 26.0.

AE = adverse event; DB = double-blind; Exp = exposure; MedDRA = Medical Dictionary for Regulatory Activities; N = number of patients in treatment group; OLE = Open-label extension; PT = preferred term; PY = patient-years; SAF = serious adverse. event; SOC = system organ class

OLE Period: There were no clinically meaningful differences in the frequency and event rate of SAEs between the benralizumab and mepolizumab/benralizumab groups during the OLE period. With the exception of Clostridium difficile infection in the mepolizumab/benralizumab group all SAEs were assessed as having no causal relationship to the IP and most events were resolved.

## Other Significant Adverse Events

Injection Site Reactions: Similar proportions of patients were identified  with injection site reaction AEs during the DB period between the benralizumab group and the mepolizumab group (Table 24).

<div style=\"page-break-after: always\"></div>

Table 24. AEs of Injection Site Reactions - DB Period (Safety Analysis Set)

|                                           | Benralizumab 30 mg (N = 70) (Exp = 70.2 years) a   | Benralizumab 30 mg (N = 70) (Exp = 70.2 years) a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years) a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years) a   |
|-------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| PT                                        | Number (%) of patients b                           | Event rate (per 100 PY)°                           | Number (%) of patients b                           | Event rate (per 100 PY)°                           |
| Patients with any injection site reaction | 11 (15.7)                                          | 15.67                                              | 12 (17.1)                                          | 17.07                                              |
| Injection site bruising                   | 2 (2.9)                                            | 2.85                                               | 4 (5.7)                                            | 5.69                                               |
| Injection site pain                       | 3 (4.3)                                            | 4.27                                               | 3 (4.3)                                            | 4.27                                               |
| Injection site erythema                   | 2 (2.9)                                            | 2.85                                               | 2 (2.9)                                            | 2.84                                               |
| Injection site haematoma                  | 2 (2.9)                                            | 2.85                                               | 0                                                  | 0                                                  |
| Injection site induration                 | 1 (1.4)                                            | 1.42                                               | 1 (1.4)                                            | 1.42                                               |
| Injection sitepruritus                    | 1 (1.4)                                            | 1.42                                               | 1 (1.4)                                            | 1.42                                               |
| Injection site urticaria                  | 0                                                  | 0                                                  | 2 (2.9)                                            | 2.84                                               |
| Injectionsitehypoaesthesia                | 1 (1.4)                                            | 1.42                                               | 0                                                  | 0                                                  |
| Injection site oedema                     | 0                                                  | 0                                                  | 1 (1.4)                                            | 1.42                                               |
| Injection site reaction                   | 0                                                  | 0                                                  | 1 (1.4)                                            | 1.42                                               |

- The event rate per 100 patient-years was defined as the number of patients with an AE divided by the total PY multiplied by 100.

An AE during the DB period was defined as an AE with an onset date on or after day of the first dose of study DB treatment and prior to the first dose of open-label benralizumab (up to end of study for patients who did not roll over to the OLE period).

Adverse events were coded using MedDRA version 26.0.

Adverse events of all injection sites are displayed.

AE = adverse event; DB = double-blind; Exp = exposure; MedDRA = Medical Dictionary for Regulatory Activities; N = number of patients in treatment group; OLE = open-label extension; PY = patient-years; PT = preferred term

Injection site reaction AEs were reported in low numbers during the DB period and were non-serious with mild or moderate intensity. All injection site reaction AEs were assessed as possibly related to IP. Overall, during the DB period no consistent pattern or trend in the injection site reaction AEs was observed in the benralizumab and mepolizumab groups. However, a n increase was observed in the frequency of injection site AEs for benralizumab group in the current study compared with the respective frequency for the same dosing schedule (Q4W) in the Phase III asthma exacerbation studies (15.7% vs 3.2%). This increase could possibly be explained by the increase in the number of injections/visit: in MANDARA study each patient in the  benralizumab  group  received  4 injections  (1x30mg  +  1  placebo/visit,  double-dummy  design) vs 1x30mg injection in the Phase III asthma studies.

A similar increase in frequency was also observed in mepolizumab group in the current study compared with  the  mepolizumab  group  in  MIRRA  (17.1% vs 10%):  in  MANDARA  study  each  patient  received  4 injections (3x100mg + 1 placebo/visit, double-dummy design) vs 3x100mg injections in MIRRA. The applicant was asked to discuss this issue (see discussion below).

Other: Helminth infections and malignancy are considered AEs of interest in the context of benralizumab mechanism of action. Malignancy is considered an important potential risk of the eosinophil lowering therapies based on the putative effect of eosinophils in neoplastic diseases, although a definite link has yet to be established. Overall, no helminth infections were reported in the study. Three events of malignant neoplasm were reported in the DB period of which 2 serious events of prostate cancer in the mepolizumab group that led to study discontinuation and 1 nonserious event of marginal zone lymphoma

<div style=\"page-break-after: always\"></div>

in the benralizumab group.  A total of 2 malignant neoplasm events in the benralizumab group were also reported during the OLE period. None of the malignant neoplasm events, reported in the DB/OLE periods, were assessed as possibly related to the IP.

## Laboratory findings

The results from clinical laboratory evaluations for haematology, clinical chemistry and urinalysis variables were analysed as: changes in mean values over time, changes in individual patients over time and individual clinically important abnormalities. Overall, no new safety concerns regarding clinical laboratory evaluations were identified. During the DB period, the proportions of patients with AEs related to laboratory parameters were low across treatment groups, with no AEs leading to discontinuation of the IP.

## Discontinuation due to adverse events

The number of subjects experiencing AEs leading to discontinuation of IP are presented in Table 25 for the DB period and Table 26 for DB+OLE periods. During the DB period there were two patients from the mepolizumab group which experienced AEs that led to discontinuation of IP. During the DB and OLE period there were two patients from the benralizumab group, which discontinued IP due to EGPA.

Table 25. AEs Leading to Discontinuation of IP - DB Period (Safety Analysis Set)

|                                                                     | Benralizumab 30 mg (N = 70) (Exp = 70.2 years)a   | Benralizumab 30 mg (N = 70) (Exp = 70.2 years)a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years)a   | Mepolizumab 300 mg (N = 70) (Exp = 70.3 years)a   |
|---------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| SOC PT                                                              | Number (%) of patients b                          | Event rate (per 100 PY)                           | Number (%) of patients b                          | Event rate (per 100 PY) “                         |
| Patients with any AE causing discontinuation of IP                  | 0                                                 | 0                                                 | 2 (2.9)                                           | 2.84                                              |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0                                                 | 0                                                 | 2 (2.9)                                           | 2.84                                              |
| Prostate cancer                                                     | 0                                                 | 0                                                 | 2 (2.9)                                           | 2.84                                              |

Adverse events were coded using MedDRA version 26.0.

AE = adverse event; DB = double-blind; Exp = exposure; IP = investigational product; MedDRA = Medical Dictionary forRegulatory Activities; N=number of patients in treatment group; PT =preferred term; PY = patient-years; SOC = system organ class

<div style=\"page-break-after: always\"></div>

Table 26. AEs Leading to Discontinuation of IP - DB and OLE Periods (Safety Analysis Set)

|                                                                     | Benralizumab 30 mg (N =70) (Exp = 146.0 years) a d   | Benralizumab 30 mg (N =70) (Exp = 146.0 years) a d   | Mepolizumab 300 mg (N=70) (Exp = 148.8 years) a d   | Mepolizumab 300 mg (N=70) (Exp = 148.8 years) a d   | Total while on Benralizumab 30 mg (N =132) (Exp = 224.7 years) a e   | Total while on Benralizumab 30 mg (N =132) (Exp = 224.7 years) a e   |
|---------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| SOC PT                                                              | Number (%) of patients b                             | Event rate (per 100 PY)                              | Number (%) of patients b                            | Event rate (per 100 PY)c                            | Number (%) of patients b                                             | Event rate (per 100PY)c                                              |
| Patients with anyAE causing discontinuation ofIP                    | 2 (2.9)                                              | 1.37                                                 | 3 (4.3)                                             | 2.02                                                | 3 (2.3)                                                              | 1.34                                                                 |
| Immune system disorders                                             | 2 (2.9)                                              | 1.37                                                 | 0                                                   | 0                                                   | 2 (1.5)                                                              | 0.89                                                                 |
| Eosinophilicgranulomatosiswithpolyangiitis                          | 2 (2.9)                                              | 1.37                                                 | 0                                                   | 0                                                   | 2 (1.5)                                                              | 0.89                                                                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0                                                    | 0                                                    | 2 (2.9)                                             | 1.34                                                | 0                                                                    | 0                                                                    |
| Prostate cancer                                                     | 0                                                    | 0                                                    | 2 (2.9)                                             | 1.34                                                | 0                                                                    | 0                                                                    |
| Infections andinfestations                                          | 0                                                    | 0                                                    | 1 (1.4)                                             | 0.67                                                | 1 (0.8)                                                              | 0.45                                                                 |
| Clostridium difficileinfection                                      | 0                                                    | 0                                                    | 1 (1.4)                                             | 0.67                                                | 1 (0.8)                                                              | 0.45                                                                 |

Adverse events were coded using MedDRA version 26.0.

AE = adverse event; DB = double-blind; Exp = exposure; IP = investigational product; MedDRA = Medical Dictionary for Regulatory Activities; N = number of patients in treatment group; OLE =open-label extension;PT=preferred term;PY =patient-years;SOC = system organ class

The CHMP noted that during the DB period, there were no patients from the benralizumab group who discontinued IP. During the DB+OLE period, there were 3 patients who discontinued IP, 2 patients in the benralizumab group as a result of EGPA, and one patient in the mepolizumab switched to benralizumab group who developed Clostridium Difficile infection. These differences are small, and applicant will continue to monitor the discontinuation rate until the end of OLE period.

## Post marketing experience

Benralizumab is approved for the treatment of severe eosinophilic asthma in 80 countries. The summary of safety data from post-marketing sources is regularly presented in periodic safety update reports.

## 2.5.1. Discussion on clinical safety

The safety profile of benralizumab is updated with the data from MANDARA study, conducted with patients with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) on corticosteroid therapy with  or  without  stable  immunosuppressive  therapy.  The  Safety  Analysis  Set  included  all  randomized patients (N=140) who were assigned to the two treated groups. The primary analysis of MANDARA study provided all safety data of benralizumab in EGPA from the complete follow-up of the 52-week DB period and exposure and AE data from the OLE period until the primary analysis data cut-off date. The applicant's large safety database already contains data from the long-term pivotal studies SIROCCO, CALIMA and BORA in patients with a history of asthma exacerbations and severe asthma. It is noted that the safety profile of benralizumab is comparable between the two dosing frequencies, Q4W and Q8W applied in the long-term studies on asthma. The safety data from the current study are generally consistent with data from the applicant's long-term pivotal studies considering that the predominant characteristic in the majority of EGPA patients is eosinophilic vasculitis combined with asthma.

Treatment  with  benralizumab  in  patients  with  EGPA  was  in  general  well  tolerated  with  no  new  safety findings. The most common AEs reported during the DB period in the benralizumab group were COVID-19, headache and arthralgia. Differences were observed between the two treatment groups for asthenia (higher

<div style=\"page-break-after: always\"></div>

% number of patients in the benralizumab group vs no patients in the mepolizumab group), abdominal pain and pain in extremities (higher % number of patients for both PTs in the mepolizumab group), however these events were not multiplicity corrected and no clinical relevance is expected. Most common AEs were transient in nature with mild or moderate intensity and with similar pattern between the benralizumab and mepolizumab treatment groups when analysed according to age, gender, race and geographic region.

The  higher  frequency  of  injection  site  reactions  reported  for  benralizumab  group in  MANDARA  study compared with long-term Phase III studies on asthma and MIRRA study was highlighted to the applicant during  the  assessment.  The  applicant's  argument  on  the  possible  outsized  effect  of  few  events  in comparisons between studies, when taking into consideration the difference in size of MANDARA and the pivotal  Phase  III  studies  in  patients  with  severe  asthma  was  acknowledged  by  the  CHMP.  It  is  also recognised that due to the nature of EGPA, similar numbers for patient recruitment are difficult to achieve.

There were no clinically meaningful differences observed in AE or SAE rates between patients who  had treatment-emergent ADAs compared with those who were ADA negative. During the DB period, 5 patients in the benralizumab group who were treatment-emergent ADA positive reported AEs, none of which were serious. There were no anaphylactic reactions reported. Two nonserious hypersensitivity reactions were reported in patients with treatment-emergent ADA positive status in the benralizumab group; both were assessed as mild and not possibly related to the IP by the investigator.

During the DB period the proportion of patients reporting AEs and the event rates in any category were higher compared to the OLE period for both treatment groups. No death was reported in the DB period in any of the two treatment groups.  One death from pulmonary embolism occurred during the OLE period in the mepolizumab switched to benralizumab group which was considered 'not possibly related to the IP'. Since  fatal  pulmonary  embolism  was  also  reported  in  the  Phase  III  exacerbation  studies,  the  CHMP questioned the applicant. A causal relationship of pulmonary embolism with benralizumab administration at present cannot be clearly excluded and therefore the applicant agreed to follow up SAE 'Pulmonary embolism' in the PSURs.

Safety data from MANDARA study do not provide evidence for increase in malignancy AEs during the DB and OLE period of the study and no new safety concerns were identified from laboratory evaluations.

Based on the safety profile of benralizumab in asthma indication, it is considered important to further monitor  AEs  related  to  malignancies  in  light  of  the  frequent  dosing  schedule  for  benralizumab  in  the proposed indication. To this direction, the results from the on-going PASS evaluating the potential risk on malignancy are considered mostly relevant.

## 2.5.2. Conclusions on clinical safety

The primary evidence for safety of benralizumab in EGPA is based on the analysis of MANDARA, which contains all safety data from the complete follow-up of the 52-week DB period and exposure and AE data from the OLE period by the primary analysis data cut-off date. The selected dose of 30 mg Q4W was well tolerated in patients with EGPA with no new safety findings. The analyzed safety data demonstrated a safety profile that was generally consistent with benralizumab's known safety profile in asthma. It is noted that some AEs were assessed as related to benralizumab (i.e. headache, fatigue) and reported with higher frequency for benralizumab in MANDARA compared with the asthma database of the applicant. No additional ADRs were identified. There are no major concerns regarding the safety profile of benralizumab in patients with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) who are on corticosteroids with or without stable immunosuppressive. The MAH will continue to monitor the safety profile in the PSURs. The SmPC has been updated with the relevant safety information.

Overall, the safety profile is considered similar to that of benralizumab in asthma.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application. The CHMP received the following PRAC Advice on the submitted Risk Management Plan. The PRAC considered that the risk management plan version 6.2 is acceptable.

## Safety concerns

| Important identified risks   | None                                |
|------------------------------|-------------------------------------|
| Important potential risks    | Malignancies                        |
| Missing information          | Use in pregnant and lactating women |

The summary of safety concerns in the RMP is acceptable.

## Pharmacovigilance plan

| Study Status                                                                                                                                                                  | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                       | Safety concerns addressed                                     | Milestones for EMA                                                                         | Due dates for EMA                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Category 1 - Not applicable                                                                                                                                                   | Category 1 - Not applicable                                                                                                                                                                                                                                                                                                                                                                 | Category 1 - Not applicable                                   | Category 1 - Not applicable                                                                | Category 1 - Not applicable                                   |
| Category 2 - Not applicable                                                                                                                                                   | Category 2 - Not applicable                                                                                                                                                                                                                                                                                                                                                                 | Category 2 - Not applicable                                   | Category 2 - Not applicable                                                                | Category 2 - Not applicable                                   |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                               | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                              | Category 3 - Required additional pharmacovigilance activities |
| D3250R00042 Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Therapies, a Post Authorization Safety Study. Ongoing | The primary objective of this study is to assess the incidence of malignancies in severe asthma patients receiving benralizumab compared with those receiving non-benralizumab biologics, and those not receiving biologics. The secondary objective is to describe the clinical characteristics of the new malignancy cases that develop in severe asthma patients and relevant subgroups. | Important potential risk: Malignancy                          | Start of data collection End of data collection Submit final report of study results (CSR) | Q1 2018 Q4 2023 Q4 2024                                       |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

| Safety concern                 | Risk minimisation measures                           | Pharmacovigilance activities                                                                                                                                                                                                                   |
|--------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks     |                                                      |                                                                                                                                                                                                                                                |
| None                           |                                                      |                                                                                                                                                                                                                                                |
| Important potential risks      |                                                      |                                                                                                                                                                                                                                                |
| Malignancy                     | Routine risk minimisation measures: None             | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: Adverse event follow-up for spontaneous reports Additional pharmacovigilance activities: D3250R00042 (Malignancy Post Authorization Safety Study) |
| Missing information            |                                                      |                                                                                                                                                                                                                                                |
| Use in pregnancy and lactation | Routine risk minimisation measures: SmPC Section 4.6 | None                                                                                                                                                                                                                                           |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is also updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The EGPA, formerly known as Churg-Strauss syndrome, is a rare, multisystemic, immune mediated inflammatory disease. EGPA is considered a form of antineutrophil cytoplasmic antibody-associated vasculitis, along with granulomatosis with polyangiitis and microscopic polyangiitis. It is histologically defined by eosinophil-rich, necrotising granulomatous inflammation primarily involving the respiratory tract, along with necrotising vasculitis of small- to medium-sized arteries. These diverse processes are

<div style=\"page-break-after: always\"></div>

responsible for heterogeneous clinical manifestations and therefore clinical phenotypes can be variable. Vasculitis is often not apparent in the initial phases of the disease. The prevalence of ANCAs in patients with EGPA varies widely (30-47% EGPA patients are ANCA positive) and their clinical significance remains uncertain. Eosinophils play a pathological role across the spectrum of EGPA regardless of ANCA status.

## 3.1.2. Available therapies and unmet medical need

Systemic corticosteroids, immunosuppressants, and biologics (rituximab and mepolizumab) are currently recommended in treatment guidelines for EGPA, with mepolizumab being the only approved therapy. A key therapeutic goal in treatment of EGPA is to induce and maintain remission while reducing the burden of corticosteroids and immunosuppressants because these therapies are often associated with significant adverse events, including toxicity, and a high relapse rate. Rituximab has limited evidence to support efficacy in EGPA, particularly in controlling airway manifestations and reducing corticosteroid dependency. A high proportion of EGPA patients treated with mepolizumab either do not achieve remission and/or relapse, with limited reduction in corticosteroid dependency. Therefore, a significant unmet medical need remains for patients with EGPA.

## 3.1.3. Main clinical studies

The benralizumab EGPA clinical development programme consists of the pivotal Phase III MANDARA study. MANDARA was a randomised, double-blind, multicentre, parallel group, active-controlled, NI study that evaluated the efficacy and safety of benralizumab compared with mepolizumab in the treatment of patients with  relapsing  or  refractory  EGPA  on  corticosteroid  therapy  with  or  without  stable  immunosuppressive therapy.

## 3.2. Favourable effects

On the primary endpoint (proportion of patients who achieved main remission at both weeks 36 and 48), benralizumab was non-inferior to mepolizumab as demonstrated by the lower bound of 95% CI falling wellabove the prespecified clinical NI margin of -25% for the difference in remission rate (1.21, 95% CI [14.11,16.53]) at both Week 36 and Week 48. Using an indirect method to compensate for the absence of placebo  control  in  MANDARA,  it  was  demonstrated  that  a  statistically  significant  higher  proportion  of patients on benralizumab achieved remission at both Weeks 36 and 48 when compared with the historical placebo control from MIRRA study. The analysis of the primary endpoint was further supported by the results on treatment comparisons for pre-specified subgroups of patients (including age, gender, region, blood eosinophil count at baseline, BMI, time since EGPA diagnosis, OCS dose at baseline, VDI score, immunosuppressive  therapy  at  baseline,  race,  ANCA  -historical  or  at  baseline  positive  status),  who achieved main remission at weeks 36 and 48.

Based on the results from the assessment of benralizumab efficacy compared with mepolizumab on clinically relevant secondary endpoints, a marked difference between benralizumab and mepolizumab groups was observed for the effect on average daily dose of OCS use during Week 48 through Week 52.  A 100% reduction  in  average  daily  OCS  dose  was  observed  in  a  statistically  significant  percentage  of  patients receiving benralizumab compared with mepolizumab. In addition, reductions of at least 50% in the average daily  dose  of  OCS  were  observed  in  numerically  higher  proportions  of  patients  receiving  benralizumab compared with mepolizumab.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

The target population in the proposed indication was wider compared to the population investigated in MANDARA study and hence, the indication was narrowed. The level of evidence presented by the applicant to justify the decision to use the Q4W dosing regimen of benralizumab in EGPA is limited but can be acceptable. Study limitations were identified in the primary analysis: imbalances in disease burden between the groups at baseline, that could benefit the benralizumab group were observed for biopsy evidence of EOS vasculitis/inflammation and maximum value for absolute eosinophil count. Similar results were obtained for both benralizumab and mepolizumab from the comparative assessment of secondary endpoints. Only numerical differences were reported in favour of benralizumab for the proportion of patients who achieved an average daily prednisolone/prednisone dose of ≤ 4 mg/day. No difference between the two treatment groups was observed for the time to first relapse, the proportion of patients who achieved remission within the first 24 weeks and the annualized relapse rate.

## 3.4. Unfavourable effects

Treatment with benralizumab in patients with EGPA was in general well tolerated with no new safety findings for benralizumab. The most common AEs reported during the DB period were COVID-19, headache, and arthralgia in the benralizumab group compared with COVID-19, headache, and nasopharyngitis in the mepolizumab group.

There were no clinically meaningful differences observed in AE or SAE rates between patients who had treatment-emergent ADAs compared with those who were ADA negative. During the DB period, 5 patients in the benralizumab group who were treatment-emergent ADA positive reported AEs, none of which were serious. There were no anaphylactic reactions reported. Two nonserious hypersensitivity reactions (rash and vulvovaginal rash) were reported in patients with treatment-emergent ADA positive status in the benralizumab group; both were assessed as mild and not possibly related to the IP. During the DB period the proportion of patients reporting AEs and the event rates in any category were higher compared to the OLE period for both treatment groups.

There were no clinically meaningful differences in the frequency and event rate of SAEs between benralizumab and mepolizumab groups during the DB period. Similarly, there were no clinically meaningful differences in the frequency and event rate of SAEs between the benralizumab and mepolizumab/benralizumab groups during the OLE period.

No death was reported in the DB period in any of the two treatment groups.  One death from pulmonary embolism occurred during the OLE period in the mepolizumab/benralizumab group which was considered 'not possibly related to the IP'. Since fatal pulmonary embolism was also reported in the Phase III exacerbation studies, the applicant will monitor these events and report them in the PSUR.

Safety data from MANDARA study do not provide evidence for increase in malignancy AEs during the DB and OLE period of the study.

## 3.5. Uncertainties and limitations about unfavourable effects

The TEAEs headache, fatigue, asthenia occurred at a higher frequency in the benralizumab group compared to mepolizumab group. Conversely, injection site bruising/pain/erythema/haematoma were more frequent in the benralizumab group. It is also noted that headache and fatigue AEs assessed by the investigator as related to benralizumab treatment i.e. were reported with higher frequency in MANDARA study compared with the asthma studies.

<div style=\"page-break-after: always\"></div>

Noted is also the higher frequency of injection site reactions reported in MANDARA study compared with long-term Phase III studies on asthma and MIRRA study, although not numerically significant.

Further evaluation of SAEs occurring in the mepolizumab switched to benralizumab group during the OLE period which were attributed to mepolizumab treatment per investigator's opinion despite occurrence post benralizumab treatment will be conducted.

## 3.6. Effects Table

Table 27. . Effects Table for FASENRA in EGPA (data cut-off: 10 August 2023)

| Effect                                       | Short description                                                                                                                               | Unit                 | Treatment Benralizumab (30 mg)                  | Control mepolizumab (300 mg)                     | Uncertainties / Strength of evidence                  | References           |
|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------------------------------------------------|--------------------------------------------------|-------------------------------------------------------|----------------------|
| Favourable Effects                           | Favourable Effects                                                                                                                              | Favourable Effects   | Favourable Effects                              | Favourable Effects                               | Favourable Effects                                    | Favourable Effects   |
| Remission at both Week 36 and 48             | Proportion of Subjects who achieved main remission at both Week 36 and 48 n (%)                                                                 | % subjects           | 40 (57.1)                                       | 40 (57.1)                                        | Difference 1.21 95% CI 1-14.11, 16.53 p-value <0.8773 | Primary endpoint     |
|                                              | BVAS = 0                                                                                                                                        | % subjects           | 58 (82.9)                                       | 59 (84.3)                                        | Difference -1.17 95% CI -13.27,10.94 p-value <0.8502  |                      |
|                                              | OCS dose ≤ 4 mg/day                                                                                                                             | % subjects           | 42 (60)                                         | 41 (58.6)                                        | Difference 2.64 95% CI -12.67, 17.95 p-value <0.7354  |                      |
| Total duration of remission during DB period | Subjects with total accrued duration of remission during DB period n (%) 0 weeks > 0 to < 12 weeks 12 to < 24 weeks 24 to < 36 weeks ≥ 36 weeks | % subjects           | 9 (12.9) 13 (18.6) 8 (11.4) 20 (28.6) 20 (28.6) | 15 (21.4) 10 (14.3) 8 (11.4) 19 (27.1) 18 (25.7) | OR 1.32 95% CI 0.72, 2.40 p-value <0.3653             | Secondary endpoint   |
| Average daily dose of OCS                    | Average daily dose of Prednisolone /prednisone during Week 48 through 52: 0 mg > 0 to ≤ 4.0 mg > 4.0 to ≤ 7.5 mg > 7.5 mg                       | % subjects           | 29 (41.4) 19 (27.1) 15 (21.4) 7 (10.0)          | 19 (27.1) 30 (42.9) 13 (18.6) 8 (11.4)           | OR 1.38 95% CI 0.75, 2.54 p-value <0.3062             |                      |
|                                              | Subjects with 100% OCS reduction during weeks 48 to 52 n (%)                                                                                    | % subjects           | 29 (41.4)                                       | 18 (25.7)                                        | Difference 15.69 95% CI -0.67, 30.71 p-value <0.0406  | Secondary endpoint   |
|                                              | Subjects with 50% OCS reduction during weeks 48 to 52 n (%)                                                                                     | % subjects           | 59 (84.3)                                       | 52 (74.3)                                        | Difference 10.79 95% CI -2.25, 23.83 p-value <0.1047  | Secondary endpoint   |
| Unfavourable Effects                         | Unfavourable Effects                                                                                                                            | Unfavourable Effects | Unfavourable Effects                            | Unfavourable Effects                             | Unfavourable Effects                                  | Unfavourable Effects |
|                                              | Any AE                                                                                                                                          | % subjects           | 63 (90.0)                                       | 67 (95.7)                                        |                                                       | MANDARA              |
|                                              | Any AE with outcome of death                                                                                                                    | % subjects           | 0                                               | 0                                                |                                                       | MANDARA              |
|                                              | Any SAE (incl. events with outcome of death)                                                                                                    | % subjects           | 4 (5.7)                                         | 9 (12.9)                                         |                                                       | MANDARA              |
|                                              | Patients with any related AE                                                                                                                    | % subjects           | 20 (28.6)                                       | 16 (22.9)                                        |                                                       | MANDARA              |
|                                              | Any AE leading to discontinuation of IP                                                                                                         | % subjects           | 0                                               | 2 (2.9)                                          |                                                       | MANDARA              |

<div style=\"page-break-after: always\"></div>

| Effect   | Short description                 | Unit       | Treatment Benralizumab (30 mg)   | Control mepolizumab (300 mg)   | Uncertainties / Strength of evidence   | References   |
|----------|-----------------------------------|------------|----------------------------------|--------------------------------|----------------------------------------|--------------|
|          | Covid-19                          | % subjects | 15 (21.4)                        | 19 (27.1)                      |                                        | MANDARA      |
|          | Headache                          | % subjects | 12 (17.1)                        | 11 (15.7)                      |                                        | MANDARA      |
|          | Arthralgia                        | % subjects | 12 (17.1)                        | 8 (11.4)                       |                                        | MANDARA      |
|          | Nasopharyngitis                   | % subjects | 6 (8.6)                          | 10 (14.3)                      |                                        | MANDARA      |
|          | Sinusitis                         | % subjects | 5 (7.1)                          | 8 (11.4)                       |                                        | MANDARA      |
|          | Fatigue                           | % subjects | 5 (7.1)                          | 6 (8.6)                        |                                        | MANDARA      |
|          | Upper respiratory tract infection | % subjects | 4 (5.7)                          | 4 (5.7)                        |                                        | MANDARA      |
|          | Asthenia                          | % subjects | 6 (8.6)                          | 0                              |                                        | MANDARA      |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The  efficacy  and  safety  of  benralizumab  compared  to  mepolizumab  in  the  treatment  of  EGPA  were investigated in MANDARA study. Based on the analysis of the primary endpoint of the study, Non-Inferiority was demonstrated for Benralizumab compared to mepolizumab by the lower bound of 95% CI falling wellabove the prespecified clinical NI margin of -25% for the difference in remission rate at both Week 36 and Week 48. This is not considered clinically meaningful. MANDARA was a well conducted study with low IPDs, low study discontinuation rate, and high data quality. Benralizumab showed similar efficacy for the primary endpoint and a consistent trend of efficacy for all secondary endpoints, including OCS reduction endpoints, compared to mepolizumab, which will be a clinically relevant benefit to EGPA patients.

The analysis of the secondary endpoints indicated that benralizumab did not demonstrate superior efficacy in  EGPA  compared  with  mepolizumab.  A  higher  treatment  effect  for  benralizumab  compared  with mepolizumab was achieved for the average daily dose of OCS use during Week 48 through Week 52: 100% reduction  in  average  daily  OCS  dose  was  observed  in  a  statistically  significant  percentage  of  patients receiving benralizumab (41.4%) compared with patients receiving mepolizumab (25.7%) during Week 48 through Week 52. Reductions of at least 50% in the average daily dose of OCS were observed in numerically higher proportions of patients receiving benralizumab compared with mepolizumab. A numerically similar proportion of  patients  achieved  an  average  daily  OCS  dose  of  ≤4mg/day  in  the  two  treatment groups (68.6% in the benralizumab group vs. 70.0% in the mepolizumab group).

Treatment  of  patients  with  refractory  or  relapsing  EGPA  receiving  standard  of  care  therapy,  with benralizumab was in general well tolerated with no new safety findings for benralizumab. The AEs assessed by the investigator as related to benralizumab treatment (headache, fatigue) were reported with higher frequency  in  MANDARA  study  compared  with  the  asthma  studies.  Injection  site  reactions  were  more frequent in the benralizumab group. There were no clinically meaningful differences in the frequency and event rate of SAEs between benralizumab and mepolizumab groups during the DB period, however a higher proportion of patients reported SAEs and SAE event rates in the OLE period compared to the DB period. No hypersensitivity AEs were serious, and no events of anaphylactic reactions were reported. No fatal events were reported during the DB period of the study. One death from pulmonary embolism occurred during the OLE period in the mepolizumab/benralizumab group.

<div style=\"page-break-after: always\"></div>

The pharmacodynamic effect of benralizumab in patients with EGPA was consistent with its effect observed in patients with severe asthma, showing rapid and near complete depletion of blood eosinophils.

## 3.7.2. Balance of benefits and risks

Regarding efficacy evaluation, uncertainties initially identified regarding the representation of the study population  in  the  proposed  indication  were  resolved  by  narrowing  the  indication  to  reflect  the  studied population. The frequency of the dosing regimen selected for the treatment is agreed. Some uncertainties remain in relation to the safety evaluation, in aspects related to the frequency of AEs in MANDARA study compared  with  long-term  asthma  studies.  Considering  all  the  favourable  and  unfavourable  effects evaluated, benralizumab is recommended for treatment of patients with EGPA, as per the agreed indication.

## 3.8. Conclusions

The overall B/R of Fasenra is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis, based results from study D3253C00001 (Mandara); this was a randomised, double-blind, multicentre, parallel group, active-controlled, non-inferiority study that evaluated the efficacy and safety of benralizumab compared with mepolizumab in treatment of patients with EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.2 of the RMP has been agreed. In addition, the MAH took this opportunity to introduce editorial changes.

The variation leads to amendments to the Summary of Product Characteristics, Package Leaflet and to the RMP.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.